Macrocyclic compounds, method of preparation of these and use thereof.

Abstract

Compounds shown as Formula (I) or stereoisomers thereof, or pharmaceutically acceptable salts, solvates or prodrugs thereof, a pharmaceutical composition comprising the same, and the use thereof in the preparation of drugs for preventing and / or treating diseases or disorders related to RAS protein activity, such as cancer.

Description

Macrocyclic compound and its preparation method and use

[0001] This application claims priority to a prior application with patent number 202311130834X filed with the State Intellectual Property Office of China on September 1, 2023, a prior application with patent number 2024104662832 filed with the State Intellectual Property Office of China on April 17, 2024, a prior application with patent number 2024106442663 filed with the State Intellectual Property Office of China on May 22, 2024, a prior application with patent number 2024108449718 filed with the State Intellectual Property Office of China on June 26, 2024, and a prior application with patent number 2024111714441 filed with the State Intellectual Property Office of China on August 23, 2024. The entire contents of the five prior applications are incorporated into this application by reference. Technical Field

[0002] The present disclosure belongs to the field of medicine, and specifically relates to a macrocyclic compound capable of inhibiting RAS protein activity, and a preparation method and use thereof. Background Art

[0003] The RAS gene (Rat sarcoma viral oncogene homolog) encodes a family of small GTP hydrolase proteins with a molecular weight of approximately 21 kDa. The mammalian RAS family includes three members: HRAS, KRAS, and NRAS. They function as molecular switches in various cellular signaling processes. When bound to GDP, RAS is in a dormant or inactive state. When cells are exposed to certain growth-promoting stimuli, RAS is induced to exchange the bound GDP for GTP, thereby becoming activated. It then recruits and activates other downstream target proteins (such as Raf and PI3K), promoting cell proliferation. RAS proteins inherently have the ability to hydrolyze GTP to GDP (thus converting themselves to an inactive state), but the conversion rate is low. However, when bound to GTPase-activating proteins (GAPs), the interaction greatly accelerates the rate at which RAS proteins convert GTP to GDP, allowing them to rapidly return to their inactive state upon termination of cellular stimulation and shut down signaling pathways.

[0004] RAS gene mutations are found in approximately 30% of human tumors; KRAS mutations are the most common, accounting for approximately 85%, followed by NRAS and HRAS at 12% and 3%, respectively. KRAS mutations are predominant in pancreatic cancer (86%), colorectal cancer (41%), and lung cancer (32%). NRAS mutations are more common in melanoma and acute myeloid leukemia, and HRAS mutations are more common in bladder cancer and head and neck cancer. In tumors, RAS gene mutations primarily occur through point mutations. Over 150 different RAS point mutations have been identified, with mutations at positions G12 and G13, as well as Q61, being the most common. These pathogenic mutations often impair the interaction between RAS and GAP and the endogenous GTP hydrolase activity of RAS, resulting in the mutant RAS protein being primarily present in the GTP-bound, activated form within the cell. This results in the constitutive activation of the signaling pathway mediated by the RAS protein, leading to uncontrolled cell proliferation and ultimately promoting tumor formation.

[0005] Currently, the targeted drugs AMG510 and MRTX849 have been approved for the treatment of KRAS G12C mutation-bearing non-small cell lung cancer. However, there are no approved targeted drugs for KRAS G12D and KRAS G12V mutations, which are frequently seen in pancreatic and colorectal cancers, or for NRAS and HRAS mutations, which are common in melanoma and head and neck cancers. Therefore, the development of highly effective inhibitors targeting multiple RAS mutations holds significant clinical value and represents both a hot topic and a challenge in the field of new drug development.

[0006] Summary of the Invention

[0007] The present disclosure provides a class of RAS inhibitors that can inhibit RAS activity by driving the formation of a high-affinity ternary complex between the RAS protein and a cytoplasmic chaperone protein (such as cyclophilin A). The non-covalent interaction between the RAS protein and the cytoplasmic chaperone protein can inhibit RAS activity.

[0008] The RAS inhibitors disclosed herein have the advantages of high activity and low toxicity and side effects, and are expected to have good physicochemical properties and drug-forming properties.

[0009] The first aspect of the present disclosure provides a compound represented by formula (I) or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof:

[0010] Where,

[0011] Ring A is

[0012] is phenyl, 5- or 6-membered heteroaryl or 5- or 6-membered heterocyclic group; one or two ring atoms of the 5- or 6-membered heteroaryl group are heteroatoms selected from nitrogen, oxygen or sulfur; one or two ring atoms of the 5- or 6-membered heterocyclic group are heteroatoms selected from nitrogen, oxygen or sulfur; the 5- or 6-membered heterocyclic group is a fully saturated heterocyclic group or a partially unsaturated heterocyclic group; or wherein W1 is CH, C or N; W2 is CH, C or N; W3 is CR 13 , O, S, N or NH; W4 is CR 13 , O, S, N or NH; W5 is absent, O or CR 14 ; Indicates the site of connection with the left part;

[0013] W6 selected from CR 13 or N;

[0014] X is

[0015] Y1 is N or CH; wherein N can be oxidized (N + -O - );

[0016] Y2 is N or CH; wherein N can be oxidized (N + -O - );

[0017] R 42 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 43 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or

[0018] R 42 and R 43 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0019] R 40 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 41 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or

[0020] R 40 and R 41 Connected to form -CH2- or -CH2CH2-; wherein -CH2- or -CH2CH2- is optionally replaced by one or more selected from deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl radical substitution;

[0021] When ring A is When L1 is -N(R 00 )C(=O)-、-N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1- 4-alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -L2-substituted or unsubstituted C 6-10 Aryl-, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl-, -L2-substituted or unsubstituted 8- or 10-membered bicyclic heteroaryl-, or -L2-substituted or unsubstituted 3- to 8-membered heterocyclic group-; L2 is C 3-6 Cycloalkyl, 3 to 8 membered heterocyclic group, -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-;

[0022] When ring A is hour;

[0023] When at least one of W1, W2, W3, W4, and W5 is a heteroatom selected from O, S, N, or NH; L1 is -N(R 00 )C(=O)-、-N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-, substituted or unsubstituted C 3-6Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -L2-substituted or unsubstituted C 6-10 Aryl-, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl-, or -L2-substituted or unsubstituted 3- to 8-membered heterocyclyl-;

[0024] L2 is -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-;

[0025] or,

[0026] When W1 and W2 are C; W3, W4, and W5 are CH, L1 is -N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-N(R 00 )C(=O)-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O- or -substituted or unsubstituted C 2-6 alkenyl-O-;

[0027] R 00 is hydrogen or C 1-6 alkyl;

[0028] R1 is hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0029] R2 is hydrogen, deuterium, halogen, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0030] R 3a C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0031] R 4a is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 3-6a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0032] R5 is hydrogen, -NR 01 R 02 、-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C(=O)-NR 01 R 02 、-C 1-4 Alkyl-C(=O)-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C(=O)-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(=O)-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-N(R 06 )C(=O)-NR 01 R 02 、-C 1-4 Alkyl-N(R 06 )C(=O)-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-N(R 06 )C(=O)-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-N(R 06 )C(=O)-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-OC 1-4 Alkyl-NR 01 R 02 、-OC 1-4 Alkyl-C(R 05 )R 03 R 04 、-OC1-4 Alkyl-N(R 06 )C(=O)-R 03 、-OC(R 05 )R 03 R 04 、-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-N(R 06 )C(=O)-NR 01 R 02 、-N(R 06 )C(=O)-C(R 05 )R 03 R 04 、-C 2-4 Alkynyl-NR 01 R 02 、-C 2-4 Alkynyl-C(=O)-NR 01 R 02 、-C 2-4 Alkynyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkynyl-NR 01 R 02 、-C 1-4 Alkyl-C 2-4 Alkynyl-C(R 05 )R 03 R 04 、-C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 、-C 2-4 Alkynyl-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 、-CH=CR 01 R 02 、-C 2-4 Alkenyl-NR 01 R 02 、-C 2-4 Alkenyl-C(R 05 )R03 R 04 、-C 1-4 Alkyl-C 2-4 Alkenyl-NR 01 R 02 、-C 1- 4-alkyl-C 2-4 Alkenyl-C(R 05 )R 03 R 04 、-C 2-4 Alkenyl-C 1-4 Alkyl-NR 01 R 02 、-C 2-4 Alkenyl-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkenyl-C 1-4 Alkyl-NR 01 R 02 、-C=CR 03 R 04 、-OC 1-4 Alkyl-substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, -OC 1-4 Alkyl-substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, -OC 1-4 alkyl-substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, -O-substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group, -O-substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, -O-substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, -N=S(=O)(R 06 )(-C 1-4 Alkyl-NR 01 R 02 )、-N(R 06 )-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)(R 06 )(=NR 06 )、-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )(=NR 06 )、-S(=O)2(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)2(-C1-4 Alkyl-C(R 05 )R 03 R 04 )、-S(=O)(-C 1-4 Alkyl-C(R 05 )R 03 R 04 ),-C 2-4 Alkynyl-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, -C 2-4 Alkynyl-substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -C 2-4 Alkynyl-substituted or unsubstituted 6- to 12-membered heteroaryl heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, substituted or unsubstituted C 6-10 aryl-substituted or unsubstituted 3 to 8 membered monocyclic heterocyclic group, substituted or unsubstituted 5 or 6 membered monocyclic heteroaryl-substituted or unsubstituted 3 to 8 membered monocyclic heterocyclic group, substituted or unsubstituted C 6-10 Aryl-C 1-4 Alkyl-substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, substituted or unsubstituted 5 or 6-membered monocyclic heteroaryl-C 1-4 Alkyl-substituted or unsubstituted 3 to 8 membered monocyclic heterocyclic group, substituted or unsubstituted C 6-10 substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, substituted or unsubstituted 5 or 6-membered monocyclic heteroaryl and substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, substituted or unsubstituted C 6-10 Aryl-C 1-4 Alkyl-NR 01 R 02 or substituted or unsubstituted 5 or 6 membered monocyclic heteroaryl-C 1-4 Alkyl-NR 01 R 02 ;

[0033] R 01 、R 02 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; or,

[0034] R 01 、R 02Together with the nitrogen atom to which it is attached, it forms a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, or a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group;

[0035] R 03 、R 04 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; wherein the C 1-6 Alkyl, C 1-6 The two hydrogen atoms on the same carbon atom of the alkoxy group are optionally replaced simultaneously by -(CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or

[0036] R 03 、R 04 Together with the carbon atom to which it is attached, it forms a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group, a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl group, or a substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl group;

[0037] R 05 For hydrogen, deuterium, halogen, deuterated C 1-6 Alkyl or C 1-6 alkyl;

[0038] R 06 is hydrogen, deuterium or C 1-6 alkyl;

[0039] Y3 is -C(=O)R6, -C(=S)R6, -S(=O)(R 07 )(=NR 08 )、-S(=O)(R 07 )(R 08 )、-S(=O)2(R 07 )(R 08 ),-P(=O)(R 07 )(R 08 ), -C(=O)-C 1-4 Alkyl-NR6-S(=O)(R 07 )(=NR 08 ), -C(=O)-C 1-4 Alkyl-N=S(=O)(R 07 )(R 08 ) or R 11 ; R 12 For hydrogen, C1-6 Alkyl or deuterated C 1-6 alkyl;

[0040] or Y3, R 12 Together with the nitrogen atom to which they are attached, they form a substituted or unsubstituted nitrogen-containing 3- to 8-membered heterocyclic group; one ring atom of the nitrogen-containing 3- to 8-membered heterocyclic group is a nitrogen atom and optionally one or more (e.g., 1, 2, or 3) ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus;

[0041] R6 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0042] R 11 is a substituted or unsubstituted 3- to 10-membered heterocyclyl, a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, a substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, a substituted or unsubstituted 6- to 12-membered heteroarylcycloalkyl, a substituted or unsubstituted 6- to 12-membered heteroarylheterocyclyl, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclyl, or a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclyl;

[0043] R 07 is hydrogen, deuterium, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 3-6 Cycloalkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium, C 1-6 Alkyl, C 1-6 heteroalkyl and 5- or 6-membered monocyclic heteroaryl;

[0044] R 08 is hydrogen, deuterium, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 3-6 Cycloalkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium, C 1-6 Alkyl, C 1-6 heteroalkyl and 5- or 6-membered monocyclic heteroaryl;

[0045] R 09 is hydrogen, deuterium, halogen or substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium and halogen;

[0046] R 10 is hydrogen, deuterium, halogen or substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium and halogen;

[0047] Y5 is O or S;

[0048] Y4 is O or S;

[0049] R3 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0050] R 13 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 1-6 Alkoxy; R 14 is hydrogen, halogen or substituted or unsubstituted C 1-6 Alkyl; or

[0051] In W4 and W5, R 13 and R 14 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 3- to 8-membered heterocyclic group; or

[0052] R in W5 14 and R3 together with the atoms to which it is connected form a substituted or unsubstituted nitrogen-containing 4- to 8-membered monocyclic heterocyclic group; one ring atom of the nitrogen-containing 4- to 8-membered monocyclic heterocyclic group is a nitrogen atom and optionally one or more (such as 1, 2 or 3) ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; or

[0053] R in W6 13 and R3 together with the atoms to which it is attached form a substituted or unsubstituted nitrogen-containing 3- to 8-membered monocyclic heterocyclic group or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl group; one ring atom of the nitrogen-containing 3- to 8-membered monocyclic heterocyclic group is a nitrogen atom and optionally one or more (e.g., 1, 2, or 3) ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus;

[0054] In each of the above groups, the substitution independently refers to the above groups being independently substituted by 1, 2, 3, 4, 5 or 6 groups selected from Group S1; the groups of Group S1 are independently selected from the following groups: -SF5, deuterium, oxo (=O), thio (=S), =CR e R f 、=NR e , halogen, cyano, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-20 Cycloalkyl, 3 to 20 membered heterocyclic group, C 6-14 Aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, -OC 3-20 Cycloalkyl, -O-3 to 20-membered heterocyclic group, -OC 6-14 Aryl, -O-5 or 6-membered monocyclic heteroaryl, -O-8 to 10-membered bicyclic heteroaryl, -C≡CC 3-20 Cycloalkyl, -C≡C-3 to 20-membered heterocyclic group, -C≡CC 6-14 Aryl, -C≡C-5 or 6-membered monocyclic heteroaryl, -C≡C-8 to 10-membered bicyclic heteroaryl, -C≡CC 1-4 Alkyl-C 3-20 Cycloalkyl, -C≡CC 1-4 Alkyl-3 to 20-membered heterocyclic group, -C≡CC 1-4 Alkyl-C 6-14 Aryl, -C≡CC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C≡CC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-C 3-20 Cycloalkyl, -C 1-4 Alkyl-OC 3-20 Cycloalkyl, -C 1-4 alkyl-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C 6-14 Aryl, -C 1-4 Alkyl-OC 6-14 Aryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C 1-4Alkyl-O-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -OC 1- 4-alkyl-hydroxyl, -OC 1-4 Alkyl-cyano, -OC 1-4 Alkyl-C 1-6 Alkyl, -OC 1-4 Alkyl-C 1-6 Alkoxy, -OC 1-4 Alkyl-C 3-20 Cycloalkyl, -OC 1-4 Alkyl-OC 3-20 Cycloalkyl, -OC 1-4 Alkyl-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-C 6-14 Aryl, -OC 1-4 Alkyl-OC 6-14 Aryl, -OC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -OC 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-20 Cycloalkyl, -S(=O)2-3 to 20-membered heterocyclic group, -C(=O)OC 1-6 Alkyl, -C(=O)OC 3-20 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-20 Cycloalkyl, -C(=O)-C 6-14 Aryl, -NR a1 R b1 、-C(=O)-NR a1 R b1 、-C(=O)-NR d1 -C 1-4 Alkyl-R c1 、-OR c1 、-C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-20 Cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 20-membered heterocyclic group, -C 1-4Alkyl-C(=O)OC 1-6 Alkyl, -C 1-4 Alkyl-C(=O)OC 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 1-6 Alkyl, -C 1-4 Alkyl-C(=O)-C 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 6-14 aryl, -C(=O)-5 or 6-membered monocyclic heteroaryl, -C(=O)-8 to 10-membered bicyclic heteroaryl, -C(=O)-C 1-6 Alkyl-C 3-20 Cycloalkyl, -C(=O)-C 1-6 alkyl-3 to 20-membered heterocyclic group, -C(=O)-C 1-6 Alkyl-C 6-14 Aryl, -C(=O)-C 1-6 Alkyl-5 or 6-membered monocyclic heteroaryl, -C(=O)-C 1-6 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-NR a1 R b1 、-C 1-4 Alkyl-C(=O)-NR a1 R b1 、-C≡CC(=O)-NR a1 R b1 、-C≡CC 1-4 Alkyl-C(=O)-NR a1 R b1 、-C 1-4 Alkyl-OR c1 、-C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2, -C 1-4 Alkyl-NR d1 -C(=O)-R c1 、-C 1-4 Alkyl-NR d1 -C(=O)-NR a1 R b1 、-C 1-4 Alkyl-NR d1 -S(=O)2-R c1 、-C 1-4 Alkyl-S(=O)2-NR a1 R b1 、-C 1-4 Alkyl-NR d1 -S(=O)2-NRa1 R b1 、-NR d1 -C(=O)-R c1 、-NR d1 -C(=O)-C 1-4 Alkyl-R c1 、-NR d1 -C(=O)-NR a1 R b1 、-NR d1 -S(=O)2-R c1 、-S(=O)2-NR a1 R b1 、-NR d1 -S(=O)2-NR a1 R b1 and -P(=O)-(C 1-6 Alkyl) 2; wherein the C 1-6 Alkyl, the C 1-6 Alkoxy, the C 2-6 Alkenyl, the C 2-6 Each alkynyl group is independently optionally substituted by 1, 2 or 3 groups selected from halogen, deuterium, cyano or hydroxy; 3-20 Cycloalkyl, the 3 to 20 membered heterocyclic group, the C 6-14 The aryl group, the 5- or 6-membered monocyclic heteroaryl group, and the 8- to 10-membered bicyclic heteroaryl group are each independently optionally substituted by 1, 2, 3 or 4 groups selected from Group S2;

[0055] In the above groups, each R a1 、R b1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-6 Monocyclic cycloalkyl, -S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-6 monocyclic cycloalkyl or -C(=O)-3 to 6-membered monocyclic heterocyclic group; wherein the C 3-6 The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 alkyl)2; or

[0056] Each R a1 and R b1 Together with the nitrogen atom to which they are attached, they form a 3- to 20-membered heterocyclic group; wherein the 3- to 20-membered heterocyclic group is independently optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1- 6 alkoxy, halogenated C 1-6 Alkoxy, deuterated C1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 Alkyl)2;

[0057] In the above groups, each R d1 Each independently is H, C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0058] In the above groups, each R c1 Each independently is H, C 1-6 Alkyl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-NR a1 R b1 , halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl or -C 1-4 Alkyl-8 to 10 membered bicyclic heteroaryl; said C 3-6The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, C 3-6 Monocyclic cycloalkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 or -P(=O)-(C 1-6 Alkyl)2;

[0059] In the above groups, each group of S2 is independently selected from the following groups: deuterium, oxo (=O), thio (=S), CR e R f 、=NR e , halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -(C=O)-NHC 1-6 Alkyl, -(C=O)-N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 alkyl)2, -(C=O)C 1-6 Alkyl and -SF5;

[0060] In the above groups, the -C 1-4 Alkyl- is unsubstituted; or -C 1-4 1, 2, 3 or 4 hydrogen atoms on the alkyl group are independently selected from halogen, cyano, hydroxyl, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -CH2-hydroxy, -CH2-cyano, phenyl, C 3-6 or C 1-4The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by -(CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by =CR e R f replace;

[0061] In the above groups, R e are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0062] In the above groups, R f are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0063] In each of the above groups, one or more (e.g., 1, 2, 3, or 4) ring atoms of the 3- to 8-membered heterocyclic group, the 3- to 10-membered heterocyclic group, or the 3- to 8-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; 1-6 One or more (e.g., 1, 2, 3, or 4) ring atoms of the heteroalkyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 7- to 12-membered bicyclic heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 3- to 20-membered heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- or 6-membered monocyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 8- to 10-membered bicyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 3- to 6-membered monocyclic heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- to 15-membered tricyclic heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloalkyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloheterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloheterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus;

[0064] Wherein, when the ring atom is a sulfur atom, the sulfur atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above;

[0065] Wherein, when the ring atom is a phosphorus atom, the phosphorus atom is optionally substituted by one or two groups selected from oxo and =NR e The group substituted; R e Same definition as above.

[0066] In order to further explain The position of connection to the rest of the molecule can be expressed as The middle asterisk connects to the left part; The wavy line connects it to the rest of the molecule.

[0067] In one embodiment, R 40 is hydrogen; R 41 For hydrogen.

[0068] The first aspect of the present disclosure further provides a compound represented by formula (ID) or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof:

[0069] Where,

[0070] Ring A is

[0071] is phenyl, a 5- or 6-membered monocyclic heteroaryl or a 5- or 6-membered monocyclic heterocyclic group; one or two ring atoms of the 5- or 6-membered monocyclic heteroaryl are heteroatoms selected from nitrogen, oxygen or sulfur; one or two ring atoms of the 5- or 6-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen or sulfur; the 5- or 6-membered monocyclic heterocyclic group is a fully saturated heterocyclic group or a partially unsaturated heterocyclic group; or wherein W1 is CH, C or N; W2 is CH, C or N; W3 is CR 13 , O, S, N or NH; W4 is CR 13 , O, S, N or NH; W5 is absent, O or CR 14 ; Indicates the site of connection with the left part;

[0072] W6 is CR 13 or N;

[0073] X is

[0074] Y1 is N or CH; wherein N can be oxidized (N + -O - );

[0075] Y2 is N or CH; wherein N can be oxidized (N + -O - );

[0076] R 42 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 43 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or

[0077] R 42 and R 43 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 a monocyclic cycloalkyl group or a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclyl group;

[0078] R 40 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 41 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or

[0079] R 40 and R 41 Connected to form -CH2- or -CH2CH2-; wherein -CH2- or -CH2CH2- is optionally replaced by one or more selected from deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl radical substitution;

[0080] When ring A is When L1 is -N(R 00 )C(=O)-、-N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1- 4-alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-, substituted or unsubstituted C 3-6 Monocyclic cycloalkyl, substituted or unsubstituted 3 to 8 membered monocyclic heterocyclic group, substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -L2-substituted or unsubstituted C 6-10 Aryl-, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl-, -L2-substituted or unsubstituted 8- or 10-membered bicyclic heteroaryl-, or -L2-substituted or unsubstituted 3- to 8-membered monocyclic heterocyclyl-; L2 is C 3-6Monocyclic cycloalkyl, 3 to 8 membered monocyclic heterocyclic group, -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-;

[0081] When ring A is hour;

[0082] When at least one of W1, W2, W3, W4, and W5 is a heteroatom selected from O, S, N, or NH; L1 is -N(R 00 )C(=O)-、-N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-, substituted or unsubstituted C 3-6 Monocyclic cycloalkyl, substituted or unsubstituted 3 to 8 membered monocyclic heterocyclic group, substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -L2-substituted or unsubstituted C 6-10 Aryl-, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl-, or -L2-substituted or unsubstituted 3- to 8-membered monocyclic heterocyclyl-;

[0083] L2 is -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-;

[0084] or,

[0085] When W1 and W2 are C; W3, W4, and W5 are CH, L1 is -N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-N(R00 )C(=O)-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O- or -substituted or unsubstituted C 2-6 alkenyl-O-;

[0086] R 00 is hydrogen or C 1-6 alkyl;

[0087] R1 is hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0088] R2 is hydrogen, deuterium, halogen, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0089] R 3a C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0090] R 4a is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 3-6 a monocyclic cycloalkyl group or a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclyl group;

[0091] R5 is hydrogen, -NR 01 R 02 、-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C(=O)-NR 01 R 02 、- C 1-4 Alkyl-C(=O)-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C(=O)-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(=O)-C 1-4 Alkyl-C(R05 )R 03 R 04 、-C 1-4 Alkyl-N(R 06 )C(=O)-NR 01 R 02 、-C 1-4 Alkyl-N(R 06 )C(=O)-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-N(R 06 )C(=O)-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-N(R 06 )C(=O)-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-OC 1-4 Alkyl-NR 01 R 02 、-OC 1-4 Alkyl-C(R 05 )R 03 R 04 、-OC 1-4 Alkyl-N(R 06 )C(=O)-R 03 、-OC(R 05 )R 03 R 04 、-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-N(R 06 )C(=O)-NR 01 R 02 、-N(R 06 )C(=O)-C(R 05 )R 03 R 04 、-C 2-4 Alkynyl-NR 01 R 02 、-C 2-4 Alkynyl-C(=O)-NR 01 R 02 、-C 2-4 Alkynyl-C(R 05 )R 03R 04 、-C 1-4 Alkyl-C 2-4 Alkynyl-NR 01 R 02 、-C 1-4 Alkyl-C 2-4 Alkynyl-C(R 05 )R 03 R 04 、-C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 、-C 2-4 Alkynyl-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 、-CH=CR 01 R 02 、-C 2-4 Alkenyl-NR 01 R 02 、-C 2-4 Alkenyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkenyl-NR 01 R 02 、-C 1-4 Alkyl-C 2-4 Alkenyl-C(R 05 )R 03 R 04 、-C 2-4 Alkenyl-C 1-4 Alkyl-NR 01 R 02 、-C 2-4 Alkenyl-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkenyl-C 1-4 Alkyl-NR 01 R 02 、-C=CR 03 R 04 、-OC 1-4 Alkyl-substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, -OC 1-4Alkyl-substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, -OC 1-4 alkyl-substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, -O-substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group, -O-substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, -O-substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, -N=S(=O)(R 06 )(-C 1-4 Alkyl-NR 01 R 02 )、-N(R 06 )-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)(R 06 )(=NR 06 )、-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )(=NR 06 )、-S(=O)2(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)2(-C 1-4 Alkyl-C(R 05 )R 03 R 04 )、-S(=O)(-C 1-4 Alkyl-C(R 05 )R 03 R 04 ),-C 2-4 Alkynyl-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, -C 2-4 Alkynyl-substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl or -C 2-4 Alkynyl-substituted or unsubstituted 6- to 12-membered heteroaryl heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, substituted or unsubstituted C 6-10 aryl-substituted or unsubstituted 3 to 8 membered monocyclic heterocyclic group, substituted or unsubstituted 5 or 6 membered monocyclic heteroaryl-substituted or unsubstituted 3 to 8 membered monocyclic heterocyclic group, substituted or unsubstituted C 6-10 Aryl-C 1-4 Alkyl-substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, substituted or unsubstituted 5 or 6-membered monocyclic heteroaryl-C 1-4Alkyl-substituted or unsubstituted 3 to 8 membered monocyclic heterocyclic group, substituted or unsubstituted C 6-10 substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, substituted or unsubstituted 5 or 6-membered monocyclic heteroaryl and substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, substituted or unsubstituted C 6-10 Aryl-C 1-4 Alkyl-NR 01 R 02、 Substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl-C 1-4 Alkyl-NR 01 R 02 ;

[0092] R 01 、R 02 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 3-6 Monocyclic cycloalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; or,

[0093] R 01 、R 02 Together with the nitrogen atom to which it is attached, it forms a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, or a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group;

[0094] R 03 、R 04 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; wherein the C 1-6 Alkyl, C 1-6 The two hydrogen atoms on the same carbon atom of the alkoxy group are optionally replaced simultaneously by -(CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or

[0095] R 03 、R 04 Together with the carbon atom to which it is attached, it forms a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclyl, a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclyl, a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclyl, a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or a substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0096] R 05For hydrogen, deuterium, halogen, deuterated C 1-6 Alkyl or C 1-6 alkyl;

[0097] R 06 is hydrogen, deuterium or C 1-6 alkyl;

[0098] Y3 is -C(=O)R6, -C(=S)R6, -S(=O)(R 07 )(=NR 08 )、-S(=O)(R 07 )(R 08 )、-S(=O)2(R 07 )(R 08 ),-P(=O)(R 07 )(R 08 ), -C(=O)-C 1-4 Alkyl-NR6-S(=O)(R 07 )(=NR 08 ), -C(=O)-C 1-4 Alkyl-N=S(=O)(R 07 )(R 08 ) or R 11 ; R 12 For hydrogen, C 1-6 Alkyl or deuterated C 1-6 Alkyl; or

[0099] Y3, R 12 Together with the nitrogen atom to which they are attached, they form a substituted or unsubstituted nitrogen-containing 3- to 8-membered monocyclic heterocyclic group; one ring atom of the nitrogen-containing 3- to 8-membered monocyclic heterocyclic group is a nitrogen atom and optionally one or more (e.g., 1, 2, or 3) ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus;

[0100] R6 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 3-6 Monocyclic cycloalkyl, substituted or unsubstituted 3 to 8 membered monocyclic heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0101] R 11is a substituted or unsubstituted 3- to 10-membered monocyclic heterocyclyl, a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, a substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, a substituted or unsubstituted 6- to 12-membered heteroarylcycloalkyl, a substituted or unsubstituted 6- to 12-membered heteroarylcycloheterocyclyl, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclyl, or a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclyl;

[0102] R 07 is hydrogen, deuterium, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 3-6 Monocyclic cycloalkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium, C 1-6 Alkyl, C 1-6 heteroalkyl, 5- or 6-membered monocyclic heteroaryl;

[0103] R 08 is hydrogen, deuterium, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 3-6 Monocyclic cycloalkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium, C 1-6 Alkyl, C 1-6 heteroalkyl, 5- or 6-membered monocyclic heteroaryl;

[0104] R 09 is hydrogen, deuterium, halogen, substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3, or 4) groups selected from the group consisting of deuterium, halogen;

[0105] R 10 is hydrogen, deuterium, halogen, substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3, or 4) groups selected from the group consisting of deuterium, halogen;

[0106] Y5 is O or S;

[0107] Y4 is O or S;

[0108] R3 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-6 Monocyclic cycloalkyl, substituted or unsubstituted 3 to 8 membered monocyclic heterocyclic group, substituted or unsubstituted C 6-10aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0109] R 13 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 1-6 Alkyl; R 14 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or

[0110] In W4 and W5, R 13 and R 14 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 Monocyclic cycloalkyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 3- to 8-membered monocyclic heterocyclyl; or

[0111] R in W5 14 and R3 together with the atoms to which it is connected form a substituted or unsubstituted nitrogen-containing 4- to 8-membered monocyclic heterocyclic group; one ring atom of the nitrogen-containing 4- to 8-membered monocyclic heterocyclic group is a nitrogen atom and optionally one or more (such as 1, 2 or 3) ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; or

[0112] R in W6 13 and R3 and the atoms to which it is connected together form a substituted or unsubstituted nitrogen-containing 3- to 8-membered monocyclic heterocyclic group, or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl group; one ring atom of the nitrogen-containing 3- to 8-membered monocyclic heterocyclic group is a nitrogen atom and optionally one or more (e.g., 1, 2, or 3) ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus;

[0113] In each of the above groups, the substitution independently refers to the above groups being independently substituted by 1, 2, 3, 4, 5 or 6 groups selected from Group S1; the groups of Group S1 are independently selected from the following groups: -SF5, deuterium, oxo (=O), thio (=S), =CR e R f 、=NR e , halogen, cyano, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-20 Cycloalkyl, 3 to 20 membered heterocyclic group, C 6-14 Aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, -OC 3-20 Cycloalkyl, -O-3 to 20-membered heterocyclic group, -OC 6-14Aryl, -O-5 or 6-membered monocyclic heteroaryl, -O-8 to 10-membered bicyclic heteroaryl, -C≡CC 3-20 Cycloalkyl, -C≡C-3 to 20-membered heterocyclic group, -C≡CC 6-14 Aryl, -C≡C-5 or 6-membered monocyclic heteroaryl, -C≡C-8 to 10-membered bicyclic heteroaryl, -C≡CC 1-4 Alkyl-C 3-20 Cycloalkyl, -C≡CC 1-4 Alkyl-3 to 20-membered heterocyclic group, -C≡CC 1-4 Alkyl-C 6-14 Aryl, -C≡CC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C≡CC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-C 3-20 Cycloalkyl, -C 1-4 Alkyl-OC 3-20 Cycloalkyl, -C 1-4 alkyl-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C 6-14 Aryl, -C 1-4 Alkyl-OC 6-14 Aryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -OC 1- 4-alkyl-hydroxyl, -OC 1-4 Alkyl-cyano, -OC 1-4 Alkyl-C 1-6 Alkyl, -OC 1-4 Alkyl-C 1-6 Alkoxy, -OC 1-4 Alkyl-C 3-20 Cycloalkyl, -OC 1-4 Alkyl-OC 3-20 Cycloalkyl, -OC 1-4 Alkyl-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -OC1-4 Alkyl-C 6-14 Aryl, -OC 1-4 Alkyl-OC 6-14 Aryl, -OC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -OC 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-20 Cycloalkyl, -S(=O)2-3 to 20-membered heterocyclic group, -C(=O)OC 1-6 Alkyl, -C(=O)OC 3-20 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-20 Cycloalkyl, -C(=O)-C 6-14 Aryl, -NR a1 R b1 、-C(=O)-NR a1 R b1 、-C(=O)-NR d1 -C 1-4 Alkyl-R c1 、-OR c1 、-C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-20 Cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C(=O)OC 1-6 Alkyl, -C 1-4 Alkyl-C(=O)OC 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 1-6 Alkyl, -C 1-4 Alkyl-C(=O)-C 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 6-14 aryl, -C(=O)-5 or 6-membered monocyclic heteroaryl, -C(=O)-8 to 10-membered bicyclic heteroaryl, -C(=O)-C 1-6 Alkyl-C 3-20 Cycloalkyl, -C(=O)-C 1-6 alkyl-3 to 20-membered heterocyclic group, -C(=O)-C 1-6 Alkyl-C6-14 Aryl, -C(=O)-C 1-6 Alkyl-5 or 6-membered monocyclic heteroaryl, -C(=O)-C 1-6 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-NR a1 R b1 、-C 1-4 Alkyl-C(=O)-NR a1 R b1 、-C≡CC(=O)-NR a1 R b1 、-C≡CC 1-4 Alkyl-C(=O)-NR a1 R b1 、-C 1-4 Alkyl-OR c1 、-C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2, -C 1-4 Alkyl-NR d1 -C(=O)-R c1 、-C 1-4 Alkyl-NR d1 -C(=O)-NR a1 R b1 、-C 1-4 Alkyl-NR d1 -S(=O)2-R c1 、-C 1-4 Alkyl-S(=O)2-NR a1 R b1 、-C 1-4 Alkyl-NR d1 -S(=O)2-NR a1 R b1 、-NR d1 -C(=O)-R c1 、-NR d1 -C(=O)-C 1-4 Alkyl-R c1 、-NR d1 -C(=O)-NR a1 R b1 、-NR d1 -S(=O)2-R c1 、-S(=O)2-NR a1 R b1 、-NR d1 -S(=O)2-NR a1 R b1 、-P(=O)-(C 1-6Alkyl) 2; wherein the C 1-6 Alkyl, the C 1-6 Alkoxy, the C 2-6 Alkenyl, the C 2-6 Each alkynyl group is independently optionally substituted by 1, 2 or 3 groups selected from halogen, deuterium, cyano or hydroxy; 3-20 Cycloalkyl, the 3 to 20 membered heterocyclic group, the C 6-14 The aryl group, the 5- or 6-membered monocyclic heteroaryl group, and the 8- to 10-membered bicyclic heteroaryl group are each independently optionally substituted by 1, 2, 3 or 4 groups selected from Group S2;

[0114] In the above groups, each R a1 、R b1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-6 Monocyclic cycloalkyl, -S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-6Monocyclic cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-6 Monocyclic cycloalkyl, -C(=O)-3 to 6-membered monocyclic heterocyclic group; wherein the C 3-6 The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 alkyl)2; or

[0115] Each R a1 and R b1 Together with the nitrogen atoms to which they are attached, they form a 3- to 20-membered heterocyclic group; wherein the 3- to 20-membered heterocyclic group is independently optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1- 6 alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2;

[0116] In the above groups, each R d1 Each independently is H, C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0117] In the above groups, each R c1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl or -C 1-4 Alkyl-8 to 10 membered bicyclic heteroaryl; said C 3-6 The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2;

[0118] In the above groups, each group of S2 is independently selected from the following groups: deuterium, oxo (=O), thio (=S), CR e R f 、=NR e , halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -(C=O)-NHC 1-6 Alkyl, -(C=O)-N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 alkyl)2, -(C=O)C 1-6 Alkyl, -SF5;

[0119] In the above groups, the -C 1-4 Alkyl- is unsubstituted; or -C 1-4 1, 2, 3 or 4 hydrogen atoms on the alkyl group are independently selected from halogen, cyano, hydroxyl, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -CH2-hydroxy, -CH2-cyano, phenyl group substituted; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by -(CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by =CR e R f replace;

[0120] In the above groups, R e are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0121] In the above groups, R f are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0122] In the above groups, one or more (e.g., 1, 2, 3, or 4) ring atoms of the 3- to 6-membered monocyclic heterocyclic group, the 3- to 10-membered monocyclic heterocyclic group, or the 3- to 8-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; 1-6One or more (such as 1, 2, 3 or 4) ring atoms of the heteroalkyl group are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (such as 1, 2, 3, 4 or 5) ring atoms of the 7-12 membered bicyclic heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (such as 1, 2, 3, 4 or 5) ring atoms of the 3-20 membered heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (such as 1, 2, 3, 4 or 5) ring atoms of the 5- or 6-membered monocyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the aryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- to 15-membered tricyclic heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloalkyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloheterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus;

[0123] Wherein, when the ring atom is a sulfur atom, the sulfur atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above;

[0124] Wherein, when the ring atom is a phosphorus atom, the phosphorus atom is optionally substituted by one or two groups selected from oxo and =NR e The group substituted; R e Same definition as above.

[0125] The first aspect of the present disclosure further provides a compound represented by formula (IC) or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof:

[0126] Where,

[0127] Ring A is

[0128] is phenyl, 5- or 6-membered heteroaryl, or 5- or 6-membered heterocyclic group; one or two ring atoms of the 5- or 6-membered heteroaryl group are heteroatoms selected from nitrogen, oxygen, or sulfur; one or two ring atoms of the 5- or 6-membered heterocyclic group are heteroatoms selected from nitrogen, oxygen, or sulfur; and the 5- or 6-membered heterocyclic group is a fully saturated heterocyclic group or a partially unsaturated heterocyclic group; Indicates the site of connection with the left part;

[0129] Wherein, W1 and W2 are each independently selected from C or N;

[0130] W3 and W4 are each independently selected from CR 13 , O, S, N or NH;

[0131] W6 selected from CR 13 or N;

[0132] W5 is selected from absent, O or CR 14 ;

[0133] X is

[0134] Y1 is N or CH; wherein N can be oxidized (N + -O - );

[0135] Y2 is N or CH; wherein N can be oxidized (N + -O - );

[0136] R 42 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 43 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or

[0137] R 42 and R 43 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0138] R 40 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 41 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or

[0139] R 40 and R 41 Connected to form -CH2- or -CH2CH2-; wherein -CH2- or -CH2CH2- is optionally replaced by one or more selected from deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl radical substitution;

[0140] When ring A is When L1 is -N(R 00 )C(=O)-、-N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C1- 4-alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -L2-substituted or unsubstituted C 6-10 Aryl-, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl-, or -L2-substituted or unsubstituted 3- to 8-membered heterocyclic group-; L2 is C 3-6 Cycloalkyl, 3 to 8 membered heterocyclic group, -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-;

[0141] When ring A is hour;

[0142] When at least one of W1, W2, W3, W4, and W5 is a heteroatom selected from O, S, N, or NH; L1 is -N(R 00 )C(=O)-、-N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -L2-substituted or unsubstituted C 6-10 Aryl-, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl-, or -L2-substituted or unsubstituted 3- to 8-membered heterocyclyl-;

[0143] L2 is -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-;

[0144] or,

[0145] When W1 and W2 are C; W3, W4, and W5 are CH, L1 is -N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-N(R 00 )C(=O)-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O- or -substituted or unsubstituted C 2-6 alkenyl-O-;

[0146] R 00 is hydrogen or C 1-6 alkyl;

[0147] R1 is hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0148] R2 is hydrogen, deuterium, halogen, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0149] R 3a C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0150] R3 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0151] R 4ais substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 3-6 a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0152] R5 is hydrogen, -NR 01 R 02 、-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C(=O)-NR 01 R 02 、-C 1-4 Alkyl-C(=O)-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C(=O)-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(=O)-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-N(R 06 )C(=O)-NR 01 R 02 、-C 1-4 Alkyl-N(R 06 )C(=O)-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-N(R 06 )C(=O)-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-N(R 06 )C(=O)-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-OC 1-4 Alkyl-NR 01 R 02 、-OC 1-4 Alkyl-C(R05 )R 03 R 04 、-OC 1-4 Alkyl-N(R 06 )C(=O)-R 03 、-OC(R 05 )R 03 R 04 、-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-N(R 06 )C(=O)-NR 01 R 02 、- N(R 06 )C(=O)-C(R 05 )R 03 R 04 、-C 2-4 Alkynyl-NR 01 R 02 、-C 2-4 Alkynyl-C(=O)-NR 01 R 02 、-C 2-4 Alkynyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkynyl-NR 01 R 02 、-C 1-4 Alkyl-C 2-4 Alkynyl-C(R 05 )R 03 R 04 、-C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 、-C 2-4 Alkynyl-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 、-CH=CR 01 R 02 、-C 2-4 Alkenyl-NR 01 R02 、-C 2-4 Alkenyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkenyl-NR 01 R 02 、-C 1-4 Alkyl-C 2-4 Alkenyl-C(R 05 )R 03 R 04 、-C 2-4 Alkenyl-C 1-4 Alkyl-NR 01 R 02 、-C 2-4 Alkenyl-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkenyl-C 1-4 Alkyl-NR 01 R 02 、-C=CR 03 R 04 、-OC 1-4 Alkyl-substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, -OC 1-4 Alkyl-substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, -OC 1-4 alkyl-substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, -O-substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group, -O-substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, -O-substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, -N=S(=O)(R 06 )(-C 1-4 Alkyl-NR 01 R 02 )、-N(R 06 )-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)(R 06 )(=NR 06 )、-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )(=NR 06 )、-S(=O)2(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)(-C 1-4Alkyl-NR 01 R 02 )、-S(=O)2(-C 1-4 Alkyl-C(R 05 )R 03 R 04 )、-S(=O)(-C 1-4 Alkyl-C(R 05 )R 03 R 04 );

[0153] R 01 、R 02 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; or,

[0154] R 01 、R 02 Together with the nitrogen atom to which it is attached, it forms a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, or a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group;

[0155] R 03 、R 04 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; wherein the C 1-6 Alkyl, C 1-6 The two hydrogen atoms on the same carbon atom of the alkoxy group are optionally replaced simultaneously by -(CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or

[0156] R 03 、R 04 Together with the carbon atom to which it is attached, it forms a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclyl, a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclyl, a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclyl, a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or a substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0157] R 05 For hydrogen, deuterium, halogen, deuterated C 1-6 Alkyl or C 1-6 alkyl;

[0158] R 06 is hydrogen, deuterium or C 1-6 alkyl;

[0159] Y3 is -C(=O)R6, -C(=S)R6, -S(=O)(R 07 )(=NR 08 )、-S(=O)(R 07 )(R 08 )、-S(=O)2(R 07 )(R 08 ),-P(=O)(R 07 )(R 08 ), -C(=O)-C 1-4 Alkyl-NR6-S(=O)(R 07 )(=NR 08 ), -C(=O)-C 1-4 Alkyl-N=S(=O)(R 07 )(R 08 ) or R 11 ; R 12 For hydrogen, C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0160] or Y3, R 12 Together with the nitrogen atom to which they are attached, they form a substituted or unsubstituted nitrogen-containing 3- to 8-membered heterocyclic group; one ring atom of the nitrogen-containing 3- to 8-membered heterocyclic group is a nitrogen atom and optionally one or more (e.g., 1, 2, or 3) ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus;

[0161] R6 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0162] R 11 is a substituted or unsubstituted 3- to 10-membered heterocyclyl, a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, a substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, a substituted or unsubstituted 6- to 12-membered heteroarylcycloalkyl, a substituted or unsubstituted 6- to 12-membered heteroarylheterocyclyl, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclyl, or a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclyl;

[0163] R 07 is hydrogen, deuterium, substituted or unsubstituted C1-6 Alkyl or substituted or unsubstituted C 3-6 Cycloalkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium, C 1-6 Alkyl, C 1-6 heteroalkyl, 5- or 6-membered monocyclic heteroaryl;

[0164] R 08 is hydrogen, deuterium, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 3-6 Cycloalkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium, C 1-6 Alkyl, C 1-6 heteroalkyl, 5- or 6-membered monocyclic heteroaryl;

[0165] R 09 is hydrogen, deuterium, halogen, substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3, or 4) groups selected from the group consisting of deuterium, halogen;

[0166] R 10 is hydrogen, deuterium, halogen, substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3, or 4) groups selected from the group consisting of deuterium, halogen;

[0167] Y5 is O or S;

[0168] Y4 is O or S;

[0169] R 13 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 14 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or

[0170] R 13 and R 14 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0171] In each of the above groups, the substitution independently refers to the above groups being independently substituted by 1, 2, 3, 4, 5 or 6 groups selected from Group S1; the groups of Group S1 are independently selected from the following groups: -SF5, deuterium, oxo (=O), thio (=S), =CR e R f 、=NR e , halogen, cyano, hydroxyl, carboxyl, nitro, C 1-6Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-20 Cycloalkyl, 3 to 20 membered heterocyclic group, C 6-14 Aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, -OC 3-20 Cycloalkyl, -O-3 to 20-membered heterocyclic group, -OC 6-14 Aryl, -O-5 or 6-membered monocyclic heteroaryl, -O-8 to 10-membered bicyclic heteroaryl, -C≡CC 3-20 Cycloalkyl, -C≡C-3 to 20-membered heterocyclic group, -C≡CC 6-14 Aryl, -C≡C-5 or 6-membered monocyclic heteroaryl, -C≡C-8 to 10-membered bicyclic heteroaryl, -C≡CC 1-4 Alkyl-C 3-20 Cycloalkyl, -C≡CC 1-4 Alkyl-3 to 20-membered heterocyclic group, -C≡CC 1-4 Alkyl-C 6-14 Aryl, -C≡CC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C≡CC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-C 3-20 Cycloalkyl, -C 1-4 Alkyl-OC 3-20 Cycloalkyl, -C 1-4 alkyl-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C 6-14 Aryl, -C 1-4 Alkyl-OC 6-14 Aryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -OC 1- 4-alkyl-hydroxyl, -OC 1-4 Alkyl-cyano, -OC 1-4 Alkyl-C 1-6 Alkyl, -OC 1-4Alkyl-C 1-6 Alkoxy, -OC 1-4 Alkyl-C 3-20 Cycloalkyl, -OC 1-4 Alkyl-OC 3-20 Cycloalkyl, -OC 1-4 Alkyl-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-C 6-14 Aryl, -OC 1-4 Alkyl-OC 6-14 Aryl, -OC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -OC 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-20 Cycloalkyl, -S(=O)2-3 to 20-membered heterocyclic group, -C(=O)OC 1-6 Alkyl, -C(=O)OC 3-20 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-20 Cycloalkyl, -C(=O)-C 6-14 Aryl, -NR a1 R b1 、-C(=O)-NR a1 R b1 、-C(=O)-NR d1 -C 1-4 Alkyl-R c1 、-OR c1 、-C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-20 Cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C(=O)OC 1-6 Alkyl, -C 1-4 Alkyl-C(=O)OC 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 1-6 Alkyl, -C 1-4 Alkyl-C(=O)-C 3-20 Cycloalkyl, -C 1-4Alkyl-C(=O)-C 6-14 aryl, -C(=O)-5 or 6-membered monocyclic heteroaryl, -C(=O)-8 to 10-membered bicyclic heteroaryl, -C(=O)-C 1-6 Alkyl-C 3-20 Cycloalkyl, -C(=O)-C 1-6 alkyl-3 to 20-membered heterocyclic group, -C(=O)-C 1-6 Alkyl-C 6-14 Aryl, -C(=O)-C 1-6 Alkyl-5 or 6-membered monocyclic heteroaryl, -C(=O)-C 1-6 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-NR a1 R b1 、-C 1-4 Alkyl-C(=O)-NR a1 R b1 、-C≡CC(=O)-NR a1 R b1 、-C≡CC 1-4 Alkyl-C(=O)-NR a1 R b1 、-C 1-4 Alkyl-OR c1 、-C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2, -C 1-4 Alkyl-NR d1 -C(=O)-R c1 、-C 1-4 Alkyl-NR d1 -C(=O)-NR a1 R b1 、-C 1-4 Alkyl-NR d1 -S(=O)2-R c1 、-C 1-4 Alkyl-S(=O)2-NR a1 R b1 、-C 1-4 Alkyl-NR d1 -S(=O)2-NR a1 R b1 、-NR d1 -C(=O)-R c1 、-NR d1 -C(=O)-C 1-4 Alkyl-R c1 、-NR d1 -C(=O)-NR a1 Rb1 、-NR d1 -S(=O)2-R c1 、-S(=O)2-NR a1 R b1 、-NR d1 -S(=O)2-NR a1 R b1 、-P(=O)-(C 1-6 Alkyl) 2; wherein the C 1-6 Alkyl, the C 1-6 Alkoxy, the C 2-6 Alkenyl, the C 2-6 Each alkynyl group is independently optionally substituted by 1, 2 or 3 groups selected from halogen, deuterium, cyano or hydroxy; 3-20 Cycloalkyl, the 3 to 20 membered heterocyclic group, the C 6-14 The aryl group, the 5- or 6-membered monocyclic heteroaryl group, and the 8- to 10-membered bicyclic heteroaryl group are each independently optionally substituted by 1, 2, 3 or 4 groups selected from Group S2;

[0172] In the above groups, each R a1 、R b1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl, -C 1-4Alkyl-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-6 Monocyclic cycloalkyl, -S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-6 Monocyclic cycloalkyl, -C(=O)-3 to 6-membered monocyclic heterocyclic group; wherein the C 3-6 The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 alkyl)2; or

[0173] Each R a1 and R b1 Together with the nitrogen atom to which they are attached, they form a 3- to 20-membered heterocyclic group; wherein the 3- to 20-membered heterocyclic group is independently optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1- 6 alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2;

[0174] In the above groups, each Rd1 Each independently is H, C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0175] In the above groups, each R c1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl or -C 1-4 Alkyl-8 to 10 membered bicyclic heteroaryl; said C 3-6 The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6Alkyl)2;

[0176] In the above groups, each group of S2 is independently selected from the following groups: deuterium, oxo (=O), thio (=S), CR e R f 、=NR e , halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -(C=O)-NHC 1-6 Alkyl, -(C=O)-N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 alkyl)2, -(C=O)C 1-6 Alkyl, -SF5;

[0177] In the above groups, the -C 1-4 Alkyl- is unsubstituted; or -C 1-4 1, 2, 3 or 4 hydrogen atoms on the alkyl group are independently selected from halogen, cyano, hydroxyl, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -CH2-hydroxy, -CH2-cyano, phenyl group substituted; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by -(CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by =CR e R f replace;

[0178] In the above groups, R e are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0179] In the above groups, R f are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6alkyl;

[0180] In each of the above groups, one or more (e.g., 1, 2, 3, or 4) ring atoms of the 3- to 8-membered heterocyclic group, the 3- to 10-membered heterocyclic group, or the 3- to 8-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; 1-6 One or more (e.g., 1, 2, 3, or 4) ring atoms of the heteroalkyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 7- to 12-membered bicyclic heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 3- to 20-membered heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- or 6-membered monocyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 8- to 10-membered bicyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 3- to 6-membered monocyclic heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- to 15-membered tricyclic heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloalkyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloheterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloheterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus;

[0181] Wherein, when the ring atom is a sulfur atom, the sulfur atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above;

[0182] Wherein, when the ring atom is a phosphorus atom, the phosphorus atom is optionally substituted by one or two groups selected from oxo and =NR e The group substituted; R e Same definition as above.

[0183] The first aspect of the present disclosure further provides a compound represented by formula (IB) or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof:

[0184] Where,

[0185] Ring A is is phenyl, 5- or 6-membered heteroaryl, or 5- or 6-membered heterocyclic group; one or two ring atoms of the 5- or 6-membered heteroaryl group are heteroatoms selected from nitrogen, oxygen, or sulfur; one or two ring atoms of the 5- or 6-membered heterocyclic group are heteroatoms selected from nitrogen, oxygen, or sulfur; the 5- or 6-membered heterocyclic group is a fully saturated heterocyclic group or a partially unsaturated heterocyclic group; or

[0186] Wherein, W1 and W2 are each independently selected from C or N;

[0187] W3 and W4 are each independently selected from CR 13 , O, S, N or NH;

[0188] W5 is selected from absent, O or CR 14 ;

[0189] W6 selected from CR 13 or N;

[0190] X is

[0191] Y1 is N or CH; wherein N can be oxidized (N + -O - );

[0192] Y2 is N or CH; wherein N can be oxidized (N + -O - );

[0193] R 42 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 43 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or

[0194] R 42 and R 43 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0195] R 40 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 41 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or

[0196] R 40 and R 41 Connected to form -CH2- or -CH2CH2-; wherein -CH2- or -CH2CH2- is optionally substituted by halogen;

[0197] Ring A is When L1 is -N(R00 )C(=O)-、-N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-, substituted or unsubstituted C 3- 6-membered cycloalkyl, substituted or unsubstituted 3- to 8-membered heterocyclic group, substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -L2-substituted or unsubstituted C 6-10 Aryl-, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl-, or -L2-substituted or unsubstituted 3- to 8-membered heterocyclic group-; L2 is -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-;

[0198] Ring A is hour;

[0199] When at least one of W1, W2, W3, W4, and W5 is a heteroatom selected from O, S, N, or NH; L1 is -N(R 00 )C(=O)-、-N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -L2-substituted or unsubstituted C6-10 Aryl-, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl-, or -L2-substituted or unsubstituted 3- to 8-membered heterocyclyl-;

[0200] L2 is -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-;

[0201] or,

[0202] When W1 and W2 are C; W3, W4, and W5 are CH, L1 is -N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-N(R 00 )C(=O)-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O- or -substituted or unsubstituted C 2-6 alkenyl-O-;

[0203] R 00 is hydrogen or C 1-6 alkyl;

[0204] R1 is hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0205] R2 is hydrogen, deuterium, halogen, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0206] R 3a C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0207] R3 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0208] R 4a is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 3-6 a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0209] R5 is hydrogen, -NR 01 R 02 、-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C(=O)-NR 01 R 02 、-C 1-4 Alkyl-C(=O)-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C(=O)-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(=O)-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-N(R 06 )C(=O)-NR 01 R 02 、-C 1-4 Alkyl-N(R 06 )C(=O)-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-N(R 06 )C(=O)-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-N(R 06 )C(=O)-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-OC1-4 Alkyl-NR 01 R 02 、-OC 1-4 Alkyl-C(R 05 )R 03 R 04 、-OC 1-4 Alkyl-N(R 06 )C(=O)-R 03 、-OC(R 05 )R 03 R 04 、-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-N(R 06 )C(=O)-NR 01 R 02 、-N(R 06 )C(=O)-C(R 05 )R 03 R 04 、-C 2-4 Alkynyl-NR 01 R 02 、-C 2-4 Alkynyl-C(=O)-NR 01 R 02 、-C 2-4 Alkynyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkynyl-NR 01 R 02 、-C 1-4 Alkyl-C 2-4 Alkynyl-C(R 05 )R 03 R 04 、-C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 、-C 2-4 Alkynyl-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 、-CH=CR01 R 02 、-C 2-4 Alkenyl-NR 01 R 02 、-C 2-4 Alkenyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkenyl-NR 01 R 02 、-C 1-4 Alkyl-C 2-4 Alkenyl-C(R 05 )R 03 R 04 、-C 2-4 Alkenyl-C 1-4 Alkyl-NR 01 R 02 、-C 2-4 Alkenyl-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkenyl-C 1-4 Alkyl-NR 01 R 02 、-C=CR 03 R 04 、-OC 1-4 Alkyl-substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, -OC 1-4 Alkyl-substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, -OC 1-4 alkyl-substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, -O-substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group, -O-substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, -O-substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, -N=S(=O)(R 06 )(-C 1-4 Alkyl-NR 01 R 02 )、-N(R 06 )-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)(R 06 )(=NR 06 )、-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )(=NR 06 )、-S(=O)2(-C1-4 Alkyl-NR 01 R 02 )、-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)2(-C 1-4 Alkyl-C(R 05 )R 03 R 04 )、-S(=O)(-C 1-4 Alkyl-C(R 05 )R 03 R 04 );

[0210] R 01 、R 02 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; or,

[0211] R 01 、R 02 Together with the nitrogen atom to which it is attached, it forms a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, or a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group;

[0212] R 03 、R 04 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; wherein optionally, the C 1-6 Alkyl, C 1-6 The two hydrogen atoms on the same carbon atom of the alkoxy group are simultaneously replaced by -(CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or

[0213] R 03 、R 04 Together with the carbon atom to which it is attached, it forms a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclyl, a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclyl, a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclyl, a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or a substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0214] R05 For hydrogen, deuterium, halogen, deuterated C 1-6 Alkyl or C 1-6 alkyl;

[0215] R 06 is hydrogen, deuterium or C 1-6 alkyl;

[0216] Y3 is -C(=O)R6, -C(=S)R6, -S(=O)(R 07 )(=NR 08 )、-S(=O)(R 07 )(R 08 )、-S(=O)2(R 07 )(R 08 ),-P(=O)(R 07 )(R 08 ), -C(=O)-C 1-4 Alkyl-NR6-S(=O)(R 07 )(=NR 08 ), -C(=O)-C 1-4 Alkyl-N=S(=O)(R 07 )(R 08 ) or R 11 ; R 12 For hydrogen, C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0217] or Y3, R 12 Together with the nitrogen atom to which they are attached, they form a substituted or unsubstituted nitrogen-containing 3- to 8-membered heterocyclic group; one ring atom of the nitrogen-containing 3- to 8-membered heterocyclic group is a nitrogen atom and optionally one or more (e.g., 1, 2, or 3) ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus;

[0218] R6 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0219] R 11is a substituted or unsubstituted 3- to 10-membered heterocyclyl, a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, a substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, a substituted or unsubstituted 6- to 12-membered heteroarylcycloalkyl, a substituted or unsubstituted 6- to 12-membered heteroarylheterocyclyl, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclyl, or a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclyl;

[0220] R 07 is hydrogen, deuterium, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 3-6 Cycloalkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium, C 1-6 Alkyl, C 1-6 heteroalkyl, 5- or 6-membered monocyclic heteroaryl;

[0221] R 08 is hydrogen, deuterium, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 3-6 Cycloalkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium, C 1-6 Alkyl, C 1-6 heteroalkyl, 5- or 6-membered monocyclic heteroaryl;

[0222] R 09 is hydrogen, deuterium, halogen, substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3, or 4) groups selected from the group consisting of deuterium, halogen;

[0223] R 10 is hydrogen, deuterium, halogen, substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3, or 4) groups selected from the group consisting of deuterium, halogen;

[0224] Y5 is O or S;

[0225] Y4 is O or S;

[0226] R 13 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 14 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or

[0227] R 13 and R 14 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0228] In each of the above groups, the substitution independently refers to the above groups being independently substituted by 1, 2, 3, 4, 5 or 6 groups selected from Group S1; the groups of Group S1 are independently selected from the following groups: deuterium, oxo (=O), thio (=S), CR e R f 、=NR e , halogen, cyano, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-20 Cycloalkyl, 3 to 20 membered heterocyclic group, C 6-14 Aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, -OC 3-20 Cycloalkyl, -O-3 to 20-membered heterocyclic group, -OC 6-14 Aryl, -O-5 or 6-membered monocyclic heteroaryl, -O-8 to 10-membered bicyclic heteroaryl, -C≡CC 3-20 Cycloalkyl, -C≡C-3 to 20-membered heterocyclic group, -C≡CC 6-14 Aryl, -C≡C-5 or 6-membered monocyclic heteroaryl, -C≡C-8 to 10-membered bicyclic heteroaryl, -C≡CC 1-4 Alkyl-C 3-20 Cycloalkyl, -C≡CC 1-4 Alkyl-3 to 20-membered heterocyclic group, -C≡CC 1-4 Alkyl-C 6-14 Aryl, -C≡CC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C≡CC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-C 3-20 Cycloalkyl, -C 1-4 Alkyl-OC 3-20 Cycloalkyl, -C 1-4 alkyl-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C 6-14 Aryl, -C 1-4 Alkyl-OC 6-14 Aryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -OC 1-4 Alkyl-hydroxyl, -OC 1-4 Alkyl-cyano, -OC 1-4 Alkyl-C 1-6 Alkyl, -OC 1-4 Alkyl-C 1-6 Alkoxy, -OC 1-4 Alkyl-C 3-20 Cycloalkyl, -OC 1-4 Alkyl-OC 3-20 Cycloalkyl, -OC 1-4 Alkyl-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-C 6-14 Aryl, -OC 1-4 Alkyl-OC 6-14 Aryl, -OC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -OC 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-20 Cycloalkyl, -S(=O)2-3 to 20-membered heterocyclic group, -C(=O)OC 1-6 Alkyl, -C(=O)OC 3-20 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-20 Cycloalkyl, -C(=O)-C 6-14 Aryl, -NR a1 R b1 、-C(=O)-NR a1 R b1 、-C(=O)-NR d1 -C 1-4 Alkyl-R c1 、-OR c1 、-C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-20 Cycloalkyl, -C 1- 4-alkyl-S(=O)2-3 to 20-membered heterocyclic group, -C1-4 Alkyl-C(=O)OC 1-6 Alkyl, -C 1-4 Alkyl-C(=O)OC 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 1-6 Alkyl, -C 1-4 Alkyl-C(=O)-C 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 6-14 aryl, -C(=O)-5 or 6-membered monocyclic heteroaryl, -C(=O)-8 to 10-membered bicyclic heteroaryl, -C(=O)-C 1-6 Alkyl-C 3-20 Cycloalkyl, -C(=O)-C 1-6 alkyl-3 to 20-membered heterocyclic group, -C(=O)-C 1-6 Alkyl-C 6-14 Aryl, -C(=O)-C 1-6 Alkyl-5 or 6-membered monocyclic heteroaryl, -C(=O)-C 1-6 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-NR a1 R b1 、-C 1-4 Alkyl-C(=O)-NR a1 R b1 、-C≡CC(=O)-NR a1 R b1 、-C≡CC 1-4 Alkyl-C(=O)-NR a1 R b1 、-C 1-4 Alkyl-OR c1 、-C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2, -C 1-4 Alkyl-NR d1 -C(=O)-R c1 、-C 1-4 Alkyl-NR d1 -C(=O)-NR a1 R b1 、-C 1-4 Alkyl-NR d1 -S(=O)2-R c1 、-C 1-4 Alkyl-S(=O)2-NR a1 R b1 、-C 1-4 Alkyl-NR d1-S(=O)2-NR a1 R b1 、-NR d1 -C(=O)-R c1 、-NR d1 -C(=O)-C 1-4 Alkyl-R c1 、-NR d1 -C(=O)-NR a1 R b1 、-NR d1 -S(=O)2-R c1 、-S(=O)2-NR a1 R b1 、-NR d1 -S(=O)2-NR a1 R b1 、-P(=O)-(C 1-6 Alkyl) 2; wherein the C 1-6 Alkyl, the C 1-6 Alkoxy, the C 2-6 Alkenyl, the C 2-6 Each alkynyl group is independently optionally substituted by 1, 2 or 3 groups selected from halogen, deuterium, cyano or hydroxy; 3-20 Cycloalkyl, the 3 to 20 membered heterocyclic group, the C 6-14 The aryl group, the 5- or 6-membered monocyclic heteroaryl group, and the 8- to 10-membered bicyclic heteroaryl group are each independently optionally substituted by 1, 2, 3 or 4 groups selected from Group S2;

[0229] In the above groups, each R a1 、R b1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC3-6 Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-6 Monocyclic cycloalkyl, -S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-6 Monocyclic cycloalkyl, -C(=O)-3 to 6-membered monocyclic heterocyclic group; wherein the C 3-6 The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 alkyl)2; or

[0230] Each R a1 and R b1 Together with the nitrogen atom to which they are attached, they form a 3- to 20-membered heterocyclic group; wherein the 3- to 20-membered heterocyclic group is independently optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1- 6 alkoxy, halogenated C 1-6Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2;

[0231] In the above groups, each R d1 Each independently is H, C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0232] In the above groups, each R c1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl or -C 1-4 Alkyl-8 to 10 membered bicyclic heteroaryl; said C 3-6 The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2;

[0233] In the above groups, each group of S2 is independently selected from the following groups: deuterium, oxo (=O), thio (=S), CR e R f 、=NR e , halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -(C=O)-NHC 1-6 Alkyl, -(C=O)-N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 alkyl)2, -(C=O)C 1-6 Alkyl, -SF5;

[0234] In the above groups, the -C 1-4 Alkyl- is unsubstituted; or -C 1-4 1, 2, 3 or 4 hydrogen atoms on the alkyl group are independently selected from halogen, cyano, hydroxyl, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -CH2-hydroxy, -CH2-cyano, phenyl group substituted; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by -(CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by =CR e R f replace;

[0235] In the above groups, Re are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0236] In the above groups, R f are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0237] In each of the above groups, one or more (e.g., 1, 2, 3, or 4) ring atoms of the 3- to 8-membered heterocyclic group, the 3- to 10-membered heterocyclic group, or the 3- to 8-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; 1-6 One or more (e.g., 1, 2, 3, or 4) ring atoms of the heteroalkyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 7- to 12-membered bicyclic heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 3- to 20-membered heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- or 6-membered monocyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 8- to 10-membered bicyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 3- to 6-membered monocyclic heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- to 15-membered tricyclic heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloalkyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloheterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloheterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus;

[0238] Wherein, when the ring atom is a sulfur atom, the sulfur atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above;

[0239] Wherein, when the ring atom is a phosphorus atom, the phosphorus atom is optionally substituted by one or two groups selected from oxo and =NR e The group substituted; R e Same definition as above.

[0240] The first aspect of the present disclosure further provides a compound represented by formula (IA) or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof:

[0241] Where,

[0242] Ring A is

[0243] is phenyl, 5- or 6-membered heteroaryl, or 5- or 6-membered heterocyclic group; one or two ring atoms of the 5- or 6-membered heteroaryl group are heteroatoms selected from nitrogen, oxygen, or sulfur; one or two ring atoms of the 5- or 6-membered heterocyclic group are heteroatoms selected from nitrogen, oxygen, or sulfur; and the 5- or 6-membered heterocyclic group is a fully saturated heterocyclic group or a partially unsaturated heterocyclic group;

[0244] Wherein, W1 and W2 are each independently selected from C or N;

[0245] W3 and W4 are each independently selected from CR 13 , O, S, N or NH;

[0246] W5 is selected from absent, O or CR 14 ;

[0247] W6 selected from CR 13 or N;

[0248] X is

[0249] Y1 is N or CH; wherein N can be oxidized (N + -O - );

[0250] Y2 is N or CH; wherein N can be oxidized (N + -O - );

[0251] R 42 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 43 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or

[0252] R 42 and R 43 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0253] Ring A is When L1 is -N(R 00 )C(=O)-、-N(R00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-, substituted or unsubstituted C 3- 6-membered cycloalkyl, substituted or unsubstituted 3- to 8-membered heterocyclic group, substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -L2-substituted or unsubstituted C 6-10 Aryl, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl or -L2-substituted or unsubstituted 3- to 8-membered heterocyclic group; L2 is -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-;

[0254] Ring A is hour;

[0255] When at least one of W1, W2, W3, W4, and W5 is a heteroatom selected from O, S, N, or NH; L1 is -N(R 00 )C(=O)-、-N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -L2-substituted or unsubstituted C 6-10aryl, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or -L2-substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0256] L2 is -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-;

[0257] or,

[0258] When W1 and W2 are C, W3, W4, and W5 are CH, L1 is -N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-N(R 00 )C(=O)-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O- or -substituted or unsubstituted C 2-6 alkenyl-O-;

[0259] Alternatively, when W1, W2, W3, W4, and W5 are all C or CH, L1 is -N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O- or -substituted or unsubstituted C 2-6 Alkenyl-O-; R 00 is hydrogen or C 1-6 alkyl;

[0260] R1 is hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0261] R2 is hydrogen, deuterium, halogen, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0262] R 3a C1-6 Alkyl or deuterated C 1-6 Alkyl; R3 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0263] R 4a is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 3-6 Cycloalkyl or substituted or unsubstituted 3 to 8 membered heterocyclic group; R5 is hydrogen, -NR 01 R 02 、-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C(=O)-NR 01 R 02 、-C 1-4 Alkyl-C(=O)-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C(=O)-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(=O)-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-N(R 06 )C(=O)-NR 01 R 02 、-C 1-4 Alkyl-N(R 06 )C(=O)-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-N(R06 )C(=O)-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-N(R 06 )C(=O)-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-OC 1-4 Alkyl-NR 01 R 02 、-OC 1-4 Alkyl-C(R 05 )R 03 R 04 、-OC 1-4 Alkyl-N(R 06 )C(=O)-R 03 、-OC(R 05 )R 03 R 04 、-C 1-4 Alkyl-NR 01 R 02 、-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-N(R 06 )C(=O)-NR 01 R 02 、-N(R 06 )C(=O)-C(R 05 )R 03 R 04 、-C 2-4 Alkynyl-NR 01 R 02 、-C 2-4 Alkynyl-C(=O)-NR 01 R 02 、-C 2-4 Alkynyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkynyl-NR 01 R 02 、-C 1-4 Alkyl-C 2-4 Alkynyl-C(R 05 )R 03 R 04 、-C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R02 、-C 2-4 Alkynyl-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 、-CH=CR 01 R 02 、-C 2-4 Alkenyl-NR 01 R 02 、-C 2-4 Alkenyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkenyl-NR 01 R 02 、-C 1-4 Alkyl-C 2-4 Alkenyl-C(R 05 )R 03 R 04 、-C 2-4 Alkenyl-C 1-4 Alkyl-NR 01 R 02 、-C 2-4 Alkenyl-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-C 1-4 Alkyl-C 2-4 Alkenyl-C 1-4 Alkyl-NR 01 R 02 、-C=CR 03 R 04 、-OC 1-4 Alkyl-substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, -OC 1-4 Alkyl-substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, -OC 1-4 alkyl-substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, -O-substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group, -O-substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, -O-substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, -N=S(=O)(R 06 )(-C 1-4 Alkyl-NR 01 R 02 )、-N(R 06)-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)(R 06 )(=NR 06 )、-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )(=NR 06 )、-S(=O)2(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)2(-C 1-4 Alkyl-C(R 05 )R 03 R 04 )、-S(=O)(-C 1-4 Alkyl-C(R 05 )R 03 R 04 );

[0264] R 01 、R 02 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; or,

[0265] R 01 、R 02 Together with the nitrogen atom to which it is attached, it forms a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, or a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group;

[0266] R 03 、R 04 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; wherein optionally, the C 1-6 Alkyl, C 1-6 The two hydrogen atoms on the same carbon atom of the alkoxy group are simultaneously replaced by -(CH2) j-substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or

[0267] R 03 、R 04 Together with the carbon atom to which it is attached, it forms a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclyl, a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclyl, a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclyl, a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or a substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0268] R 05 For hydrogen, deuterium, halogen, deuterated C 1-6 Alkyl or C 1-6 alkyl;

[0269] R 06 is hydrogen, deuterium or C 1-6 alkyl;

[0270] Y3 is -C(=O)R6, -C(=S)R6, -S(=O)(R 07 )(=NR 08 )、-S(=O)(R 07 )(R 08 )、-S(=O)2(R 07 )(R 08 ),-P(=O)(R 07 )(R 08 ), -C(=O)-C 1-4 Alkyl-NR6-S(=O)(R 07 )(=NR 08 ), -C(=O)-C 1-4 Alkyl-N=S(=O)(R 07 )(R 08 ) or R 11 ; R 12 For hydrogen, C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0271] or Y3, R 12 Together with the nitrogen atom to which they are attached, they form a substituted or unsubstituted nitrogen-containing 3- to 8-membered heterocyclic group; one ring atom of the nitrogen-containing 3- to 8-membered heterocyclic group is a nitrogen atom and optionally one or more (e.g., 1, 2, or 3) ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus;

[0272] R6 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0273] R 11 is a substituted or unsubstituted 3- to 10-membered heterocyclyl, a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, a substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, a substituted or unsubstituted 6- to 12-membered heteroarylcycloalkyl, a substituted or unsubstituted 6- to 12-membered heteroarylheterocyclyl, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclyl, or a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclyl;

[0274] R 07 is hydrogen, deuterium, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 3-6 Cycloalkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium, C 1-6 Alkyl, C 1-6 heteroalkyl, 5- or 6-membered monocyclic heteroaryl;

[0275] R 08 is hydrogen, deuterium, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 3-6 Cycloalkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium, C 1-6 Alkyl, C 1-6 heteroalkyl, 5- or 6-membered monocyclic heteroaryl;

[0276] R 09 is hydrogen, deuterium, halogen, substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3, or 4) groups selected from the group consisting of deuterium, halogen;

[0277] R 10 is hydrogen, deuterium, halogen, substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3, or 4) groups selected from the group consisting of deuterium, halogen;

[0278] Y5 is O or S;

[0279] Y4 is O or S;

[0280] R 13 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 14 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or

[0281] R 13 and R 14 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0282] In each of the above groups, the substitution independently refers to the above groups being independently substituted by 1, 2, 3, 4, 5 or 6 groups selected from Group S1; the groups of Group S1 are independently selected from the following groups: deuterium, oxo (=O), thio (=S), CR e R f 、=NR e , halogen, cyano, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-20 Cycloalkyl, 3 to 20 membered heterocyclic group, C 6-14 Aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, -OC 3-20 Cycloalkyl, -O-3 to 20-membered heterocyclic group, -OC 6-14 Aryl, -O-5 or 6-membered monocyclic heteroaryl, -O-8 to 10-membered bicyclic heteroaryl, -C≡CC 3-20 Cycloalkyl, -C≡C-3 to 20-membered heterocyclic group, -C≡CC 6-14 Aryl, -C≡C-5 or 6-membered monocyclic heteroaryl, -C≡C-8 to 10-membered bicyclic heteroaryl, -C≡CC 1-4 Alkyl-C 3-20 Cycloalkyl, -C≡CC 1-4 Alkyl-3 to 20-membered heterocyclic group, -C≡CC 1-4 Alkyl-C 6-14 Aryl, -C≡C- C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C≡CC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-C 3-20 Cycloalkyl, -C 1-4 Alkyl-OC 3-20 Cycloalkyl, -C 1-4 alkyl-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C6-14 Aryl, -C 1-4 Alkyl-OC 6-14 Aryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -OC 1-4 Alkyl-hydroxyl, -OC 1-4 Alkyl-cyano, -OC 1-4 Alkyl-C 1-6 Alkyl, -OC 1-4 Alkyl-C 1-6 Alkoxy, -OC 1-4 Alkyl-C 3-20 Cycloalkyl, -OC 1-4 Alkyl-OC 3-20 Cycloalkyl, -OC 1-4 Alkyl-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-C 6-14 Aryl, -OC 1-4 Alkyl-OC 6-14 Aryl, -OC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -OC 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-20 Cycloalkyl, -S(=O)2-3 to 20-membered heterocyclic group, -C(=O)OC 1-6 Alkyl, -C(=O)OC 3-20 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-20 Cycloalkyl, -C(=O)-C 6-14 Aryl, -NR a1 R b1 、-C(=O)-NR a1 R b1 、-C(=O)-NR d1 -C 1-4 Alkyl-R c1 、-OR c1 、-C 1-4 Alkyl-S(=O)2-C 1-6Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-20 Cycloalkyl, -C 1- 4-alkyl-S(=O)2-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C(=O)OC 1-6 Alkyl, -C 1-4 Alkyl-C(=O)OC 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 1-6 Alkyl, -C 1-4 Alkyl-C(=O)-C 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 6-14 aryl, -C(=O)-5 or 6-membered monocyclic heteroaryl, -C(=O)-8 to 10-membered bicyclic heteroaryl, -C(=O)-C 1-6 Alkyl-C 3-20 Cycloalkyl, -C(=O)-C 1-6 alkyl-3 to 20-membered heterocyclic group, -C(=O)-C 1-6 Alkyl-C 6-14 Aryl, -C(=O)-C 1-6 Alkyl-5 or 6-membered monocyclic heteroaryl, -C(=O)-C 1-6 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-NR a1 R b1 、-C 1-4 Alkyl-C(=O)-NR a1 R b1 、-C≡CC(=O)-NR a1 R b1 、-C≡CC 1-4 Alkyl-C(=O)-NR a1 R b1 、-C 1-4 Alkyl-OR c1 、-C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2, -C 1-4 Alkyl-NR d1 -C(=O)-R c1 、-C 1-4 Alkyl-NR d1 -C(=O)-NR a1 R b1 、-C 1-4 Alkyl-NR d1 -S(=O)2-R c1 、-C1-4 Alkyl-S(=O)2-NR a1 R b1 、-C 1-4 Alkyl-NR d1 -S(=O)2-NR a1 R b1 、-NR d1 -C(=O)-R c1 、-NR d1 -C(=O)-C 1-4 Alkyl-R c1 、-NR d1 -C(=O)-NR a1 R b1 、-NR d1 -S(=O)2-R c1 、-S(=O)2-NR a1 R b1 、-NR d1 -S(=O)2-NR a1 R b1 、-P(=O)-(C 1-6 Alkyl) 2; wherein the C 1-6 Alkyl, the C 1-6 Alkoxy, the C 2-6 Alkenyl, the C 2-6 Each alkynyl group is independently optionally substituted by 1, 2 or 3 groups selected from halogen, deuterium, cyano or hydroxy; 3-20 Cycloalkyl, the 3 to 20 membered heterocyclic group, the C 6-14 The aryl group, the 5- or 6-membered monocyclic heteroaryl group, and the 8- to 10-membered bicyclic heteroaryl group are each independently optionally substituted by 1, 2, 3 or 4 groups selected from Group S2;

[0283] In the above groups, each R a1 、R b1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-6 Monocyclic cycloalkyl, -S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-6 Monocyclic cycloalkyl, -C(=O)-3 to 6-membered monocyclic heterocyclic group; wherein the C 3-6 The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 alkyl)2; or

[0284] Each R a1 and R b1 Together with the nitrogen atom to which they are attached, they form a 3- to 20-membered heterocyclic group; wherein the 3- to 20-membered heterocyclic group is independently optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxyl, carboxyl, nitro, C 1-6Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1- 6 alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2;

[0285] In the above groups, each R d1 Each independently is H, C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0286] In the above groups, each R c1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl or -C 1-4 Alkyl-8 to 10 membered bicyclic heteroaryl; said C 3-6The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2;

[0287] In the above groups, each group of S2 is independently selected from the following groups: deuterium, oxo (=O), thio (=S), CR e R f 、=NR e , halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -(C=O)-NHC 1-6 Alkyl, -(C=O)-N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 alkyl)2, -(C=O)C 1-6 Alkyl, -SF5;

[0288] In the above groups, the -C 1-4 Alkyl- is unsubstituted; or -C 1-4 1, 2, 3 or 4 hydrogen atoms on the alkyl group are independently selected from halogen, cyano, hydroxyl, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -CH2-hydroxy, -CH2-cyano, phenyl group substituted; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by -(CH2) j-substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by =CR e R f replace;

[0289] In the above groups, R e are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0290] In the above groups, R f are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0291] In each of the above groups, one or more (e.g., 1, 2, 3, or 4) ring atoms of the 3- to 8-membered heterocyclic group, the 3- to 10-membered heterocyclic group, or the 3- to 8-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; 1-6 One or more (e.g., 1, 2, 3, or 4) ring atoms of the heteroalkyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 7- to 12-membered bicyclic heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 3- to 20-membered heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- or 6-membered monocyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 8- to 10-membered bicyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 3- to 6-membered monocyclic heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- to 15-membered tricyclic heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloalkyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloheterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; wherein one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 6- to 12-membered heteroarylcycloheterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus;

[0292] Wherein, when the ring atom is a sulfur atom, the sulfur atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above;

[0293] Wherein, when the ring atom is a phosphorus atom, the phosphorus atom is optionally substituted by one or two groups selected from oxo and =NR e The group substituted; R e Same definition as above.

[0294] In one embodiment, Select from the following groups: Wherein, X and R3 are respectively defined as in any one of the items of the present disclosure.

[0295] In one embodiment, Selected from Among them, R 13 , X, and R3 are each defined as in any one of the items of this disclosure.

[0296] In one embodiment, Selected from Wherein, X and R3 are respectively defined as in any one of the items of the present disclosure.

[0297] The first aspect of the present disclosure further provides a compound as represented by formula (A) or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof:

[0298] Wherein, W1 is CH, C or N; W2 is CH, C or N; W3 is CR 13 , O, S, N or NH; W4 is CR 13 , O, S, N or NH; W5 is absent, O or CR 14 ;

[0299] R1, R2, R3, R 42 、R 43 、R 4a , R5, R6, R 13 、R 14 , L1 respectively have the same definition as in any item of this disclosure.

[0300] The first aspect of the present disclosure further provides a compound as represented by formula (B) or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof:

[0301] Among them, W6 is selected from CR 13 or N;

[0302] R1, R2, R3, R 42 、R 43 、R 4a , R5, R6, R 13 , L1 respectively have the same definition as in any item of this disclosure.

[0303] The first aspect of the present disclosure further provides a compound represented by Formula (A1), Formula (A2), Formula (A3), Formula (A4), Formula (A5), Formula (A6), Formula (B1), Formula (B2), Formula (B3) or Formula (B4), or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof:

[0304] The definition of each group is the same as that in any item of the present disclosure.

[0305] In one embodiment, in Formula (A1), Formula (A2), Formula (A3), Formula (A4), Formula (A5), Formula (A6), Formula (B1), Formula (B2), Formula (B3) or Formula (B4), R 13 is hydrogen, halogen or substituted or unsubstituted C 1-6 alkyl;

[0306] R 42 is hydrogen, halogen or substituted or unsubstituted C 1-6 Alkyl; R 43 is hydrogen, halogen or substituted or unsubstituted C 1-6 Alkyl; or

[0307] R 42 and R 43 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0308] L1 is -N(R 00 )C(=O)-、-N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, substituted or unsubstituted C 1-6 Alkyl, -substituted or unsubstituted C 1-6 Alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -L2-substituted or unsubstituted C 6-10aryl, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl or -L2-substituted or unsubstituted 3- to 8-membered heterocyclic group or;

[0309] L2 is -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-;

[0310] R 00 is hydrogen or C 1-6 alkyl;

[0311] R1 is hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0312] R2 is hydrogen, deuterium, halogen, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0313] R3 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0314] R 4a is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 3-6 a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0315] R5 is -NR 01 R 02 or -C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 ;

[0316] R 01 、R 02 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6Alkoxy, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; or,

[0317] R 01 、R 02 Together with the nitrogen atom to which it is attached, it forms a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, or a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group;

[0318] R 09 is hydrogen, deuterium, halogen or substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium and halogen;

[0319] R 10 is hydrogen, deuterium, halogen or substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (eg, 1, 2, 3, or 4) groups selected from the group consisting of deuterium and halogen;

[0320] R6 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0321] In each of the above groups, the substitution independently refers to the above groups being independently substituted by 1, 2, 3, 4, 5 or 6 groups selected from Group S1; the groups of Group S1 are independently selected from the following groups: deuterium, oxo (=O), thio (=S), CR e R f 、=NR e , halogen, cyano, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-20 Cycloalkyl, 3 to 20 membered heterocyclic group, C 6-14 Aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, -OC 3-20 Cycloalkyl, -O-3 to 20-membered heterocyclic group, -OC 6-14 Aryl, -O-5 or 6-membered monocyclic heteroaryl, -O-8 to 10-membered bicyclic heteroaryl, -C≡CC3-20 Cycloalkyl, -C≡C-3 to 20-membered heterocyclic group, -C≡CC 6-14 Aryl, -C≡C-5 or 6-membered monocyclic heteroaryl, -C≡C-8 to 10-membered bicyclic heteroaryl, -C≡CC 1-4 Alkyl-C 3-20 Cycloalkyl, -C≡CC 1-4 Alkyl-3 to 20-membered heterocyclic group, -C≡CC 1-4 Alkyl-C 6-14 Aryl, -C≡CC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C≡CC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-C 3-20 Cycloalkyl, -C 1-4 Alkyl-OC 3-20 Cycloalkyl, -C 1-4 alkyl-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C 6-14 Aryl, -C 1-4 Alkyl-OC 6-14 Aryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -OC 1-4 Alkyl-hydroxyl, -OC 1-4 Alkyl-cyano, -OC 1-4 Alkyl-C 1-6 Alkyl, -OC 1-4 Alkyl-C 1-6 Alkoxy, -OC 1-4 Alkyl-C 3-20 Cycloalkyl, -OC 1-4 Alkyl-OC 3-20 Cycloalkyl, -OC 1-4 Alkyl-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-C 6-14 Aryl, -OC 1-4Alkyl-OC 6-14 Aryl, -OC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -OC 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-20 Cycloalkyl, -S(=O)2-3 to 20-membered heterocyclic group, -C(=O)OC 1-6 Alkyl, -C(=O)OC 3-20 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-20 Cycloalkyl, -C(=O)-C 6-14 Aryl, -NR a1 R b1 、-C(=O)-NR a1 R b1 、-C(=O)-NR d1 -C 1-4 Alkyl-R c1 、-OR c1 、-C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-20 Cycloalkyl, -C 1- 4-alkyl-S(=O)2-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C(=O)OC 1-6 Alkyl, -C 1-4 Alkyl-C(=O)OC 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 1-6 Alkyl, -C 1-4 Alkyl-C(=O)-C 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 6-14 aryl, -C(=O)-5 or 6-membered monocyclic heteroaryl, -C(=O)-8 to 10-membered bicyclic heteroaryl, -C(=O)-C 1-6 Alkyl-C 3-20 Cycloalkyl, -C(=O)-C 1-6 alkyl-3 to 20-membered heterocyclic group, -C(=O)-C 1-6 Alkyl-C 6-14 Aryl, -C(=O)-C 1-6Alkyl-5 or 6-membered monocyclic heteroaryl, -C(=O)-C 1-6 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-NR a1 R b1 、-C 1-4 Alkyl-C(=O)-NR a1 R b1 、-C≡CC(=O)-NR a1 R b1 、-C≡CC 1-4 Alkyl-C(=O)-NR a1 R b1 、-C 1-4 Alkyl-OR c1 、-C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2, -C 1-4 Alkyl-NR d1 -C(=O)-R c1 、-C 1-4 Alkyl-NR d1 -C(=O)-NR a1 R b1 、-C 1-4 Alkyl-NR d1 -S(=O)2-R c1 、-C 1-4 Alkyl-S(=O)2-NR a1 R b1 、-C 1-4 Alkyl-NR d1 -S(=O)2-NR a1 R b1 、-NR d1 -C(=O)-R c1 、-NR d1 -C(=O)-C 1-4 Alkyl-R c1 、-NR d1 -C(=O)-NR a1 R b1 、-NR d1 -S(=O)2-R c1 、-S(=O)2-NR a1 R b1 、-NR d1 -S(=O)2-NR a1 R b1 and -P(=O)-(C 1-6 Alkyl) 2; wherein the C 1-6 Alkyl, the C 1-6Alkoxy, the C 2-6 Alkenyl, the C 2-6 Each alkynyl group is independently optionally substituted by 1, 2 or 3 groups selected from halogen, deuterium, cyano or hydroxy; 3-20 Cycloalkyl, the 3 to 20 membered heterocyclic group, the C 6-14 The aryl group, the 5- or 6-membered monocyclic heteroaryl group, and the 8- to 10-membered bicyclic heteroaryl group are each independently optionally substituted by 1, 2, 3 or 4 groups selected from Group S2;

[0322] In the above groups, each R a1 、R b1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-6 Monocyclic cycloalkyl, -S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-6 Monocyclic cycloalkyl, -C 1-4Alkyl-S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-6 monocyclic cycloalkyl or -C(=O)-3 to 6-membered monocyclic heterocyclic group; wherein the C 3-6 The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 alkyl)2; or

[0323] Each R a1 and R b1 Together with the nitrogen atom to which they are attached, they form a 3- to 20-membered heterocyclic group; wherein the 3- to 20-membered heterocyclic group is independently optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1- 6 alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 Alkyl)2;

[0324] In the above groups, each R d1 Each independently is H, C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0325] In the above groups, each R c1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl or -C 1-4 Alkyl-8 to 10 membered bicyclic heteroaryl; said C 3-6 The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 Alkyl)2;

[0326] In the above groups, each group of S2 is independently selected from the following groups: deuterium, oxo (=O), thio (=S), CR e R f 、=NR e , halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -(C=O)-NHC 1-6 Alkyl, -(C=O)-N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 alkyl)2, -(C=O)C 1-6 Alkyl and -SF5;

[0327] In the above groups, the -C 1-4 Alkyl- is unsubstituted; or -C 1-4 1, 2, 3 or 4 hydrogen atoms on the alkyl group are independently selected from halogen, cyano, hydroxyl, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -CH2-hydroxy, -CH2-cyano, phenyl group substituted; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by -(CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by =CR e R f replace;

[0328] In the above groups, R e are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0329] In the above groups, R f are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0330] In each of the above groups, one or more (e.g., 1, 2, 3, or 4) ring atoms of the 3- to 8-membered heterocyclic group, the 3- to 10-membered heterocyclic group, or the 3- to 8-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; 1-6One or more (e.g., 1, 2, 3, or 4) ring atoms of the heteroalkyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 7- to 12-membered bicyclic heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 3- to 20-membered heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- or 6-membered monocyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; The ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g., 1, 2, 3, 4 or 5) ring atoms of the 8- to 10-membered bicyclic heteroaryl are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g., 1, 2, 3 or 4) ring atoms of the 3- to 6-membered monocyclic heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g., 1, 2, 3, 4 or 5) ring atoms of the 5- to 15-membered tricyclic heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus;

[0331] Wherein, when the ring atom is a sulfur atom, the sulfur atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above;

[0332] Wherein, when the ring atom is a phosphorus atom, the phosphorus atom is optionally substituted by one or two groups selected from oxo and =NR e The group substituted; R e Same definition as above.

[0333] In one embodiment, formula (B1) is as follows:

[0334] wherein each group has the same definition as in any one of the present disclosures.

[0335] The first aspect of the present disclosure further provides a compound as shown in formula (B5) or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof:

[0336] Among them, W6 is selected from CR 13 or N;

[0337] R1, R2, R3, R 42 、R 43 、R 4a , R5, R6, R 13 , L1 respectively have the same definition as in any item of this disclosure.

[0338] The first aspect of the present disclosure further provides a compound represented by formula (C1) or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof:

[0339] wherein each group has the same definition as in any one of the present disclosures.

[0340] In one embodiment, in formula (C1),

[0341] R 42 is hydrogen, halogen or substituted or unsubstituted C 1-6 Alkyl; R 43 is hydrogen, halogen or substituted or unsubstituted C 1-6 Alkyl; or

[0342] R 42 and R 43 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0343] L1 is -N(R 00 )C(=O)-O-、-C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O- or -substituted or unsubstituted C 2-6 alkenyl-O-;

[0344] R 00 is hydrogen or C 1-6 alkyl;

[0345] R1 is hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0346] R2 is hydrogen, deuterium, halogen, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl;

[0347] R3 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0348] R 4a is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 3-6 a cycloalkyl group or a substituted or unsubstituted 3- to 8-membered heterocyclic group;

[0349] R5 is -NR 01 R 02 or -C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 ;

[0350] R 01 、R 02 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 2-6 Alkenyl or substituted or unsubstituted C 2-6 Alkynyl; or,

[0351] R 01 、R 02 Together with the nitrogen atom to which it is attached, it forms a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, or a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group;

[0352] R6 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl;

[0353] In each of the above groups, the substitution independently refers to the above groups being independently substituted by 1, 2, 3, 4, 5 or 6 groups selected from Group S1; the groups of Group S1 are independently selected from the following groups: deuterium, oxo (=O), thio (=S), CR e R f 、=NR e , halogen, cyano, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-20 Cycloalkyl, 3 to 20 membered heterocyclic group, C 6-14Aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, -OC 3-20 Cycloalkyl, -O-3 to 20-membered heterocyclic group, -OC 6-14 Aryl, -O-5 or 6-membered monocyclic heteroaryl, -O-8 to 10-membered bicyclic heteroaryl, -C≡CC 3-20 Cycloalkyl, -C≡C-3 to 20-membered heterocyclic group, -C≡CC 6-14 Aryl, -C≡C-5 or 6-membered monocyclic heteroaryl, -C≡C-8 to 10-membered bicyclic heteroaryl, -C≡CC 1-4 Alkyl-C 3-20 Cycloalkyl, -C≡CC 1-4 Alkyl-3 to 20-membered heterocyclic group, -C≡CC 1-4 Alkyl-C 6-14 Aryl, -C≡CC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C≡CC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-C 3-20 Cycloalkyl, -C 1-4 Alkyl-OC 3-20 Cycloalkyl, -C 1-4 alkyl-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C 6-14 Aryl, -C 1-4 Alkyl-OC 6-14 Aryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -OC 1-4 Alkyl-hydroxyl, -OC 1-4 Alkyl-cyano, -OC 1-4 Alkyl-C 1-6 Alkyl, -OC 1-4 Alkyl-C 1-6 Alkoxy, -OC 1-4 Alkyl-C 3-20 Cycloalkyl, -OC 1-4 Alkyl-OC 3-20Cycloalkyl, -OC 1-4 Alkyl-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-C 6-14 Aryl, -OC 1-4 Alkyl-OC 6-14 Aryl, -OC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -OC 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-20 Cycloalkyl, -S(=O)2-3 to 20-membered heterocyclic group, -C(=O)OC 1-6 Alkyl, -C(=O)OC 3-20 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-20 Cycloalkyl, -C(=O)-C 6-14 Aryl, -NR a1 R b1 、-C(=O)-NR a1 R b1 、-C(=O)-NR d1 -C 1-4 Alkyl-R c1 、-OR c1 、-C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-20 Cycloalkyl, -C 1- 4-alkyl-S(=O)2-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C(=O)OC 1-6 Alkyl, -C 1-4 Alkyl-C(=O)OC 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 1-6 Alkyl, -C 1-4 Alkyl-C(=O)-C 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 6-14 aryl, -C(=O)-5 or 6-membered monocyclic heteroaryl, -C(=O)-8 to 10-membered bicyclic heteroaryl, -C(=O)-C 1-6 Alkyl-C 3-20Cycloalkyl, -C(=O)-C 1-6 alkyl-3 to 20-membered heterocyclic group, -C(=O)-C 1-6 Alkyl-C 6-14 Aryl, -C(=O)-C 1-6 Alkyl-5 or 6-membered monocyclic heteroaryl, -C(=O)-C 1-6 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-NR a1 R b1 、-C 1-4 Alkyl-C(=O)-NR a1 R b1 、-C≡CC(=O)-NR a1 R b1 、-C≡CC 1-4 Alkyl-C(=O)-NR a1 R b1 、-C 1-4 Alkyl-OR c1 、-C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2, -C 1-4 Alkyl-NR d1 -C(=O)-R c1 、-C 1-4 Alkyl-NR d1 -C(=O)-NR a1 R b1 、-C 1-4 Alkyl-NR d1 -S(=O)2-R c1 、-C 1-4 Alkyl-S(=O)2-NR a1 R b1 、-C 1-4 Alkyl-NR d1 -S(=O)2-NR a1 R b1 、-NR d1 -C(=O)-R c1 、-NR d1 -C(=O)-C 1-4 Alkyl-R c1 、-NR d1 -C(=O)-NR a1 R b1 、-NR d1 -S(=O)2-R c1 、-S(=O)2-NR a1 R b1 、-NR d1-S(=O)2-NR a1 R b1 and -P(=O)-(C 1-6 Alkyl) 2; wherein the C 1-6 Alkyl, the C 1-6 Alkoxy, the C 2-6 Alkenyl, the C 2-6 Each alkynyl group is independently optionally substituted by 1, 2 or 3 groups selected from halogen, deuterium, cyano or hydroxy; 3-20 Cycloalkyl, the 3 to 20 membered heterocyclic group, the C 6-14 The aryl group, the 5- or 6-membered monocyclic heteroaryl group, and the 8- to 10-membered bicyclic heteroaryl group are each independently optionally substituted by 1, 2, 3 or 4 groups selected from Group S2;

[0354] In the above groups, each R a1 、R b1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-6 Monocyclic cycloalkyl, -S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C 1-4Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-6 monocyclic cycloalkyl or -C(=O)-3 to 6-membered monocyclic heterocyclic group; wherein the C 3-6 The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 or -P(=O)-(C 1-6 alkyl)2; or

[0355] Each R a1 and R b1 Together with the nitrogen atom to which they are attached, they form a 3- to 20-membered heterocyclic group; wherein the 3- to 20-membered heterocyclic group is independently optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1- 6 alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 Alkyl)2;

[0356] In the above groups, each R d1 Each independently is H, C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0357] In the above groups, each Rc1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 Monocyclic cycloalkyl, 3 to 6 membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl or -C 1-4 Alkyl-8 to 10 membered bicyclic heteroaryl; said C 3-6 The monocyclic cycloalkyl, the 3 to 6 membered monocyclic heterocyclic group, the phenyl, the 5 or 6 membered monocyclic heteroaryl, the 8 to 10 membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 Alkyl)2;

[0358] In the above groups, each group of S2 is independently selected from the following groups: deuterium, oxo (=O), thio (=S), CR e Rf 、=NR e , halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -(C=O)-NHC 1-6 Alkyl, -(C=O)-N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 alkyl)2, -(C=O)C 1-6 Alkyl and -SF5;

[0359] In the above groups, the -C 1-4 Alkyl- is unsubstituted; or -C 1-4 1, 2, 3 or 4 hydrogen atoms on the alkyl group are independently selected from halogen, cyano, hydroxyl, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -CH2-hydroxy, -CH2-cyano, phenyl group substituted; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by -(CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by =CR e R f replace;

[0360] In the above groups, R e are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0361] In the above groups, R f are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0362] In each of the above groups, one or more (e.g., 1, 2, 3, or 4) ring atoms of the 3- to 8-membered heterocyclic group, the 3- to 10-membered heterocyclic group, or the 3- to 8-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; 1-6 One or more (e.g., 1, 2, 3, or 4) ring atoms of the heteroalkyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 7- to 12-membered bicyclic heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 3- to 20-membered heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- or 6-membered monocyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; The ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g., 1, 2, 3, 4 or 5) ring atoms of the 8- to 10-membered bicyclic heteroaryl are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g., 1, 2, 3 or 4) ring atoms of the 3- to 6-membered monocyclic heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g., 1, 2, 3, 4 or 5) ring atoms of the 5- to 15-membered tricyclic heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus;

[0363] Wherein, when the ring atom is a sulfur atom, the sulfur atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above;

[0364] Wherein, when the ring atom is a phosphorus atom, the phosphorus atom is optionally substituted by one or two groups selected from oxo and =NR e The group substituted; R e Same definition as above.

[0365] In one embodiment, R 4a -C 1-6 Alkyl-C 1-6 Alkoxy.

[0366] In one embodiment, R 4a -C 1-3 Alkyl-C 1-3 Alkoxy.

[0367] In one embodiment, R 4a is -CH(CH3)-O-CH3.

[0368] In one embodiment, R 4a for

[0369] In one embodiment, R5 is selected from hydrogen,

[0370] In one embodiment, R5 is selected from

[0371] In one embodiment, R3 is hydrogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl or C 3-6 Cycloalkyl.

[0372] In one embodiment, R3 is hydrogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl.

[0373] In one embodiment, R3 is hydrogen, C 1-3 Alkyl, halogenated C 1-3 Alkyl or deuterated C 1-3 alkyl.

[0374] In one embodiment, R3 is ethyl, isopropyl or cyclopentyl.

[0375] In one embodiment, R3 is trifluoroethyl.

[0376] In one embodiment, R 13 is hydrogen or fluorine.

[0377] In one embodiment, R 13 is hydrogen or methoxy.

[0378] In one embodiment, R1 is hydrogen; R2 is hydrogen.

[0379] In one embodiment, R 42 is methyl; R 43 It is a methyl group.

[0380] In one embodiment, Y4 is O.

[0381] In one embodiment, Y5 is O.

[0382] In one embodiment, R 12 For hydrogen.

[0383] In one embodiment, R5 is -NR 01 R 02 ; R 01 、R 02 Together with the nitrogen atom to which it is attached, it forms a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group.

[0384] In one embodiment, R5 is -C 2-4 Alkynyl-C1-4 Alkyl-NR 01 R 02 ; R 01 、R 02 Together with the nitrogen atom to which it is attached, it forms a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group.

[0385] One or more (e.g., 1, 2, 3, or 4) ring atoms of the 3- to 8-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, or sulfur; the substitutions independently refer to 1, 2, 3, 4, 5, or 6 hydrogen atoms on the above groups being replaced by groups selected from Group S1; wherein, when the ring atoms are sulfur atoms, the sulfur atoms are optionally replaced by one or two heteroatoms selected from oxo and =NR e The group substituted; R e are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl.

[0386] In one embodiment, the 3 to 8 membered monocyclic heterocyclic group is selected from Preferably, the 3- to 8-membered monocyclic heterocyclic group is unsubstituted or substituted by one or two groups selected from the group consisting of methyl, -CH2OH, cyano, -C(=O)CH2OH, and -CH2NH2.

[0387] In one embodiment, R5 is selected from

[0388] In one embodiment, Y1 is N; and Y2 is CH.

[0389] In one embodiment, Y1 is CH; Y2 is N.

[0390] In one embodiment, Y1 is N + -O - ; Y2 is CH.

[0391] In one embodiment, Y1 is CH; Y2 is N + -O - .

[0392] In one embodiment, X is For example,

[0393] In one embodiment, X is For example,

[0394] In one embodiment, L1 is

[0395] In one embodiment, L1 is Here, "*A" indicates the site connected to ring A.

[0396] In one embodiment, L1 is

[0397] In one embodiment, L1 is Here, "*A" indicates the site connected to ring A.

[0398] In one embodiment, L1 is

[0399] In one embodiment, L1 is Here, "*A" indicates the site connected to ring A.

[0400] In one embodiment, L1 is -L2-substituted or unsubstituted C 6-10 Aryl-; L2 is -O-, -C 1-4 Alkyl-, -N(R 00 )-, -C(=O)-, -C=C- or -N(R 00 )C(=S)-. In one embodiment, the C 6-10 Aryl is phenyl or naphthyl.

[0401] In one embodiment, L1 is -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl-; L2 is -O-, -C 1-4 Alkyl-, -N(R 00 )-, -C(=O)-, -C=C- or -N(R 00 In one embodiment, the 5- or 6-membered monocyclic heteroaryl group is thiazole or oxazole.

[0402] In one embodiment, L1 is -L2-substituted or unsubstituted 3 to 8 membered heterocyclyl-; L2 is -O-, -C 1-4 Alkyl-, -N(R 00 )-, -C(=O)-, -C=C- or -N(R 00 )C(=S)-. In one embodiment, the 3 to 8 membered heterocyclic group is selected from The wavy line indicates that the ring atom is a connection position, and the other connection position can be any position among the remaining ring atoms.

[0403] In one embodiment, L1 is selected from

[0404] In one embodiment, L1 is selected from Here, "*A" indicates the site connected to ring A.

[0405] In one embodiment, L1 is selected from

[0406] In one embodiment, L1 is selected from Here, "*A" indicates the site connected to ring A.

[0407] In one embodiment, R6 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 3-6 cycloalkyl or substituted or unsubstituted 3 to 8 membered heterocyclyl; the substitution is as defined herein.

[0408] In one embodiment, the C 1-6 The alkyl group is isopropyl, methyl, sec-butyl, isobutyl, n-propyl, ethyl, pentyl, neopentyl or tert-pentyl.

[0409] In one embodiment, the C 1-6 Heteroalkyl is

[0410] In one embodiment, the C 3-6 Cycloalkyl is cyclopropyl.

[0411] In one embodiment, the 3- to 8-membered heterocyclic group is azetidinyl, thietanyl, tetrahydropyrrolyl, cyclopropyltetrahydrofuran ring, cyclopropyltetrahydropyrrole ring or cyclopropyltetrahydrothiophene ring.

[0412] In one embodiment, the substitutions are each independently substituted by 1, 2, 3, 4, 5 or 6 groups selected from S1 group; the groups of S1 group are each independently selected from the following group: deuterium, oxo (=O), =NR e , halogen, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, C 3-6 Cycloalkyl, 3 to 8 membered heterocyclic group, 5 or 6 membered monocyclic heteroaryl, said 8 to 10 membered bicyclic heteroaryl, -OC 3-6 Cycloalkyl, phenyl, -C 1-4 Alkyl-C 3-6 Cycloalkyl, -C 1-4 Alkyl-phenyl and -NR a1 R b1 ; wherein, the C 1-6 Alkyl, the C 1-6alkoxy, each independently optionally substituted by 1, 2 or 3 groups selected from halogen, deuterium, cyano or hydroxy; said C 3-6 The cycloalkyl group, the 3- to 8-membered heterocyclic group, the phenyl group, the 5- or 6-membered monocyclic heteroaryl group, and the 8- to 10-membered bicyclic heteroaryl group are each independently optionally substituted with 1, 2, 3 or 4 groups selected from Group S2;

[0413] In the above groups, each R a1 、R b1 Each independently is H or C 1-6 alkyl;

[0414] In the above groups, the groups of each S2 group are independently selected from the following groups: halogen, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -(C=O)C 1-6 Alkyl, -SF5 and -CH2-hydroxy;

[0415] In the above groups, R e are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl;

[0416] In each of the above groups, one or more (e.g., 1, 2, 3, or 4) ring atoms of the 3- to 8-membered heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, or 4) ring atoms of the 5- or 6-membered monocyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 8- to 10-membered bicyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus;

[0417] Wherein, when the ring atom is a sulfur atom, the sulfur atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above;

[0418] Wherein, when the ring atom is a phosphorus atom, the phosphorus atom is optionally substituted by one or two groups selected from oxo and =NR e The group substituted; R e Same definition as above.

[0419] In one embodiment, R6 is selected from

[0420] In one embodiment, R6 is selected from

[0421] In one embodiment, R 11 Selected from

[0422] In one embodiment, R6 is substituted or unsubstituted C 3-6 cycloalkyl; the substitution is as defined herein in any one of the clauses.

[0423] In one embodiment, R6 is C 1-6 Preferably, R6 is a cyclopropyl group substituted by methyl. Preferably, R6 is a cyclopropyl group substituted by two methyl groups. For example, R6 is

[0424] In one embodiment, in the above formulas, for In one embodiment, when Y4 is oxygen,

[0425] In one embodiment, in the above formulas, for In one embodiment, when Y3 is C(=O)R6,

[0426] In one embodiment, the compound is selected from Table C:

[0427] Table C

[0428] In one embodiment, the compound is selected from Table B:

[0429] Table B

[0430] In one embodiment, the compound is selected from Table A.

[0431] The present disclosure also provides the following preparation methods, wherein the compounds shown can be prepared using synthetic methods known in the art or using a combination of methods known in the art and the methods described in the present disclosure.

[0432] The present disclosure provides a preparation method of the following intermediate 1:

[0433] The present disclosure provides a preparation method of the following intermediate 4-1:

[0434] The present disclosure provides a preparation method of the following intermediate 10-1:

[0435] The present disclosure provides a preparation method of the following intermediate 11:

[0436] The present disclosure provides a preparation method of the following intermediate 15-2:

[0437] The present disclosure provides a preparation method of the following intermediate 62-1:

[0438] The present disclosure provides a method for preparing the following intermediate 62-p:

[0439] The present disclosure provides a preparation method of the following intermediate 8-8:

[0440] Synthesis Route 1:

[0441] Synthesis route 2:

[0442] Among them, R p It is an amino protecting group well known in the art, such as formyl; acyl, such as alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as tert-butyloxycarbonyl (Boc); arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-bis-(4'-methoxyphenyl)methyl; silyl, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS), and the like.

[0443] R q It is a hydroxyl protecting group well known in the art, such as ether protecting groups (methyl ether (ROMe), tert-butyl ether (ROtBu), benzyl ether (ROBn), p-methoxybenzyl ether (ROPMB), trityl ether (ROTr); silyl ether protecting groups (trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBS), tert-butyldiphenylsilyl (TBDPS), methoxymethyl ether (MOM), tetrahydropyranyl ether (THP) etc.); ester protecting groups (acetyl (Ac), benzoyl (Bz), pivaloyl (Piv) etc.).

[0444] The compounds shown in the formula (I), formula (A) and formula (B) disclosed herein can be prepared using a synthesis method known in the art or using a method known in the art in combination with the method described in the present disclosure. The solvents, temperatures and other reaction conditions given in the present disclosure are exemplary and can be changed according to methods well known in the art. The embodiment compounds described in the present disclosure can be synthesized according to the methods described in the embodiments using appropriate starting materials according to their specific structures, or can be synthesized using methods similar to those described in the embodiments. The starting materials used to synthesize the embodiment compounds disclosed herein can be prepared by known synthesis methods or similar methods described in the literature or obtained from commercial sources. The embodiment compounds can be further split to obtain their stereoisomers by methods well known in the art, such as crystallization, chromatography, etc., as needed.

[0445] As a further illustration, the compounds of formula (B5-1) and formula (B5-2) disclosed herein can be synthesized using the following method, wherein the solvent, temperature and other reaction conditions in each step can be the same or similar to those described in the following examples, or reaction conditions known in the art can be used;

[0446] In the preparation routes of the compounds of formula (B5-1) and formula (B5-2), in each formula, R p It is an amino protecting group well known in the art, such as formyl; acyl, such as alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as tert-butyloxycarbonyl (Boc); arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-bis-(4'-methoxyphenyl)methyl; silyl, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS), and the like.

[0447] R A 、R B Each independently a halogen atom (e.g., chlorine or bromine), a boronic acid group (e.g., -B(OH)2), or a boric acid ester group (e.g., ); the condition is: R A When selected from halogen atoms, R B is selected from boronic acid or boronic ester groups, R B When selected from halogen atoms, R A Selected from boronic acid group or boric acid ester group.

[0448] W6, R3, R 42 、R 43 、R 4a , R5, and R6 are each defined as in any one of the disclosures (e.g., the same as the definitions of the corresponding groups in Formula I or Formula B5).

[0449] The above-mentioned synthesis routes of the compounds of formula (B5-1) or formula (B5-2) are exemplary. During the specific preparation process, those skilled in the art may adjust the order of the steps in the reaction route based on the existing technology and the structure of the target compound.

[0450] The second aspect of the present disclosure provides a pharmaceutical composition, which includes the compound described in the first aspect above or its stable deuterated derivative or stereoisomer, or its pharmaceutically acceptable salt, solvate or prodrug; and a pharmaceutically acceptable carrier.

[0451] A third aspect of the present disclosure provides the aforementioned compound as a medicament.

[0452] As used herein, the term "pharmaceutically acceptable carrier" refers to any formulation or carrier medium capable of delivering an effective amount of the active substance of the present invention, without interfering with the biological activity of the active substance and without toxic side effects on the host or subject. Representative carriers include water, oils, vegetables and minerals, cream bases, lotion bases, ointment bases, etc. These bases include suspending agents, viscosity increasing agents, transdermal enhancers, etc. Their preparation is well known to those skilled in the field of cosmetics or topical medicine.

[0453] In embodiments of the present invention, the pharmaceutical composition can be administered in any of the following ways: orally, by spray inhalation, rectally, nasally, buccally, topically, parenterally, such as by subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal, and intracranial injection or infusion, or via an external reservoir. Oral, intraperitoneal, or intravenous administration is preferred. Aqueous suspension formulations are typically prepared by mixing the active ingredient with a suitable emulsifier and suspending agent. If desired, sweeteners, flavorings, or coloring agents may be added to the oral formulations. For topical administration, particularly for the treatment of affected areas or organs easily accessible by topical application, such as the eyes, skin, or lower intestinal neurological diseases, the compounds of the present invention can be formulated into different topical formulations depending on the affected area or organ. For topical ocular administration, the compounds of the present invention can be formulated into a micronized suspension or solution using an isotonic, sterile saline solution at a specific pH, with or without a preservative such as benzyl chloride. For ophthalmic use, the compounds can also be formulated into ointments such as vaseline. For topical application to the skin, the compounds of the present invention can be formulated into suitable ointment, lotion, or cream formulations, wherein the active ingredient is suspended or dissolved in one or more carriers. Carriers for ointment formulations include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyethylene oxide, polypropylene oxide, emulsifying wax, and water; carriers for lotions or creams include, but are not limited to, mineral oil, sorbitan monostearate, Tween 60, cetyl esters wax, hexadecyl alcohol, 2-octyldodecanol, benzyl alcohol, and water. The compounds of the present invention can also be administered in the form of sterile injectable formulations, including sterile water for injection or oil suspensions or sterile injectable solutions. Acceptable carriers and solvents include water, Ringer's solution, and isotonic sodium chloride solution. Sterile, fixed oils, such as mono- or diglycerides, can also be used as solvents or suspending media.

[0454] Another aspect of the present disclosure provides the use of the compound described in the first aspect above, or its stable deuterated derivative or stereoisomer, or its pharmaceutically acceptable salt, solvate or prodrug, or the pharmaceutical composition described in the second aspect above, in the preparation of a medicament for preventing and / or treating a disease or condition; the disease or condition is a disease or condition related to RAS protein activity.

[0455] Another aspect of the present disclosure provides a method for preventing and / or treating diseases or conditions related to RAS protein activity, comprising the steps of: administering to a subject in need thereof a therapeutically effective amount of the compound described in the first aspect of the present disclosure, or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof; or administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition described in the second aspect of the invention.

[0456] Herein, in one embodiment, the disease or disorder associated with RAS protein activity is cancer, including but not limited to pancreatic cancer, colorectal cancer, non-small cell lung cancer, acute myeloid leukemia, multiple myeloma, thyroid adenocarcinoma, myelodysplastic syndrome, squamous cell lung cancer, esophageal cancer, ovarian cancer, uterine cancer, melanoma, bladder cancer or head and neck cancer.

[0457] In one embodiment, the cancer comprises wild-type RAS and RAS mutations. The RAS includes HRAS, KRAS, and NRAS.

[0458] In one embodiment, the RAS mutation is KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12S, KRAS G13C, KRAS G13D, KRAS Q61L, KRAS Q61H, NRAS G12C, NRAS Q61K, NRAS Q61R mutation or other RAS mutation.

[0459] Herein, the use or method further comprises administering an additional anticancer therapy. In some embodiments, the additional anticancer therapy is a HER2 inhibitor, an EGFR inhibitor, a second RAS inhibitor, a SHP2 inhibitor, a SOS1 inhibitor, a RAF inhibitor, a MEK inhibitor, an ERK inhibitor, a PI3K inhibitor, a PTEN inhibitor, an AKT inhibitor, an mTORC1 inhibitor, a BRAF inhibitor, a PD-L1 inhibitor, a PD-1 inhibitor, a CDK4 / 6 inhibitor, or a combination thereof.

[0460] Another aspect of the present disclosure provides a method for treating cancer in a subject in need thereof, the method comprising:

[0461] (a) determining that the cancer is associated with RAS protein activity; and

[0462] (b) administering to the subject a therapeutically effective amount of the compound of the first aspect of the present disclosure, or a stable deuterated derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof; or administering to the subject a therapeutically effective amount of the pharmaceutical composition of the second aspect of the present disclosure.

[0463] In one embodiment, the administration is accomplished by a route selected from the group consisting of parenteral, intraperitoneal, intradermal, intracardiac, intraventricular, intracranial, intracerebrospinal, intracavitary, intrasynovial, intrathecal, intramuscular, intravitreal, intravenous, intraarterial, oral, buccal, sublingual, transdermal, topical, intratracheal, rectal, subcutaneous, and local administration.

[0464] Another aspect of the present disclosure provides a method for inhibiting RAS protein activity in a cell, comprising the steps of: contacting the cell with the compound described in the first aspect of the present disclosure, or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof; or contacting the cell with the pharmaceutical composition described in the second aspect of the present disclosure. The cell can be in vivo or in vitro.

[0465] Another aspect of the present disclosure provides use of the compound described in the first aspect above, or its stable deuterated derivative or stereoisomer, or its pharmaceutically acceptable salt, solvate or prodrug, or the pharmaceutical composition described in the second aspect above, in the preparation of a RAS protein activity inhibitor.

[0466] Definitions and Terminology

[0467] As used herein, the term "subject" refers to an animal, particularly a mammal, preferably a human.

[0468] As used herein, the term "effective amount" or "therapeutically effective amount" refers to a non-toxic but sufficient amount of a drug or medicament that achieves the desired effect. In embodiments of the present invention, when treating a patient according to the present invention, the amount of a given drug depends on many factors, such as specific dosing regimen, disease or condition type and severity thereof, the uniqueness (e.g., body weight) of the patient or host in need of treatment, but, according to specific surrounding circumstances, including, for example, the specific drug, route of administration, condition for treatment, and the patient or host for treatment, the dosage can be conventionally determined by methods known in the art. Typically, for adult treatment, the dosage is typically in the range of 0.02-5000 mg / day, such as about 1-1500 mg / day. The desired dose can be conveniently expressed as a single dose, or simultaneously administered (or in a short period of time) or in divided doses at appropriate intervals, such as two, three, four, or more divided doses per day. It will be appreciated by those skilled in the art that, although the above-mentioned dosage range has been provided, the specific effective amount can be appropriately adjusted according to the patient's situation and in conjunction with the physician's diagnosis.

[0469] As used herein, the term "pharmaceutically acceptable salt" refers to a salt of a compound of the present invention that is pharmaceutically acceptable and possesses the pharmacological activity of the parent compound. Such salts include acid addition salts formed with inorganic or organic acids, such as nitric, phosphoric, and carbonic acids; organic acids, such as propionic, hexanoic, cyclopentanepropionic, glycolic, pyruvic, gluconic, stearic, and muconic acids; salts formed when an acidic proton present in the parent compound is replaced by a metal ion, such as an alkali metal or alkaline earth metal ion; or coordination compounds formed with an organic base, such as ethanolamine. Pharmaceutically acceptable salts of the present invention can be synthesized from parent compounds containing acid or base groups by conventional chemical methods. Generally, such salts are prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of an appropriate base or acid in water, an organic solvent, or a mixture of both. Generally, non-aqueous media, such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, are preferred. In addition to salt forms, the compounds provided herein also exist in prodrug form. Prodrugs of the compounds described herein readily undergo chemical changes under physiological conditions to convert to the compounds of the invention. Additionally, prodrugs can be converted to the compounds of the invention by chemical or biochemical methods in an in vivo environment.

[0470] As used herein, the term "solvate" refers to a compound of the present invention in combination with a pharmaceutically acceptable solvent. Pharmaceutically acceptable solvents include acetic acid, etc. Solvates include stoichiometric solvates and non-stoichiometric solvates. Certain compounds of the present invention may exist in unsolvated or solvated forms. Generally speaking, solvated forms are equivalent to unsolvated forms and are encompassed by the present invention.

[0471] As used herein, the term "stereoisomer" includes conformational isomers and configurational isomers, wherein configurational isomers mainly include cis-trans isomers and optical isomers. The compounds of the present invention may exist in the form of stereoisomers, and therefore encompass all possible stereoisomeric forms, including but not limited to cis-trans isomers, tautomers, enantiomers, diastereomers, atropisomers, etc. The compounds of the present invention may also exist in the form of any combination or any mixture of the aforementioned stereoisomers, such as mesomorphs, racemates, equal mixtures of atropisomers, etc. For example, a single enantiomer, a single diastereomer or a mixture thereof, or a single atropisomer or a mixture thereof. When the compound of the present invention contains an olefin double bond, unless otherwise specified, it includes cis-isomers and trans-isomers, and any combination thereof. The atropisomers of the present invention are stereoisomers with axial or planar chirality based on restricted intramolecular rotation. And as a drug, stereoisomers with excellent activity are preferred. The compounds of the present invention have optical isomers arising from asymmetric carbon atoms, etc., and individual isomers can be resolved and obtained, if necessary, by methods known in the art, such as crystallization or chiral chromatography.

[0472] As used herein, the =CR e R f Substitution refers to the substitution of atoms of the molecule with CR through double bonds e R f The carbon atoms (C) in the molecule are connected. That is, the atoms of the molecule are As used herein, the =NR e Substitution refers to the atoms of the molecule being bonded to NR through double bonds. e That is, the atoms of the molecule are connected to the nitrogen atoms (N). As used herein, the term "oxo" refers to an atom of the molecule being connected to an oxygen atom (O) via a double bond. As used herein, the term "thio" refers to a molecule in which the atoms are connected to a sulfur atom (S) via a double bond. As used herein, when a group such as an alkyl group is located in the middle of a structural formula, the group is a subunit. For example, an alkyl group is an alkylene group, etc.

[0473] As used herein, the term "alkyl" refers to a straight-chain or branched saturated aliphatic hydrocarbon group. 1-6 Alkyl refers to a straight or branched chain alkyl group having 1, 2, 3, 4, 5 or 6 carbon atoms. More preferably, C 1-4 More preferably, C 1-3Alkyl. Specific examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and various branched isomers thereof. The alkyl group described in the present invention may be substituted or unsubstituted. When substituted, the substituent is preferably one or more of the substituent groups described in this application.

[0474] As used herein, the term "heteroalkyl" refers to an alkyl group in which at least one carbon atom is replaced by a heteroatom (eg, O, N, or S atom), wherein the definition of alkyl is as described above. 1-6 "Heteroalkyl" refers to a straight or branched chain heteroalkyl group having 1, 2, 3, 4, 5 or 6 carbon atoms. Preferably, C 1-4 More preferably, C 1-3 Heteroalkyl groups. Heteroatoms may be present in the middle or at the end of the group. The heteroalkyl group may be substituted or unsubstituted. When substituted, the substituents are preferably one or more of the substituent groups described in this application. Exemplary heteroalkyl groups include alkoxy, alkylthio, and the like.

[0475] As used herein, the term "alkoxy" refers to a group having the structure -O-alkyl, wherein alkyl is as defined above. 1-6 "Alkoxy" refers to an alkoxy group having 1 to 6 carbon atoms. Preferably, C 1-4 Alkoxy. More preferably C 1-3 Alkoxy. Specific examples include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, isobutoxy, n-pentoxy, and the like. The alkoxy may be substituted or unsubstituted. When substituted, the substituent is preferably one or more of the substituents described in this application.

[0476] As used herein, the term "alkylthio" refers to a group having the structure -S-alkyl, wherein alkyl is as defined above. 1-6 "Alkylthio" refers to an alkylthio group having 1 to 6 carbon atoms. Preferably, C 1-4 More preferably C 1-3 Alkylthio: The alkylthio group may be substituted or unsubstituted. When substituted, the substituent is preferably one or more substituent groups described in this application.

[0477] As used herein, the term "alkenyl" refers to an alkyl group as defined above having one or more carbon-carbon double bonds at any position of the chain. 2-6 "Alkenyl" refers to an alkenyl group having 2 to 6 carbon atoms and at least one (e.g., 1 to 2) carbon-carbon double bond. Preferably, C 2-4 Alkenyl (i.e., an alkenyl group having 2 to 4 carbon atoms and 1 to 2 carbon-carbon double bonds). Specific examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, pentenyl, hexenyl, butadienyl, and the like. The alkenyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the substituent groups described herein.

[0478] As used herein, the term "alkynyl" refers to an alkyl group as defined above having one or more carbon-carbon triple bonds at any position of the chain. 2-6 "Alkynyl" refers to an alkynyl group having 2 to 6 carbon atoms and at least one (e.g., 1 to 2) carbon-carbon triple bond. Preferably, C 2-4 Alkynyl (i.e., an alkynyl group having 2 to 4 carbon atoms and 1 to 2 carbon-carbon triple bonds). Specific examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-, 2-, or 3-butynyl, and the like. The alkynyl group may be substituted or unsubstituted. When substituted, the substituent is preferably one or more of the substituent groups described herein.

[0479] As used herein, the term "halogen" refers to fluorine, chlorine, bromine, or iodine.

[0480] As used herein, the term "halo" refers to fluoro, chloro, bromo, or iodo.

[0481] As used herein, the term "haloalkyl" refers to an alkyl group in which one or more (e.g., 1, 2, 3, 4, or 5, etc.) hydrogen atoms are replaced by halogen atoms, wherein the definition of alkyl is as described above. 1-6 "Alkyl" refers to a halogenated alkyl group having 1 to 6 carbon atoms. Preferably, the halogenated C 1-4 Alkyl. More preferably halogenated C 1- 3-alkyl. Specific examples include, but are not limited to, monochloromethyl, dichloromethyl, trichloromethyl, monochloroethyl, 1,2-dichloroethyl, trichloroethyl, monobromoethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, and the like. The haloalkyl group may be substituted or unsubstituted. When substituted, the substituent is preferably one or more of the substituent groups described in this application.

[0482] As used herein, the term "haloalkoxy" refers to an alkoxy group in which one or more (e.g., 1, 2, 3, 4, or 5, etc.) hydrogen atoms are replaced by halogen atoms, wherein the definition of alkoxy is as described above. 1-6"Alkoxy" refers to a halogenated alkoxy group having 1 to 6 carbon atoms. Preferably, the halogenated C 1-4 Alkoxy. More preferably halogenated C 1-3 Alkoxy. Specific examples include, but are not limited to, trifluoromethoxy, trifluoroethoxy, monofluoromethoxy, monofluoroethoxy, difluoromethoxy, difluoroethoxy, and the like. The haloalkoxy group may be substituted or unsubstituted. When substituted, the substituent is preferably one or more of the substituent groups described in this application.

[0483] As used herein, the term "deuterated" refers to a group in which one or more (eg, 1, 2, 3, 4, or 5, etc.) hydrogen atoms are replaced by deuterium atoms.

[0484] As used herein, the term "deuterated alkyl" refers to an alkyl group in which one or more (e.g., 1, 2, 3, 4, or 5, etc.) hydrogen atoms are replaced by deuterium atoms, wherein the definition of alkyl is as described above. 1-6 "Alkyl" refers to a deuterated alkyl group having 1 to 6 carbon atoms. Preferably, it is a deuterated C 1-4 More preferably, deuterated C 1-3 Alkyl. Specific examples include, but are not limited to, monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, monodeuterioethyl, 1,2-dideuterioethyl, trideuterioethyl, and the like. The deuterated alkyl group may be substituted or unsubstituted. When substituted, the substituent is preferably one or more of the substituent groups described in this application.

[0485] As used herein, the term "deuterated alkoxy" refers to an alkoxy group in which one or more (e.g., 1, 2, 3, 4, or 5, etc.) hydrogen atoms are replaced by deuterium atoms, wherein the definition of alkoxy is as described above. 1-6 "Alkoxy" refers to a deuterated alkoxy group having 1 to 6 carbon atoms. More preferably, it is a deuterated C 1-4 Alkoxy. More preferably deuterated C 1-3 Alkoxy. Specific examples include, but are not limited to, trideuteromethoxy, trideuteroethoxy, monodeuteromethoxy, monodeuteroethoxy, dialdeuteromethoxy, dialdeuteroethoxy, and the like. The deuterated alkoxy group may be substituted or unsubstituted. When substituted, the substituent is preferably one or more of the substituent groups described in this application.

[0486] As used herein, the terms "cycloalkyl" and "cycloalkyl ring" are used interchangeably to refer to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon group. The ring carbon atoms of the cycloalkyl group may be optionally substituted with one or more (e.g., 1, 2, 3, 4, 5, etc.) oxo groups to form a cyclic ketone structure. The terms "3 to 20 membered cycloalkyl" or "C 3-20 "Cycloalkyl" refers to a cycloalkyl group having 3 to 20 ring carbon atoms. It may include monocyclic cycloalkyl, spirocyclic alkyl, fused cycloalkyl and bridged cycloalkyl. Preferably, C 3-12 Cycloalkyl (e.g., C 3-8Cycloalkyl, C 3-6 Cycloalkyl, C 3-8 Monocyclic cycloalkyl, etc.), C 5-20 Spiroalkyl, C 5-20 Condensed cycloalkyl, C 5-20 Bridged cycloalkyl, etc.

[0487] As used herein, the term "C 3-6 "Cycloalkyl" refers to a cycloalkyl group having 3 to 6 ring carbon atoms. It can be monocyclic (specific examples include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl); or it can be bicyclic (specific examples include but are not limited to cyclopropyl-cyclopropyl, cyclopropyl-cyclobutyl, cyclopropyl-cyclopentyl, etc.).

[0488] As used herein, the term "C 3-8 "Monocyclic cycloalkyl" and "3 to 8 membered monocyclic cycloalkyl" refer to saturated or partially unsaturated monocyclic hydrocarbon groups having 3 to 8 ring carbon atoms. Preferably, C 3-6 Monocyclic cycloalkyl (i.e., 3 to 6-membered monocyclic cycloalkyl) or C 4-6 Monocyclic cycloalkyl (i.e., 4- to 6-membered monocyclic cycloalkyl). More preferably, it is a C3, C4, C5, or C6 monocyclic cycloalkyl. Specific examples of monocyclic cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.

[0489] As used herein, the terms "spiroalkyl" and "spiroalkyl ring" refer to a saturated or partially unsaturated polycyclic hydrocarbon group formed by two or more monocyclic rings sharing a carbon atom (called a spiro atom). According to the number of spiro atoms shared between the rings, the group can be divided into monospiroalkyl, dispiroalkyl and polyspiroalkyl. The term "5- to 20-membered spiroalkyl" or "C 5-20 Spiroalkyl" refers to a spiroalkyl group having 5 to 20 ring carbon atoms. Preferably, it is a 6 to 14-membered (i.e., C 6- 14 ) spirocycloalkyl. More preferably, it is a 6- to 14-membered monospirocycloalkyl. More preferably, it is a 7- to 11-membered (i.e., C 7-11 ) spirocycloalkyl. More preferably, it is a 7- to 11-membered monospirocycloalkyl. More preferably, it is a 7-, 8-, 9-, 10-, or 11-membered monospirocycloalkyl. Specific examples of spirocycloalkyl include, but are not limited to: These spirocycloalkyl groups may be attached to the rest of the molecule via any of the ring atoms.

[0490] As used herein, the terms "fused cycloalkyl" and "fused cycloalkyl ring" refer to a saturated or partially unsaturated polycyclic hydrocarbon group formed by two or more monocyclic rings sharing a pair of adjacent carbon atoms. Depending on the number of rings formed, fused cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic or polycyclic. The terms "5- to 20-membered fused cycloalkyl" or "C 5-20"Fused cycloalkyl" refers to a fused cycloalkyl having 5 to 20 ring carbon atoms. Preferably, it is a 6 to 14-membered (i.e., C 6-14 ) fused cycloalkyl. More preferably, it is a 6- to 14-membered difused cycloalkyl. More preferably, it is a 7- to 10-membered (i.e., C 7-10 ) fused cycloalkyl. More preferably, it is a 7- to 10-membered di-fused cycloalkyl. More preferably, it is an 8-, 9-, or 10-membered di-fused cycloalkyl. Specific examples of fused cycloalkyl include, but are not limited to: These fused cycloalkyl groups may be attached to the rest of the molecule via any one of the ring atoms.

[0491] As used herein, the terms "bridged cycloalkyl" and "bridged cycloalkyl ring" refer to a saturated or partially unsaturated polycyclic hydrocarbon group formed by sharing two carbon atoms that are not directly connected between two or more monocyclic rings. Depending on the number of rings formed, the bridged cycloalkyl group can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl groups. The terms "5- to 20-membered bridged cycloalkyl" and "C 5-20 "Bridged cycloalkyl" refers to a bridged cycloalkyl group having 5 to 20 ring carbon atoms. Preferably, it is a 6 to 14-membered (i.e., C 6-14 ) bridged cycloalkyl. More preferably 7 to 10 members (ie C 7-10 ) bridged cycloalkyl. Specific examples of bridged cycloalkyl include, but are not limited to: These bridged cycloalkyl groups can be attached to the rest of the molecule via any ring atom.

[0492] The above-mentioned cycloalkyl groups may be substituted or unsubstituted. When substituted, the substituents are preferably one or more substituent groups described in the present application.

[0493] As used herein, the terms "heterocyclyl" and "heterocyclyl ring" are used interchangeably and refer to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon group in which one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, etc.) ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen, or sulfur, but excluding the ring portion of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. When the ring atom is a nitrogen atom, it may be substituted or unsubstituted (i.e., N or NR, R is hydrogen or other substituents as defined herein) and / or the nitrogen atom may form a quaternary ammonium salt. When the heteroatom is a sulfur atom, the sulfur atom may be optionally oxidized (e.g., S(=O) m ', m' is an integer from 0 to 2). When the heteroatom is a phosphorus atom, the phosphorus atom may be optionally oxidized (eg, P(=O) m", m" is an integer 0, 1 or 2). For example, it includes monocyclic heterocyclic groups, spiro heterocyclic groups, fused heterocyclic groups and bridged heterocyclic groups. The ring carbon atoms of the heterocyclic group may be optionally substituted by one or more (e.g., 1, 2, 3, 4 or 5, etc.) oxo groups to form a cyclic ketone, cyclic lactone or cyclic lactam structure. The term "3 to 20 membered heterocyclic group" refers to a heterocyclic group having 3 to 20 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, 5, etc.) ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen or sulfur. The 3 to 20 membered heterocyclic group is preferably a 3 to 10 membered heterocyclic group, a 3 to 12 membered monocyclic heterocyclic group (e.g., a 3 to 8 membered monocyclic heterocyclic group), a 5 to 20 membered spiro heterocyclic group, a 5 to 20 membered fused heterocyclic group, a 5 to 20 membered bridged heterocyclic group, etc.

[0494] The term "3- to 10-membered heterocyclic group" refers to a saturated or partially unsaturated cyclic hydrocarbon group having 3 to 10 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, or 5, etc.) of the ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen, or sulfur. The term "3- to 8-membered heterocyclic group" refers to a saturated or partially unsaturated cyclic hydrocarbon group having 3 to 8 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, or 5, etc.) of the ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen, or sulfur. The heterocyclic group may be monocyclic (specific examples are described in the definition of 3- to 8-membered monocyclic heterocyclic groups) or bicyclic (specific examples include, but are not limited to, cyclopropylcyclotetrahydropyrrole ring, cyclopropylcyclotetrahydrofuran ring, etc.).

[0495] As used herein, the terms "3- to 8-membered monocyclic heterocyclyl," "3- to 8-membered monocyclic heterocyclyl," and "3- to 8-membered monocyclic heterocyclyl ring" refer to a saturated or partially unsaturated monocyclic hydrocarbon group having 3 to 8 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, or 5, etc.) of the ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen, or sulfur. Preferably, it is a 3- to 6-membered monocyclic heterocyclyl group having 3 to 6 ring atoms, wherein one or more (e.g., 1 or 2, etc.) of the ring atoms are heteroatoms. More preferably, it is a 4- to 6-membered monocyclic heterocyclyl group having 4 to 6 ring atoms, wherein one or more (e.g., 1 or 2, etc.) of the ring atoms are heteroatoms. More preferably, it is a 5- or 6-membered monocyclic heterocyclyl group having 5 or 6 ring atoms, wherein one or more (e.g., 1 or 2, etc.) of the ring atoms are heteroatoms.Specific examples of monocyclic heterocyclic groups include, but are not limited to, aziridine, oxirane, azetidine, azetidine-2-one, oxetane, oxetane-2-one, oxazolidine, pyrrolidone, pyrrolidine-2,5-dione, 1,3-dioxolane, dihydrofuran-2(3H)-one, dihydrofuran-2,5-dione, piperidine-2-one, piperidine-2,6-dione, tetrahydro-2H-pyran-2-one, imidazolidine, tetrahydrofuran, tetrahydrothiophene, tetrahydropyrrole, 1,3-dioxolane-2-one, oxazolidin-2-one, imidazolidin-2-one, piperidine, piperazine, piperazin-2-one, morpholine, morpholine-3-one, morpholine-2-one, thiophene ... Morpholin-3-one 1,1-dioxide, thiomorpholine, thiomorpholine-1,1-dioxide, tetrahydropyran, 1,2-dihydroazetadiene, 1,2-dihydrooxetadiene, 2,5-dihydro-1H-pyrrole, 2,5-dihydrofuran, 2,3-dihydrofuran, 2,3-dihydro-1H-pyrrole, 3,4-dihydro-2H-pyran, 1,2,3,4-tetrahydropyridine, 3,6-dihydro-2H-pyran, 1,2,3,6-tetrahydropyridine, 1,3-oxazinane, hexahydropyrimidine, 1,4-dioxane, tetrahydropyrimidin-2(1H)-one, 1,4-dioxane-2-one, 5,6-dihydro-2H-pyran-2-one, 5,6-dihydropyrimidin-4(3H)-one, 3,4-dihydropyridin-2(1H)-one, 5,6-dihydropyridin-2(1H)-one, 5,6-dihydropyrimidin-4(1H)-one, pyrimidin-4(3H)-one, pyrimidin-4(1H)-one, 4,5-dihydro-1H-imidazole, 2,3-dihydro-1H-imidazole, 2,3-dihydrooxazole, 1,3-dioxole, 2,3-dihydrothiophene, 2,5-dihydrothiophene, 3,4-dihydro-2H-1,4-oxazine, 3,4-dihydro-2H-1,4-thiazine 1,1-dioxide, 1,2,3,4-tetrahydropyrazine, 1,3-dihydro-2H-pyrrole-2- Ketone, 1,5-dihydro-2H-pyrrol-2-one, 1H-pyrrole-2,5-dione, furan-2(3H)-one, furan-2(5H)-one, 1,3-dioxol-2-one, oxazole-2(3H)-one, 1,3-dihydro-2H-imidazole-2-one, furan-2,5-dione, 3,6-dihydropyridine-2(1H)-one, pyridine-2,6-(1H,3H)-dione, 5,6-dihydro-2H-pyran-2-one, 3,6-dihydro-2H-pyran-2-one, 3,4-dihydro-2H-1,3-oxazine, 3,6-dihydro-2H-1,3-oxazine, 1,2,3,4-tetrahydropyrimidine, etc.

[0496] As used herein, the term "nitrogen-containing 3 to 8 membered heterocyclic group" refers to a saturated or partially unsaturated cyclic hydrocarbon group having 3 to 8 ring atoms, wherein 1 ring atom is a nitrogen atom, and the other (e.g., 1, 2, 3, 4, or 5, etc.) ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen, or sulfur. The term "nitrogen-containing 4 to 8 membered heterocyclic group" refers to a saturated or partially unsaturated cyclic hydrocarbon group having 4 to 8 ring atoms, wherein 1 ring atom is a nitrogen atom, and the other (e.g., 1, 2, 3, 4, or 5) ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen, or sulfur. The heterocyclic group may be monocyclic or bicyclic. Specific examples include, but are not limited to, aziridine, azetidinyl, azepanyl (i.e., tetrahydropyrrole), azahexyl (i.e., hexahydropyridine), morpholinyl, piperazinyl, and oxazolidine.

[0497] The two ring atoms connected to the monocyclic heterocyclyl ring, including C—C and C—N, can be optionally fused with a cycloalkyl, heterocyclyl, aryl, or heteroaryl group, such as a monocyclic cycloalkyl ring, a monocyclic heterocyclyl ring, a monoaryl ring, a 5- or 6-membered monocyclic heteroaryl ring, as defined herein, to form a fused polycyclic ring. The two ring atoms connected to the monocyclic heterocyclyl ring forming a fused ring with another ring are preferably C—C.

[0498] As used herein, the terms "spiroheterocyclyl" and "spiroheterocyclyl ring" refer to a polycyclic heterocyclic group formed by sharing a carbon atom (called a spiro atom) between two or more saturated or partially unsaturated monocyclic rings, wherein one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, etc.) ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen or sulfur, and the remaining ring atoms are carbon. Each monocyclic ring may contain one or more double bonds, but no ring has a completely conjugated π electron system. According to the number of spiro atoms shared between rings, it can be divided into a single spiroheterocyclyl, a double spiroheterocyclyl or a multi-spiroheterocyclyl. The term "5- to 20-membered spiroheterocyclyl" refers to a spiroheterocyclyl group having 5 to 20 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, 5, etc.) ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen or sulfur. Preferably, it is a 6- to 14-membered spiro heterocyclic group having 6 to 14 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, or 5, etc.) of the ring atoms are heteroatoms. More preferably, it is a 7- to 11-membered spiro heterocyclic group having 7 to 11 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, or 5, etc.) of the ring atoms are heteroatoms. Most preferably, it is a 7-, 8-, or 10-membered monospiro heterocyclic group. Specific examples of spiro heterocyclic groups include, but are not limited to:

[0499] These spiroheterocyclyl groups may be attached to the rest of the molecule via any suitable ring atom.

[0500] As used herein, the terms "fused heterocyclyl" and "fused heterocyclyl ring" refer to a polycyclic heterocyclic group formed by two or more saturated or partially unsaturated monocyclic rings sharing a pair of adjacent ring atoms, wherein one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, etc.) ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen or sulfur, and the remaining ring atoms are carbon. Each monocyclic ring may contain one or more double bonds, but no ring has a completely conjugated π electron system. The shared adjacent ring atom pairs may be CC or NC. Depending on the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups. The term "5- to 20-membered fused heterocyclic group" refers to a fused heterocyclic group having 5 to 20 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, 5, etc.) ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen or sulfur. Preferably, it is a 6 to 14-membered fused heterocyclic group having 6 to 14 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, or 5, etc.) of the ring atoms are heteroatoms. More preferably, it is a 6 to 10-membered fused heterocyclic group having 6 to 10 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, or 5, etc.) of the ring atoms are heteroatoms. More preferably, it is an 8 to 10-membered fused heterocyclic group having 8 to 10 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, or 5, etc.) of the ring atoms are heteroatoms. Most preferably, it is an 8-, 9-, or 10-membered bicyclic fused heterocyclic group. Specific examples of fused heterocyclic groups include, but are not limited to:

[0501] These fused heterocyclic groups may be attached to the rest of the molecule through any suitable ring atom.

[0502] As used herein, the terms "bridged heterocyclic group" and "bridged heterocyclic ring" refer to a polycyclic heterocyclic group formed by two or more saturated or partially unsaturated monocyclic rings sharing two ring atoms that are not directly connected, wherein one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, etc.) ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen or sulfur, and the remaining ring atoms are carbon. According to the number of rings formed, they can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl groups. The term "5 to 20 membered bridged heterocyclic group" refers to a bridged heterocyclic group having 5 to 20 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, 5, etc.) ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen or sulfur. Each monocyclic ring may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is a 6 to 14 membered bridged heterocyclic group. More preferably, it is a 7 to 10 membered bridged heterocyclic group. Specific examples of bridged heterocyclic groups include, but are not limited to:

[0503] These bridged heterocyclic groups may be attached to the rest of the molecule via any suitable ring atom.

[0504] In the present invention, various heterocyclic groups may be optionally substituted. When substituted, the substituents are preferably one or more substituent groups described in this application.

[0505] The term "5- to 15-membered tricyclic heterocyclic group" refers to a tricyclic heterocyclic group having 5 to 15 ring atoms, wherein the three rings may be connected by one or more means selected from spiro-connection, fusion connection, and bridge connection. Specific examples include, but are not limited to, a first monocyclic ring being a 6-membered monocyclic heterocyclic ring, a second monocyclic ring being a 6-membered monocyclic heterocyclic ring, and a third monocyclic ring being a 3- to 6-membered monocyclic heterocyclic ring; wherein the first monocyclic ring is fused to the second monocyclic ring, and the third monocyclic ring is spiro-connected to the second monocyclic ring.

[0506] The term "7- to 12-membered bicyclic heterocyclic group" refers to a bicyclic heterocyclic group having 7 to 12 ring atoms, wherein the two rings are connected by a method selected from spiro, fused, and bridged. Specific examples can be selected from the specific examples of spiro heterocyclic groups, fused heterocyclic groups, and bridged heterocyclic groups described above.

[0507] As used herein, the terms "aryl", "aryl ring" and "aromatic ring" are used interchangeably to refer to an all-carbon monocyclic, all-carbon non-fused polycyclic (rings are connected by covalent bonds and are not fused) or all-carbon fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group, at least one of the rings in the group is aromatic, i.e., has a conjugated π electron system. The term "C 6-14 "Aryl" refers to an aromatic group having 6 to 14 ring atoms. Preferably, C 6-10 Aryl. The C 6-14 The aryl group includes a monocyclic aryl group, a non-condensed polycyclic aryl group, an aromatic condensed polycyclic group, and the like. Examples of the monocyclic aryl group include a phenyl group, and examples of the non-condensed polycyclic aryl group include a biphenyl group.

[0508] In the present invention, when C 6-14 When the aryl group is an aromatic fused polycyclic ring, the aromatic fused polycyclic ring may be a polycyclic group formed by condensing a single aryl ring with one or more single aryl rings, and non-limiting examples thereof include naphthyl, anthracenyl, and the like.

[0509] In some embodiments of the present invention, when C 6-14When the aromatic group is an aromatic fused polycyclic ring, the aromatic fused polycyclic ring may also be a polycyclic group formed by the fusion of a single aromatic ring (such as a phenyl group) and one or more non-aromatic rings, wherein the ring connected to the parent structure is an aromatic ring or a non-aromatic ring. The non-aromatic ring includes but is not limited to a 3- to 6-membered monocyclic heterocyclic ring (preferably a 5- or 6-membered monocyclic heterocyclic ring, the ring carbon atoms of which may be substituted by 1 to 2 oxo groups to form a cyclic lactam or cyclic lactone structure), a 3- to 6-membered monocyclic cycloalkyl ring (preferably a 5- or 6-membered monocyclic cycloalkyl ring, the ring carbon atoms of which may be substituted by 1 or 2 oxo groups to form a cyclic ketone structure). The polycyclic group in which the above-mentioned single aromatic ring is fused to one or more non-aromatic rings may be connected to other groups or the parent structure through nitrogen atoms or carbon atoms, and the ring connected to the parent structure is a single aromatic ring or a non-aromatic ring.

[0510] In the present invention, various aryl groups may be substituted or unsubstituted. When substituted, the substituents are preferably one or more substituent groups described in this application.

[0511] As used herein, the terms "heteroaryl", "heteroaryl ring" and "heteroaromatic ring" are used interchangeably and refer to a monocyclic or fused polycyclic (i.e., shared adjacent ring atom pairs, where the shared adjacent ring atom pairs can be CC or NC) group whose ring atoms are substituted by at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, etc.) heteroatom independently selected from phosphorus, nitrogen, oxygen or sulfur. The heteroaryl group has 6, 10 or 14 shared π electrons, and at least one ring in the group is aromatic. When the ring atom is a nitrogen atom, it can be substituted or unsubstituted (i.e., N or NR, R is hydrogen or other substituents defined herein) and / or the nitrogen atom can form a quaternary ammonium salt. When the heteroatom is a sulfur atom, the sulfur atom can be optionally oxidized (e.g., S(=O) m ', m' is an integer from 0 to 2). When the heteroatom is a phosphorus atom, the phosphorus atom may be optionally oxidized (eg, P(=O) m ", m" is an integer of 0, 1 or 2). The term "5- to 14-membered heteroaryl" refers to a heteroaryl group having 5 to 14 ring atoms, wherein one or more (e.g., 1, 2, 3, 4 or 5, etc.) of the ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen or sulfur. Preferably, it is a 5- to 10-membered heteroaryl group having 5 to 10 ring atoms, wherein one or more (e.g., 1, 2, 3, 4 or 5, etc.) of the ring atoms are heteroatoms. The 5- to 14-membered heteroaryl group may be a monocyclic heteroaryl group, a fused bicyclic heteroaryl group, a fused tricyclic heteroaryl group, or the like.

[0512] As used herein, the term "5- or 6-membered monocyclic heteroaryl" refers to a monocyclic heteroaryl group having 5 or 6 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, or 5, etc.) of the ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen, or sulfur. Specific examples of monocyclic heteroaryl groups include, but are not limited to, thiophene, furan, thiazole, isothiazole, imidazole, oxazole, pyrrole, pyrazole, triazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, tetrazole, isoxazole, oxadiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, and the like.

[0513] As used herein, the term "8- to 10-membered bicyclic heteroaryl" refers to a fused bicyclic heteroaryl group having 8 to 10 ring atoms, wherein one or more (e.g., 1, 2, 3, 4, or 5, etc.) of the ring atoms are heteroatoms selected from phosphorus, nitrogen, oxygen, or sulfur. The fused bicyclic heteroaryl group can be a bicyclic group (preferably a 9- or 10-membered bicyclic heteroaryl ring) formed by fusion of a monocyclic heteroaryl ring (e.g., phenyl) and a monocyclic heteroaryl ring (preferably a 5- or 6-membered monocyclic heteroaryl ring), or a bicyclic group (preferably a 5- or 6-membered monocyclic heteroaryl ring) and a monocyclic heteroaryl ring (preferably a 5- or 6-membered monocyclic heteroaryl ring).

[0514] Any two connected ring atoms on the monocyclic heteroaryl ring, including CC, NC, and NN, can be fused with a cycloalkyl, heterocyclyl, aryl, or heteroaryl group, such as a monocyclic cycloalkyl ring, a monocyclic heterocyclyl ring, a monoaryl ring, a 5- or 6-membered monocyclic heteroaryl ring, to form a fused polycyclic ring. The two connected ring atoms on the monocyclic heteroaryl ring forming a fused ring with another ring are preferably CC, including, but not limited to, the following forms:

[0515] In the above groups The labeled ring atoms are attached to the rest of the molecule.

[0516] Non-limiting examples of 8- to 10-membered bicyclic heteroaryls include benzo[d]isoxazole, 1H-indole, isoindole, 1H-benzo[d]imidazole, benzo[d]isothiazole, 1H-benzo[d][1,2,3]triazole, benzo[d]oxazole, benzo[d]thiazole, indazole, benzofuran, benzo[b]thiophene, quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, pyrido[3,2-d]pyrimidine, pyrido[2,3-d]pyrimidine, pyrido[3,4-d]pyrimidine, pyrido[4,3-d]pyrimidine, 1,8-naphthyridine, 1,7-naphthyridine, 1,6-naphthyridine, 1,5-naphthyridine, pyrazolo[1,5-a]pyrimidine, imidazo[1,2-b]pyridazine, and the like.

[0517] Specific examples of bicyclic heteroaryl groups include, but are not limited to: These groups may be attached to the rest of the molecule via any suitable ring atom. The ring attached to the parent structure may be a monocyclic heteroaryl ring or a benzene ring.

[0518] In some embodiments of the present invention, the fused bicyclic heteroaryl or fused tricyclic heteroaryl can be a polycyclic group formed by the fusion of a monocyclic heteroaryl ring (preferably a 5- or 6-membered monocyclic heteroaryl ring) and one or more non-aromatic rings, wherein the ring connected to the parent structure is a monocyclic heteroaryl ring or a non-aromatic ring. The non-aromatic ring includes but is not limited to a 3- to 6-membered monocyclic heterocyclyl ring (preferably a 5- or 6-membered monocyclic heterocyclyl ring, the ring carbon atoms of the monocyclic heterocyclyl ring may be substituted by 1 to 2 oxo groups to form a cyclic lactam or cyclic lactone structure), a 3- to 6-membered monocyclic cycloalkyl ring (preferably a 5- or 6-membered monocyclic cycloalkyl ring, the ring carbon atoms of the monocyclic cycloalkyl ring may be substituted by 1 or 2 oxo groups to form a cyclic ketone structure), etc. The polycyclic group formed by the fusion of the above-mentioned monocyclic heteroaryl ring and one or more non-aromatic rings can be connected to other groups or the parent structure through nitrogen atoms or carbon atoms, and the ring connected to the parent structure is a monocyclic heteroaryl ring or a non-aromatic ring.

[0519] The 6- to 12-membered heteroarylcycloalkyl group is formed by condensing a monocyclic heteroaryl group with a cycloalkyl group. The ring connected to the parent structure can be a monocyclic heteroaryl group or a cycloalkyl group. For example, a 5-membered monocyclic heteroaryl group is fused with a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group, or a 6-membered monocyclic heteroaryl group is fused with a 3-, 4-, 5-, or 6-membered cycloalkyl group.

[0520] The 6- to 12-membered heteroaryl-heterocyclic group is formed by fusion of a monocyclic heteroaryl group and a heterocyclic group. The ring connected to the parent structure can be a monocyclic heteroaryl group or a heterocyclic group. For example, a 5-membered monocyclic heteroaryl group is fused with a 3-, 4-, 5-, 6-, or 7-membered heterocyclic group, or a 6-membered monocyclic heteroaryl group is fused with a 3-, 4-, 5-, or 6-membered heterocyclic group.

[0521] The various heteroaryl groups of the present invention may be substituted or unsubstituted. When substituted, the substituents are preferably one or more substituent groups described in this application.

[0522] As used herein, the term "hydroxy" refers to -OH.

[0523] As used herein, the term "cyano" refers to -CN.

[0524] As used herein, the term "nitro" refers to -NO2.

[0525] As used herein, the term "benzyl" refers to -CH2-benzene.

[0526] As used herein, the term "oxo" refers to =0.

[0527] As used herein, the term "carboxyl" refers to -C(=O)OH.

[0528] As used herein, the term "acetyl" refers to -COCH3.

[0529] abbreviation:

[0530] Cbz: Carbamoylbenzyl; TBDPS: tert-butyl(methoxy)diphenylsilane;

[0531] NCO: isocyanate; (Bpin)2: bipyraclostrobin.

[0532] The above-mentioned alkyl, heteroalkyl, alkoxy, alkynyl, alkenyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl groups may be substituted or unsubstituted. When substituted, the substituent is preferably one or more groups described in this application.

[0533] As used herein, the term "substituted" refers to the replacement of any one or more hydrogen atoms on a particular atom by a substituent, which may include deuterium and hydrogen variants, as long as the valence of the particular atom is normal and the substituted compound is stable. When the substituent is an oxo group (i.e., =O), it means that two hydrogen atoms are replaced. The term "optionally substituted" or "optionally substituted" means that it may or may not be substituted, and unless otherwise specified, the type and number of substituents may be arbitrary on the basis of chemical achievable.

[0534] Indicates the location of chemical bonds.

[0535] It indicates that a double bond may exist at any position in the ring or not, and includes various situations including saturated ring systems, unsaturated non-aromatic ring systems with double bonds, and aromatic ring systems.

[0536] In this disclosure, Indicates the absolute configuration of a stereocenter. Unless otherwise specified Including possible use Two situations, as long as the structure allows.

[0537] When the ring appears When the connection position is uncertain, it means that the connection site is located at Any atom in the monocyclic ring, as long as the valence permits.

[0538] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 0-2 Rs, the group may be optionally substituted with up to two Rs, with each occurrence of R being an independent choice. Furthermore, combinations of substituents and / or their variants are permissible only if such combinations result in stable compounds.

[0539] In any embodiment, any or all hydrogens present in the compound, or hydrogens in a specific group or moiety within the compound, may be replaced by deuterium or tritium. From one to the maximum number of hydrogens present in the compound may be replaced by deuterium. From one to the maximum number of hydrogens present in any group in the general compound or in the specific compound may be deuterated. For example, when describing a group as ethyl, the ethyl group may be C2H5 or C2H5 in which x (1 to 5) hydrogens are replaced by deuterium, such as C2D x H 5-x When describing a group as a deuterated ethyl group, the deuterated ethyl group may be C2H5 in which x (1 to 5) hydrogen atoms are replaced by deuterium, for example, C2D x H 5-x The stable deuterated derivatives of the present invention are preferably stable deuterated isotope derivatives obtained by replacing any deuterated hydrogen atom in each formula with 1 to a maximum number (e.g., 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, etc.) of deuterium atoms.

[0540] Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. Exemplary isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 32 P. 33 P. 35 S. 18 F. 36 Cl, 123 I and 125 I. Isotope-labeled compounds (e.g. 3 H and 14 C) can be used in compound or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e.,14 C) isotopes are useful because they are easy to prepare and detect. Alternatively, heavier isotopes, such as deuterium (i.e., 2 H) substitutions may provide certain therapeutic benefits due to enhanced metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements). In some embodiments, one or more hydrogen atoms are replaced by 2 H or 3 H replacement, or one or more carbon atoms are 13 C or 14 C-enriched carbon replacement. Positron-emitting isotopes, such as 15 O. 13 N. 11 C and 18 F can be used in positron emission tomography (PET) studies to examine substrate receptor occupancy. The preparation of isotopically labeled compounds is known to those skilled in the art. For example, isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed for the compounds of the invention described herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. BRIEF DESCRIPTION OF THE DRAWINGS

[0541] Figure 1 is the X-ray single crystal diffraction molecular stereostructure of intermediate 11-e-1.

[0542] FIG2 is an X-ray single crystal diffraction molecular stereostructure diagram of intermediate 51-7A.

[0543] FIG3 is an X-ray single crystal diffraction molecular stereostructure diagram of intermediate 118-12. DETAILED DESCRIPTION

[0544] The compounds of the present invention can be prepared by various synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining the same with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include, but are not limited to, the examples of the present invention.

[0545] The present invention is described in detail below by way of examples, but this is not intended to limit the present invention in any way. The present invention has been described in detail herein, and specific embodiments thereof are disclosed. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention. Where specific conditions are not specified in the examples, the experiments were carried out under conventional conditions or the conditions recommended by the manufacturer. Where the manufacturer of the reagents or instruments is not specified, they are all conventional products that can be obtained commercially.

[0546] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and mass spectrometry (MS).

[0547] NMR measurements were performed using a Bruker Avance NEO 400 or Bruker Avance NEO 500 nuclear magnetic resonance spectrometer. Chemical shifts (δ) were expressed in parts per million (ppm). The measurement solvents were as indicated in the examples, and the internal standard was tetramethylsilane (TMS).

[0548] MS was determined using an Agilent 1100 liquid chromatograph.

[0549] High performance liquid chromatography (HPLC) analysis was performed using a Waters 2695 high performance liquid chromatograph.

[0550] High performance liquid chromatography (HPLC) was performed using a Waters 2767 HPLC.

[0551] Chiral HPLC analysis was performed using a Waters 2695 high performance liquid chromatograph or a Waters Investigator SFC system.

[0552] Chiral preparations were performed using a Gilson GX-281 chromatograph or a Waters SFC-80 chromatograph.

[0553] The thin layer chromatography silica gel plates used are Qingdao GF254 or Yantai Huanghai HSGF254 silica gel plates. The silica gel plates used for thin layer chromatography (TLC) are 0.15mm-0.2mm in size. The size used for thin layer chromatography separation and purification of products is 0.4mm-0.5mm in size.

[0554] Column chromatography generally uses an ISCO CombiFlash NextGen 300 column chromatography system using Agela Flash Column Silica-Cs series silica gel columns.

[0555] The preparative HPLC used in the following examples, unless otherwise specified, can adopt the following conditions:

[0556] Preparative HPLC (ammonium bicarbonate method 1): Column type: Waters XBridge C18, 19*250 mm, 5 μm; Mobile phase system: A: 5 mmol / L ammonium bicarbonate aqueous solution; B: preparative-grade acetonitrile; Flow rate: 15 ml / min; B% = 20%-100%; Column temperature: room temperature.

[0557] Preparative HPLC (ammonium bicarbonate method 2): chromatographic column: Welch Xtimate C18, 21.2*150 mm, 5 μm; mobile phase A: 5 mmol / L ammonium bicarbonate aqueous solution, mobile phase B: acetonitrile; flow rate: 15 mL / min; column temperature: room temperature.

[0558] Preparative HPLC (formic acid method 1): Column type: Waters XBridge C18, 19*250 mm, 5 μm; Mobile phase system: A: 0.1% formic acid in water; B: preparative-grade acetonitrile; Flow rate: 15 ml / min; B% = 20%-100%; Column temperature: room temperature.

[0559] Preparative HPLC (formic acid method 2): chromatographic column: Welch Xtimate C18, 21.2*150 mm, 5 μm; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow rate: 15 ml / min; column temperature: room temperature.

[0560] Preparative HPLC (trifluoroacetic acid method): chromatographic column: Waters XBridge C18, 190*250 mm, 5 μm; mobile phase system: A: 0.1% trifluoroacetic acid aqueous solution; B: preparative-grade acetonitrile; flow rate: 15 ml / min; B% = 20%-100%; column temperature: room temperature.

[0561] Preparative HPLC (hydrochloric acid method): chromatographic column: Waters XBridge C18, 190*250 mm, 5 μm; mobile phase system: A: 0.1% hydrochloric acid aqueous solution; B: preparative grade acetonitrile; flow rate: 15 ml / min; B% = 20%-100%; column temperature: room temperature.

[0562] Preparative HPLC (ammonia method): chromatographic column: Waters Xbridge C18, 19*150 mm, 5 μm; mobile phase A: 0.1% ammonia solution, mobile phase B: acetonitrile; flow rate: 15 mL / min; column temperature: room temperature.

[0563] 3 min LCMS conditions: A: water (0.05% TFA) B: ACN (0.05% TFA) Elution gradient: 5%-95% B in 3 min Flow rate: 1.7 ml / min Column type: SunFire C18, 4.6*50 mm, 3.5 um Column temperature: 40°C.

[0564] Analytical HPLC conditions: A: water (0.05% TFA) B: ACN (0.05% TFA) Elution gradient: 10%-95% B in 15 min Flow rate: 1 ml / min Column type: SunFire C18, 4.6*150 mm, 3.5 um Column temperature: 40°C.

[0565] Single crystal diffraction instrument parameters:

[0566] Light source: Cu target X-ray:

[0567] Detector: CMOS area detector Resolution:

[0568] Current and voltage: 50kV, 1.2mA Exposure time: 5s

[0569] Distance from surface detector to sample: 40mm Test temperature: 170(2)K

[0570] Preparation Example 1 Synthesis of Intermediate 1

[0571] Step 1: Weigh compound 1a (10 g, 46.279 mmol) and dissolve it in tetrahydrofuran (100 mL). Add diboric acid pinacol ester (17.63 g, 69.419 mmol), 1,5-cyclooctadiene iridium chloride dimer (0.93 g, 1.388 mmol), and 4,4'-di-tert-butyl-2,2'-bipyridine (1.86 g, 6.942 mmol). React at 80°C under nitrogen for 15 hours, filter with celite, and concentrate under reduced pressure to obtain crude compound 1b, which is used directly in the next reaction. ES-API[M+H + ]=260.0.

[0572] Step 2: The crude compound 1b obtained in the previous step was dissolved in acetonitrile (100 mL), and hydrogen peroxide (1308.25 mg, 11.543 mmol) was added dropwise under an ice-water bath. The mixture was reacted at room temperature for 3 hours, and a saturated sodium sulfite solution (20 mL) was added to quench the reaction. The mixture was concentrated under reduced pressure and extracted with dichloromethane (25 mL*3). The organic phase was washed with water (20 mL) and saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product. The product was purified by rapid silica gel column purification (petroleum ether / ethyl acetate = 1 / 1) to obtain intermediate 1 (7000 mg, 30.162 mmol, yield 87.10%) as a yellow solid. ES-API [M+H + ]=232.1,234.1.

[0573] Preparation Example 2 Synthesis of Intermediate 4-1

[0574] Step 1: Dissolve compound 4a (60 g, 181.609 mmol) in DMF (200 mL) and add sodium bicarbonate (45.77 g, 544.827 mmol). Add iodomethane (33.918 mL, 544.827 mmol) dropwise in an ice-water bath under nitrogen protection. React at room temperature overnight. Add water (200 mL) and extract with ethyl acetate (200 mL x 3). Wash with water (200 mL) and saturated brine (200 mL x 3), dry over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain crude compound 4b (65 g, 188.729 mmol, yield 103.92%) as an oily liquid. ES-API[M-156+H] + =189.1.

[0575] Step 2: Dissolve crude compound 4b (65 g, 188.729 mmol) in dichloromethane (200 mL). Add trifluoroacetic acid (200 mL) dropwise in an ice-water bath under nitrogen protection. Allow to react overnight at room temperature. Concentrate under reduced pressure to obtain crude compound 4c as a colorless, transparent oily liquid. Use directly in the next reaction. ES-API[M+H] + =145.1.

[0576] Step 3: Compound 4d (50 g, 136.896 mmol) was dissolved in tetrahydrofuran (300 mL) and water (75 mL). Lithium hydroxide monohydrate (9.38 g, 223.415 mmol) was added and reacted at room temperature for 4 hours. The pH was adjusted to 3 with 1N HCl. The mixture was extracted with ethyl acetate (200 mL x 3), washed with water (200 mL x 3), washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford compound 4e (48 g, 136.670 mmol, yield 99.83%) as a colorless, transparent oily liquid. [ES-API M-56+H] + =295.0.

[0577] Step 4: Compound 4c of step 2 was dissolved in anhydrous dichloromethane (200 mL), and NMM (100 g, 996 mmol) was added dropwise under nitrogen protection in an ice-water bath, followed by compound 4e (35 g, 99.655 mmol), EDCI (38.07 g, 199.311 mmol), and HOBt (4.04 g, 29.897 mmol). The mixture was reacted at room temperature for 4 hours, washed with water (200 mL), 1N HCl (80 mL), and saturated brine (200 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and slurried (petroleum ether / ethyl acetate = 8 / 1) to obtain compound intermediate 4-1 (33 g, 69.129 mmol). The mother liquor was then purified by flash silica gel column to obtain compound intermediate 4-1 (4 g, 8.34 mmol). A total of intermediate 4-1 (37 g, 77.5 mmol, yield 78.7%) was obtained. White solid ES-API M-56+H] + =477.1.

[0578] Preparation Example 3 Synthesis of Intermediate 11

[0579] Step 1: Dissolve Intermediate 1 (500 mg, 2.154 mmol) in N,N-dimethylformamide (15 mL). Add benzyl bromide (737 mg, 4.308 mmol) and potassium carbonate (893 mg, 6.462 mmol) to the solution. After the addition is complete, stir the reaction at 80°C for 17 hours. After completion of the reaction, add water (30 mL) to the reaction solution and extract with ethyl acetate (20 mL*2). The organic phase is separated, washed with saturated brine (40 mL*3), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product is purified using a flash silica gel column (methanol / dichloromethane: 0%-2%) to obtain Intermediate 4 (600 mg, 1.862 mmol, yield 86.44%) as a white solid. ES-API: [M+H] + =322.1,324.1.

[0580] Step 2: To a solution of intermediate 4 (3 g, 9.311 mmol) in tetrahydrofuran (20 mL) under nitrogen was slowly added isopropylmagnesium chloride-lithium chloride complex (10.027 mL, 13.035 mmol, 1.3 M tetrahydrofuran solution) at 0°C. The mixture was stirred at zero degrees for 0.5 hours. The above solution was then added dropwise to a solution of 3,3-dimethyltetrahydropyran-2,6-dione (1.59 g, 11.173 mmol) in tetrahydrofuran (20 mL) at -10°C, and the mixture was stirred at 0°C for 2 hours. The reaction was quenched by adding 4 M hydrochloric acid / dioxane (4 mL) dropwise to adjust the pH of the solution to 4-5. The reaction mixture was extracted with ethyl acetate (20 mL x 3), dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a silica gel column (petroleum ether / ethyl acetate = 1 / 1) to obtain compound 11-a (2.25 g, 5.837 mmol, yield 62.69%). ES-API: [M+H] + =386.2.

[0581] Step 3: To a solution of compound 11-a (1000 mg, 2.594 mmol) in ethanol (20 mL) was added (4-bromophenyl)hydrazine (970.36 mg, 5.188 mmol) and a 4M hydrochloric acid-1,4-dioxane solution (3.891 mL), and the reaction was stirred at 90°C for 36 hours. The mixture was concentrated, and the pH was adjusted to neutral by adding aqueous sodium bicarbonate solution. The mixture was diluted with water and extracted with ethyl acetate (20 mL x 3), dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a silica gel column (petroleum ether / ethyl acetate = 1 / 2) to obtain compound 11-b (1.15 g, 1.974 mmol, yield 76.09%). ES-API: [M+H] + =582.2,584.2.

[0582] Step 4: Dissolve compound 11-b (1.15 g, 1.974 mmol) in trifluoroacetic acid (10 mL). Heat the mixture to 65°C and stir for 2 hours, then concentrate under reduced pressure and dilute with ethyl acetate. Adjust the pH of the residue to 7-8 with saturated ammonium bicarbonate, then extract with ethyl acetate (20 mL x 3). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 2) to obtain compound 11-c (780 mg, 1.379 mmol, yield 69.87%). ES-API: [M+H] + =565.2,567.2.

[0583] Step 5: Compound 11-c (780 mg, 1.379 mmol) was dissolved in dry N,N-dimethylformamide (5 mL), and cesium carbonate (1347.83 mg, 4.137 mmol) and iodoethane (1075.41 mg, 6.895 mmol) were added sequentially. Under nitrogen protection, the reaction was stirred at room temperature for 2 hours. Extraction was performed with ethyl acetate (20 mL × 3). The organic layers were combined, washed with water (60 mL) and saturated brine (60 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 2) to obtain compound 11-d (750 mg, 1.264 mmol, yield 91.61%). ES-API: [M+H] + =593.2,595.2.

[0584] Step 6: Dissolve compound 11-d (750 mg, 1.264 mmol) in dry tetrahydrofuran (10 mL), cool to 0°C in an ice-water bath, and slowly add lithium aluminum tetrahydride (3.159 mL, 3.159 mmol, 1M tetrahydrofuran solution) dropwise under nitrogen protection. After the addition is complete, continue stirring at 0°C for 1 hour. LCMS indicates that the reaction is complete, and slowly add water (0.12 mL), sodium hydroxide aqueous solution (0.12 mL, 15%), and water (0.36 mL) to quench the reaction mixture. After stirring the suspension at room temperature for 30 minutes, filter through celite, and wash with ethyl acetate (100 mL). The mother liquor is dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash silica gel column (ethyl acetate / petroleum ether = 20% to 60%) to obtain two intermediate compounds. The structure of one of the intermediate compounds is: 3-((R a )-2-(5-(benzyloxy)-2-((1S)-1-methoxyethyl)pyridin-3-yl)-5-bromo-1-ethylindol-3-yl)-2,2-dimethylpropan-1-ol (11-e-1, 300 mg, 0.544 mmol, yield 43.05%). 11-e-1: Rt = 1.847 min (3 min LCMS). 1H NMR(400MHz,DMSO)δ8.48(d,J=2.8Hz,1H),7.84(d,J=2.0Hz,1H),7.45–7.30(m,7 H),7.25–7.20(m,1H),5.28–5.17(m,2H),4.46(t,J=5.2Hz,1H),4.00–3.90(m,2H) ,3.82–3.72(m,1H),3.02–2.90(m,2H),2.79(s,3H),2.55(d,J=14.0Hz,1H),2.09( d,J=14.0Hz,1H),1.32(d,J=6.0Hz,3H),1.00(t,J=7.2Hz,3H),0.55–0.48(m,6H). ES-API:[M+H] + =551.2,553.2.

[0585] Another intermediate compound structure is: 3-((S a )-2-(5-(benzyloxy)-2-((1S)-1-methoxyethyl)pyridin-3-yl)-5-bromo-1-ethylindol-3-yl)-2,2-dimethylpropan-1-ol (11-e-2, 210 mg, 0.381 mmol, yield 30.13%). ES-API: [M+H] + =551.2,553.2. 11-e-2: Rt=1.758min (3min LCMS).

[0586] Step 7: Under nitrogen, compound 11-e-1 (18 g, 32.6 mmol), bis(pinacolato)diboron (16.6 g, 65.2 mmol), potassium acetate (6.41 g, 65.27 mmol), and Pd(dppf)Cl2 (2.39 g, 3.26 mmol) were mixed in anhydrous toluene (200 mL) and stirred at 90°C for 4 h. After the reaction, the mixture was cooled and concentrated to remove the toluene. 300 mL of ethyl acetate and 500 mL of water were poured into the mixture. Extraction with ethyl acetate was performed three times, followed by washing with 500 mL of water and 500 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a flash silica gel column (0-50% petroleum ether / ethyl acetate) to obtain compound intermediate 11 (20.8 g, 85% yield). ES-API[M+H] + =599.3.

[0587] Single crystal growth of intermediate 11-e-1

[0588] Single crystal growth: Approximately 10 mg of intermediate 11-e-1 powder was weighed and added to 1 mL of acetonitrile. The mixture was sonicated until completely dissolved and then slowly evaporated in a fume hood. After a period of time, yellow-brown needle-shaped crystals, representing single crystals of intermediate 11-e-1, precipitated. X-ray single crystal diffraction analysis was performed using a Bruker D8 Venture instrument. The results are shown in Table 1 and Figure 1 below. Figure 1 shows an ellipsoidal diagram of the molecular structure.

[0589] Structural analysis and refinement process:

[0590] After the diffraction data were integrated and reduced using the SAINT program, the data were empirically corrected for absorption using the SADABS program. The single crystal structure was directly resolved using SHELXT2014 and refined using the least squares method. The hydrogen atom refinement process was performed using isotropic calculations. The hydrogen atoms on N and O were obtained using residual electron density, and the hydrogen atoms on CH were obtained using calculated hydrogenation, and were refined using the riding model. The Flack constant is 0.035 (14). In Figure 1, C22 is S-configured, and the axial chirality of C9-C17 is R. a configuration.

[0591] Crystal data:

[0592] Table 1

[0593] Preparation Example 4 Synthesis of Intermediate 10-1

[0594] Step 1: (S)-1-Boc-3-carboxypyrrolidine (1.14 g, 5.285 mmol) was dissolved in dichloromethane (40 mL). N-methyl-L-valine methyl ester hydrochloride (800 mg, 4.404 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (2.51 g, 6.606 mmol), and N,N'-diisopropylethylamine (2.84 g, 22.019 mmol) were added at 0°C. The reaction mixture was stirred at room temperature for 1 hour. Water (15 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (25 mL). The organic phase was washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by flash silica gel column purification (tetrahydrofuran / petroleum ether: 0-30%) to obtain compound intermediate 10-1 (900 mg, yield 59.7%) as a colorless liquid. ES-API: [M+Na] + =365.2.

[0595] Preparation Example 5 Synthesis of Intermediate 62-1

[0596] Step 1: Under nitrogen protection, compound 15-6 (10.5 g, 34.63 mmol), racemic-(R)-2-(1-methoxyethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (16.6 g, 63.084 mmol), CataCXium A Pd G3 (2.52 g, 3.463 mmol), toluene (30 mL), water (30 mL) and potassium phosphate (22.05 g, 103.892 mmol) were mixed in dioxane (90 mL) and stirred at 110 degrees for 4 h. After the reaction, 300 mL of ethyl acetate was added, and the mixture was washed sequentially with 150 mL of water and 150 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified using a flash silica gel column (0-80% petroleum ether / ethyl acetate) to obtain compound 62-a (12 g, 33.382 mmol, yield 96.40%). ES-API[M+H] + =360.3.

[0597] Step 2: Under nitrogen, compound 62-a (9.5 g, 26.428 mmol) was dissolved in tetrahydrofuran (300 mL) and cooled to 0°C. Lithium aluminum hydride solution (52.856 mL, 52.856 mmol) was slowly added and stirred at room temperature for 1 hour. The mixture was diluted with an appropriate amount of tetrahydrofuran and cooled to 0°C. 2 mL of water was slowly added, followed by 2 mL of 15% aqueous sodium hydroxide solution and 6 mL of water. The mixture was warmed to room temperature and stirred for 15 minutes. Anhydrous sodium sulfate was added and stirred for 15 minutes. The mixture was filtered to remove salt. The filter cake was washed with ethyl acetate, concentrated, dried, and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10:90) to give compound 62-b (2.8 g, 8.447 mmol, yield 31.96%, retention time: 1.54 minutes, structure arbitrarily assigned). ES-API[M+H] + =332.2; and 62-sp (2.5 g, 7.53 mmol, yield 28.549, retention time 1.51 minutes, structure arbitrarily assigned), ES-API [M + H] + =332.2.

[0598] Step 3: Under nitrogen protection, compound 62-b (2 g, 6.034 mmol) and NBS (2.15 g, 12.068 mmol) were mixed in N,N-dimethylformamide (5 mL) and stirred at 50 degrees for 2 h. After the reaction, 30 mL of ethyl acetate was poured into the mixture, and the mixture was washed with 15 mL of water and 15 mL of saturated brine in sequence. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a flash silica gel column (0-80% petroleum ether / ethyl acetate) to obtain compound 62-c (2.2 g, 5.361 mmol, yield 88.85%), ES-API [M+H]+ =410.1 / 412.1.

[0599] Step 4: Under nitrogen protection, compound 62-c (2 g, 4.874 mmol), DMAP (0.06 g, 0.487 mmol), acetic anhydride (0.915 mL, 9.748 mmol) and DIPEA (1.89 g, 14.621 mmol) were mixed in dichloromethane (50 mL) and stirred at 60 degrees for 18 hours. After the reaction, 100 mL of dichloromethane was poured into the mixture, and the mixture was washed with 150 mL of water and 150 mL of saturated brine in sequence. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to give compound 62-d (2.2 g, 4.87 mmol, yield 100%), ES-API [M+H] + =452.1 / 454.1.

[0600] Step 5: Under nitrogen, compound 62-d (2.2 g, 4.863 mmol), pinacol diboronate (2.47 g, 9.726 mmol), 1,5-cyclooctadiene iridium chloride dimer (0.16 g, 0.243 mmol), and 4,4'-di-tert-butyl-2,2'-bipyridine (0.13 g, 0.486 mmol) were mixed in cyclohexane (50 mL) and stirred at 80°C for 18 h. After the reaction, the mixture was concentrated to give crude compound 62-e (2.38 g).

[0601] Step 6: Compound 62-e (2.38 g, 4.8 mmol) was dissolved in acetonitrile (60 mL), H2O2 (1.632 mL, 14.400 mmol) was added at 0°C, and stirred at 20°C for 2 h. After the reaction, 100 mL of ethyl acetate and excess Na2S2O3 solution were poured into the solution, and the mixture was washed with 150 mL of water and 150 mL of saturated brine in sequence. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a flash silica gel column (0-80% petroleum ether / ethyl acetate) to give compound 62-f (1.4 g, 2.989 mmol, two-step yield: 62%), ES-API[M+H] + =468.1 / 470.1.

[0602] Step 7: Dissolve compound 62-f (800 mg, 1.708 mmol) in methanol (3 mL), tetrahydrofuran (3 mL), and water (3 mL). Add lithium hydroxide (286.67 mg, 6.832 mmol) to the above solution. After the addition is complete, the reaction is stirred at room temperature for 17 hours. After the reaction is complete, the reaction solution is acidified to weak acidity (pH = approximately 6) with dilute hydrochloric acid (1 M). The resulting solution is extracted with ethyl acetate (20 mL*3). The organic phase is washed with saturated brine (50 mL), dried, and concentrated to obtain the crude product. The crude product is purified on a flash silica gel column (ethyl acetate / petroleum ether: 0-100%) to obtain compound 62-g (700 mg, 1.642 mmol, yield 96.13%) as a light yellow solid. ES-API: [M+H] + =426.1,428.1.

[0603] Step 8: Dissolve compound 62-g (700 mg, 1.642 mmol) in toluene (15 mL), dioxane (3 mL), and water (3 mL). Add compound 15-2 (1355.67 mg, 2.463 mmol), potassium phosphate (871.22 mg, 4.105 mmol), and 1,1'-bis(di-tert-butylphosphino)ferrocenedichloropalladium(II) (160.32 mg, 0.246 mmol) to the above solution. Replace the atmosphere with nitrogen three times and stir the reaction at 80°C for 3 hours. Add ethyl acetate (30 mL) and water (20 mL) to the reaction mixture. Separate the organic phase, wash with saturated brine (60 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The crude product was purified by flash silica gel column chromatography (tetrahydrofuran / petroleum ether: 0-50%) to give the target compound 62-h (1100 mg, 1.429 mmol, yield 87.02%) as a gray solid. ES-API: [M+H] + =770.3.

[0604] Step 9: Compound 62-h (1100 mg, 1.429 mmol) was dissolved in tetrahydrofuran (10 mL) and water (10 mL). Lithium hydroxide (85.72 mg, 3.572 mmol) was added at 0°C and the reaction was stirred at room temperature for 18 hours. The reaction solution was adjusted to pH 6 with 1M dilute hydrochloric acid and extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 62-i (1000 mg, 1.323 mmol, 92.60% yield) as an oily solid. ES-API: [M+H] + =756.3.

[0605] Step 10: Dissolve compound 62-i (1100 mg, 1.455 mmol) in dichloromethane (40 mL). Add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (7811 mg, 40.745 mmol), 1-hydroxybenzotriazole (983 mg, 7.276 mmol), and diisopropylethylamine (7.6 mL, 43.655 mmol) to the solution at room temperature. After the addition is complete, stir the reaction at room temperature for 18 hours. Add dichloromethane (100 mL) to the reaction mixture, wash with dilute hydrochloric acid (0.5 M, 20 mL x 2), wash with saturated brine (100 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The crude product was purified by flash silica gel column chromatography (tetrahydrofuran / petroleum ether: 0-60%) to obtain the target compound 62-j (150 mg, 0.203 mmol, yield 13.97%) as a white solid. ES-API: [M+H] + =738.3.

[0606] Step 11: Dissolve compound 62-j (290 mg, 0.393 mmol) in dichloromethane (10 mL). Add triethylamine (0.164 mL, 1.179 mmol) and 1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide (238.67 mg, 0.668 mmol) to the solution. After the addition is complete, the reaction is stirred at room temperature for 2 hours. After the reaction is complete, the reaction solution is concentrated to obtain a crude product. The crude product is purified using a flash silica gel column (methanol / dichloromethane: 0%-3%) to obtain compound 62-k (300 mg, 0.345 mmol, yield 87.75%) as a white solid. ES-API: [M+H] + =870.1.

[0607] Step 12: Compound 62-k (50 mg, 0.057 mmol) was dissolved in methanol (0.5 mL), and 4 M hydrochloric acid / dioxane (3 mL, 0.196 mmol) was added. The mixture was reacted at room temperature under nitrogen for 1 hour. After the reaction, the mixture was concentrated under reduced pressure to obtain the intermediate compound 62-1 (39 mg, 0.045 mmol, yield 86.68%) as a yellow solid. ES-API: [M+H] + =770.2.

[0608] Preparation Example 6 Synthesis of Intermediate 62-p

[0609] Step 1: To a solution of tert-butyl 4-cyano-4-(hydroxymethyl)piperidin-1-carboxylate (3.00 g, 12.4484 mmol) in tetrahydrofuran (150 mL) were added 2H-isoindole-1,3-dione (2.02 g, 13.733 mmol), PPh3 (5.87 g, 22.472 mmol), and DIAD (4.54 g, 22.472 mmol), and the reactants were stirred at 40°C for 3 hours. After the reaction was completed, water (100 mL) and ethyl acetate (100 mL) were added. After separation of the organic layer, the mixture was further washed with saturated sodium chloride solution (100 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated. Purification by silica gel column chromatography (ethyl acetate / petroleum ether = 1 / 2) gave compound 62-1 (2500 mg, 6.767 mmol, yield 54.21%). ES-API: [M+H]+=370.1.

[0610] Step 2: Dissolve compound 62-1 (2 g, 5.414 mmol) in dichloromethane (6 mL), add trifluoroacetic acid (6.219 mL, 81.208 mmol), react at room temperature for 1 hour, concentrate in vacuo, and dry to obtain compound 62-m (1.45 g, crude product). ES-API: [M+H]+ = 270.1.

[0611] Step 3: Dissolve compound 62-m (1.45 g, crude product) in acetonitrile (15 mL), add potassium carbonate (2.31 g, 16.710 mmol) and 3-bromoprop-1-yne (0.53 g, 4.456 mmol), and react at room temperature for 3 hours. After the reaction is complete, add water (50 mL) and ethyl acetate (50 mL). After separating the organic layer, wash it with saturated sodium chloride solution (50 mL x 3), dry it over anhydrous sodium sulfate, filter it, and concentrate it. Purify compound 62-n (800 mg, 2.603 mmol, yield 46.73%) using silica gel column chromatography. ES-API: [M+H] + =308.1.

[0612] Step 4: Dissolve compound 62-n (800 mg, 2.603 mmol) in ethanol (15 mL), add 30% methylamine / methanol solution (4 g, 39.045 mmol), and heat to 80°C for 6 hours. After completion of the reaction, concentrate to remove excess methylamine to obtain compound 62-o (980 mg, crude product). ES-API: [M+H]+ = 178.1.

[0613] Step 5: Dissolve compound 62-o (980 mg, crude product) in tetrahydrofuran (15 mL), add saturated aqueous sodium bicarbonate (5 mL) and di-tert-butyl dicarbonate (1.12 mL, 5.2 mmol), and react for 1 hour. After the reaction is complete, add water (50 mL) and ethyl acetate (50 mL). After separating the organic layer, wash it with saturated sodium chloride solution (50 mL x 3), dry it over anhydrous sodium sulfate, filter it, and concentrate it. Purify it using silica gel column chromatography to obtain compound 62-p (500 mg, 1.80 mmol, two-step yield 69.3%). ES-API: [M+H] + =278.1.

[0614] Preparation Example 7 Synthesis of Intermediate 8-8

[0615] Step 1: Dissolve compound 1-10 (5 g, 9.22 mmol) in N,N-dimethylformamide (50 mL), slowly add 60% sodium hydride solid (0.55 g, 13.82 mmol) under ice bath conditions, and stir for 0.5 hours. Then add benzenesulfonyl chloride (1.25 mL, 9.77 mmol) and continue stirring for 1 hour. The reaction solution is quenched with 50 mL of saturated ammonium chloride solution and extracted three times with 50 mL of ethyl acetate. The organic phases are combined and washed with 50 mL of saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by flash silica gel column (0-5% tetrahydrofuran / petroleum ether) to obtain compound 8-8a (6.1 g) with a yield of 97% as an oil. ES-API: [M+H] + =682.0.

[0616] Step 2: Under ice-bath conditions, add a 1M solution of diisobutylaluminum hydride in n-hexane (14.65 mL, 14.65 mmol) to a solution of morpholine (1.31 g, 15.01 mmol) in tetrahydrofuran (30 mL) and stir for 30 minutes. Then, add a solution of compound 8-8a (2.5 g, 3.66 mmol) in tetrahydrofuran (30 mL) to the above reaction solution and stir at room temperature for 1 hour. After completion of the reaction, quench with 60 mL of 1M hydrochloric acid solution and extract three times with 60 mL of ethyl acetate solution. The organic phases are combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a flash silica gel column (0-5% tetrahydrofuran / petroleum ether) to obtain compound 8-8b (2 g, yield 85%) as an oil. ES-API: [M+H] + =638.0.

[0617] Step 3: Dissolve compound 8-8b (2 g, 3.13 mmol) in tetrahydrofuran (30 mL), add tetrabutylammonium fluoride solution (5 mL, 5.00 mmol), and stir at room temperature for 1 hour. The reaction solution was quenched with 10 mL of saturated ammonium chloride solution and extracted three times with 10 mL of ethyl acetate solution. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified using a flash silica gel column (0-8% methanol / dichloromethane) to obtain compound 8-8c (1.5 g, yield 96%) as a yellow oil. ES-API: [M+H] + =498.1.

[0618] Step 4: Under nitrogen protection, compound 8-8c (1.5 g, 3.01 mmol), (S)-4-(6-(1-methoxyethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester (2.02 g, 4.51 mmol, preparation method reference US2021130303A1), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (0.44 g, 0.60 mmol) and potassium carbonate (1.25 g, 9.03 mmol) in water (4 mL) and dioxane (20 mL) were stirred at 100 ° C for 2 hours. The reaction solution was poured into 50 mL of ethyl acetate and washed with 15 mL of water and 15 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified using a flash silica gel column (0-8% methanol / dichloromethane) to obtain compound 8-8d (1800 mg, yield 81%). ES-API: [M+H] + =739.3.

[0619] Step 5: Dissolve compound 8-8d (1.2 g, 1.62 mmol) in tetrahydrofuran (15 mL), slowly add 60% sodium hydride solid (0.19 g, 4.87 mmol) under ice bath conditions, and stir for 0.5 hours. Then add iodoethane (0.39 mL, 4.87 mmol) and continue stirring for 1 hour. The reaction solution is quenched with 20 mL of saturated ammonium chloride solution and extracted three times with 20 mL of ethyl acetate. The organic phases are combined and washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by flash silica gel column (0-2.5% methanol / dichloromethane) to obtain compound 8-8e (900 mg, yield 72%) as an oil. ES-API: [M+H] + =767.3.

[0620] Step 6: At -60°C, add 2.5M n-butyllithium in tetrahydrofuran (0.7 mL, 1.76 mmol) to 2,2,6,6-tetramethylpiperazine (250 mg, 1.76 mmol) in tetrahydrofuran (20 mL) and stir for 0.5 hours. Then, warm to 0°C and add bis[(pinacolato)boryl]methane (472 mg, 1.76 mmol) in tetrahydrofuran (2 mL) and stir for 10 minutes. Cool again to -60°C and add a solution of compound 8-8e (900 mg, 1.17 mmol) in tetrahydrofuran (5 mL) and stir for 3 hours. The reaction mixture is concentrated and purified using a flash silica gel column (0-6% tetrahydrofuran / petroleum ether) to obtain intermediate compound 8-8 (1000 mg, 95.67% yield). ES-API: [M+H] + =891.4.

[0621] Preparation Example 8 Synthesis of Intermediate 8-8

[0622] Step 1: Under nitrogen protection, compound 1-10 (4.5 g, 8.29 mmol), 2-[(1S)-1-methoxyethyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (3.71 g mg, 8.29 mmol, preparation method reference US2021130303A1), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (0.61 g, 0.83 mmol) and potassium carbonate (3.44 g, 24.88 mmol) in dioxane / water (10 mL / 2 mL) were stirred at 120 ° C for 2 hours. After the reaction, 30 mL of ethyl acetate was added and washed with 15 mL of water and 15 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified using a flash silica gel column (0-60% tetrahydrofuran / petroleum ether) to obtain compound 8-3 (4.3 g, yield 66%). ES-API: [M+H] + =783.3.

[0623] Step 2: Dissolve compound 8-3 (4.3 g, 5.491 mmol) in tetrahydrofuran (50 mL), cool to 0°C, slowly add sodium hydride (1.10 g, 27.46 mmol), and stir for 0.5 hours. Then, add iodoethane (1 mL, 12.50 mmol) to the reaction solution and continue stirring for 2 hours. The reaction solution is quenched with 10 mL of saturated ammonium chloride solution and extracted three times with 10 mL of ethyl acetate. The organic phase is dried over anhydrous sodium sulfate, filtered, concentrated, and purified using a flash silica gel column (0-30% tetrahydrofuran / petroleum ether) to obtain compound 8-4 as a yellow oil (4200 mg, yield 94.30%). ES-API: [M+H] + =811.3.

[0624] Step 3: Under nitrogen, compound 8-4 (500 mg, 0.616 mmol) was dissolved in tetrahydrofuran (10 mL), cooled to -70°C, and then diisobutylaluminum hydride (3.08 mL, 3.08 mmol) was added and stirred for 1 hour. After the reaction was completed, the reaction was quenched with sodium sulfate decahydrate and purified on a flash silica gel column (0-50% tetrahydrofuran / petroleum ether) to obtain compound 8-5 (200 mg, 42% yield) as a yellow oil. ES-API: [M+H] + =769.3.

[0625] Step 4: Add Dess-Martin periodinane (132 mg, 0.31 mmol) to a solution of compound 8-5 (200 mg, 0.260 mmol) in dichloromethane (5 mL) and stir at room temperature for 1 hour. After the reaction is complete, add 30 mL of dichloromethane and wash with 10 mL of water. The organic phase is dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a flash silica gel column (0-50% tetrahydrofuran / petroleum ether) to obtain compound 8-6 (200 mg, 100% yield). ES-API: [M+H] + =767.3.

[0626] Step 5: At -70°C, a solution of n-butyllithium in tetrahydrofuran (0.28 mL, 0.70 mmol) was slowly added to a solution of trimethylsilylated diazomethane (0.35 mL, 0.70 mmol) in tetrahydrofuran (2 mL) and stirred for 0.5 hours. A solution of compound 8-6 (180 mg, 0.24 mmol) in tetrahydrofuran (2 mL) was then added to the above solution and stirred for 1 hour. The reaction solution was quenched with 5 mL of saturated ammonium chloride solution and extracted three times with 5 mL of ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified using a flash silica gel column (0-80% tetrahydrofuran / petroleum ether) to obtain compound 8-7 (120 mg, yield 67.02%). ES-API: [M+H] + =763.4.

[0627] Step 6: Under nitrogen protection, a solution of cuprous chloride (8 mg, 0.08 mmol), sodium tert-butoxide (15 mg, 0.16 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (46 mg, 0.08 mmol) in tetrahydrofuran (1 mL) was stirred at room temperature for 30 minutes. A solution of di-pinacol boronate (48 mg, 0.19 mmol) in tetrahydrofuran (1 mL) was then added and stirring continued for 10 minutes. Finally, compound 8-7 (120 mg, 0.16 mmol) and methanol (0.013 mL, 0.32 mmol) were added in sequence and stirred for three hours. The reaction solution was directly concentrated and purified using a flash silica gel column (0-60% tetrahydrofuran / petroleum ether) to obtain compound 8-8 (80 mg, 57% yield) as a white solid. ES-API: [M+H] + =891.3.

[0628] Preparation Example 9 Synthesis of Intermediate 15-20-1

[0629] Step 1: Dissolve 62-k (250 mg, 0.287 mmol) in acetonitrile (5 mL). Add 4-(prop-2-yn-1-yl)thiomorpholine 1,1-dioxide (149.34 mg, 0.862 mmol), bistriphenylphosphine palladium dichloride (40.34 mg, 0.057 mmol), cuprous iodide (111.43 mg, 0.862 mmol), N,N'-diisopropylethylamine (111.43 mg, 0.862 mmol), and lithium chloride (48.73 mg, 1.149 mmol) to the solution at room temperature. After addition, stir the reaction mixture under argon at 80°C for 1 hour. After completion of the reaction, add water (30 mL) and extract with ethyl acetate (30 mL x 3). Wash the organic phase with saturated brine (30 mL x 2), dry, and concentrate to obtain the crude product. The crude product was purified by flash silica gel column chromatography (methanol / dichloromethane: 0%-3%) to give intermediate 15-19-1 (150 mg, 0.168 mmol, yield 58.31%) as a white solid. ES-API: [M+H] + =893.2.

[0630] Step 2: Add a 4M solution of dioxane hydrochloride (4 mL) to a methanol solution (8 mL) of compound 15-19-1 (150 mg, 0.168 mmol) at 0°C. Stir the reaction mixture at room temperature for 3 hours. LCMS indicates that the reaction is complete. Adjust the pH of the reaction system to 6-7 and concentrate under reduced pressure to obtain crude compound 15-20-1 (125 mg), which is directly used for the next step. ES-API: [M+H] + =793.2.

[0631] Example 1 Synthesis of Compounds Z1-1 and Z1-2

[0632] Step 1: Under nitrogen, add dry N,N-dimethylformamide (50 mL) to zinc powder (20 g, 306 mmol). Then add trimethylsilyl chloride (4 mL, 31.55 mmol) and stir at 90°C for half an hour. Cool and allow to stand, then remove most of the N,N-dimethylformamide with a syringe. Add N,N-dimethylformamide (20 mL) again, stir for half a minute, allow to stand, and remove most of the N,N-dimethylformamide with a syringe. Repeat this process three times. Add dry N,N-dimethylformamide (50 mL) to the activated zinc powder, cool to 0°C, and slowly add tert-butyl (R)-2-((tert-butoxycarbonyl)amino)-3-iodopropionate (11 g, 33.42 mmol) in N,N-dimethylformamide (50 mL). Stir for half an hour and allow to stand to obtain the corresponding zinc reagent. The resulting zinc reagent solution (60 mL) was added to tert-butyl (2-bromothiazol-4-yl)carbamate (3 g, 10.75 mmol) and [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (0.79 g, 1.08 mmol) in N,N-dimethylformamide (60 mL) and reacted at 70°C for 6 hours. After the reaction, 400 mL of ethyl acetate was added and the mixture was washed with 100 mL of saturated brine and 100 mL of water. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified using a flash silica gel column (0-40% ethyl acetate / petroleum ether) to obtain compound 1-1 (3.6 g, yield 83%) as a yellow solid. ES-API: [M+H] + =402.1.

[0633] Step 2: Add lithium hydroxide (1.32 g, 31.38 mmol) to a solution of compound 1-1 (4.2 g, 10.46 mmol) in tetrahydrofuran (40 mL) and water (8 mL) and stir at room temperature for 2 hours. After the reaction is complete, neutralize with 1M hydrochloric acid solution to pH = 6 and extract three times with 40 mL of ethyl acetate. The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 1-2 (3.9 g) as a yellow solid. ES-API: [M+H] + =388.1.

[0634] Step 3: Under ice-cooling conditions, (S)-hexahydropyridazine-3-carboxylic acid methyl ester ditrifluoroacetate (5.62 g, 15 mmol), N-methylmorpholine (11 mL, 101 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (3.86 g, 20 mmol), and 1-hydroxybenzotriazole (0.41 g, 3 mmol) were added sequentially to a solution of compound 1-2 (3.9 g, 10 mmol) in dichloromethane (40 mL) and stirred at room temperature for three hours. After completion of the reaction, the mixture was quenched with 40 mL of 1 M hydrochloric acid solution and extracted three times with 20 mL of dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a flash silica gel column (0-45% tetrahydrofuran / petroleum ether) to afford compound 1-3 (4 g, 77% yield) as a white solid. ES-API: [M+H] + =514.2.

[0635] Step 4: Dissolve compound 1-3 (1 g, 1.95 mmol) in dichloromethane (3 mL), add trifluoroacetic acid (3 mL), and stir at room temperature for 2 hours. Concentrate and dissolve in dichloromethane (3 mL), add N,N-diisopropylethylamine (3 mL, 17 mmol) and di-tert-butyl carbonate (1 mL, 4.35 mmol), and stir for 0.5 hours. After the reaction is completed, wash with 10 mL of water, concentrate, and purify with a flash silica gel column (0-10% methanol / dichloromethane) to obtain compound 1-4 (300 mg, yield 37%). ES-API: [M+H] + =414.3.

[0636] Step 5: Under nitrogen protection, a tetrahydrofuran solution of lithium aluminum tetrahydride (40 mL, 40.000 mmol) was added dropwise to a tetrahydrofuran solution of 2,2-dimethyl-4-pentenoic acid (5 g, 39 mmol) (100 mL) in an ice bath and stirred at room temperature for 4 hours. The reaction solution was quenched with water (2.6 mL), 10% sodium hydroxide solution (2.6 mL), and water (7.2 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 1-5 (3.5 g, yield 78%) as a colorless oil.

[0637] Step 6: Add imidazole (2.30 g, 33.72 mmol) and tert-butyldiphenylsilyl chloride (8 mL, 30.65 mmol) to a solution of compound 1-5 (3.5 g, 30.65 mmol) in dichloromethane (50 mL) under ice-cooling conditions. Stir at room temperature for 1 hour. Filter the reaction mixture and wash with 50 mL of water. The organic phase is dried, concentrated, and purified using a flash silica gel column (0-30% ethyl acetate / petroleum ether) to afford compound 1-6 (9 g, 83% yield).

[0638] Step 7: Under ice-bath conditions, compound 1-6 (6.9 g, 19.57 mmol) was dissolved in tetrahydrofuran (30 mL) and water (30 mL). Potassium osmate dihydrate (360 mg, 1 mmol), 2,6-lutidine (4.6 mL, 39 mmol), and sodium periodate (25 g, 117 mmol) were added sequentially and stirred at room temperature for 2 hours. After the reaction was completed, the mixture was filtered, and the filtrate was added with 30 mL of water and extracted three times with 50 mL of ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a flash silica gel column (0-5% tetrahydrofuran / petroleum ether) to obtain compound 1-7 (5.3 g, 76% yield) as a colorless oil. ES-API: [M+H] + =355.3.

[0639] Step 8: Under ice bath conditions, sodium hydroxide (0.78 g, 19.44 mmol) was added to triethyl phosphinoacetate (4.36 g, 19.43 mmol) in tetrahydrofuran (20 mL) and stirred for 0.5 hours. Subsequently, a solution of compound 1-7 (5.3 g, 14.95 mmol) in tetrahydrofuran was added and stirring continued for 2 hours. After the reaction was completed, the mixture was quenched with 20 mL of saturated ammonium chloride solution and extracted three times with 20 mL of ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified using a flash silica gel column (0-15% tetrahydrofuran / petroleum ether) to obtain compound 1-8 (4.8 g, yield 76%) as an oil. ES-API: [M+Na] + =447.2.

[0640] Step 9: Under ice bath conditions, potassium tert-butoxide in tetrahydrofuran (8 mL, 8 mmol) was added to compound 1-8 (1.14 g, 2.69 mmol) and p-toluenesulfonylmethyl isocyanide (0.68 g, 3.49 mmol) in tetrahydrofuran (20 mL) and stirred at room temperature for 2 hours. The reaction solution was quenched with 20 mL of saturated ammonium chloride solution and extracted three times with 20 mL of ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a flash silica gel column (0-20% tetrahydrofuran / petroleum ether) to obtain compound 1-9 (960 mg, yield 77%) as an oil. ES-API: [M+H] + =464.2.

[0641] Step 10: Add N-bromosuccinimide (154 mg, 0.86 mmol) to a solution of compound 1-9 (400 mL, 0.86 mmol) in tetrahydrofuran (5 mL) under ice-cooling conditions and stir for 1 hour. The reaction mixture was poured into 20 mL of ethyl acetate, washed with 10 mL of water, dried over anhydrous sodium sulfate, filtered, concentrated, and purified using a flash silica gel column (0-20% tetrahydrofuran / petroleum ether) to obtain compound 1-10 (350 mg, 75% yield). ES-API: [M+H] + =542.2,544.2.

[0642] Step 11: Under nitrogen protection, a mixture of compound 1-10 (2 g, 3.69 mmol), (S)-2-(1-methoxyethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (0.97 g, 3.69 mmol), 1,1'-bis(di-tert-butylphosphino)ferrocenepalladium dichloride (0.27 g, 0.37 mmol) and potassium carbonate (1.53 g, 11.09 mmol) in dioxane (20 mL) and water (4 mL) was stirred at 120 ° C for 2 hours. After the reaction, the reaction solution was poured into 50 mL of ethyl acetate and washed sequentially with 10 mL of saturated brine and 10 mL of water. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified using a flash silica gel column (0-100% tetrahydrofuran / petroleum ether) to obtain compound 1-11 (1.1 g, yield 50%) as a transparent oil. ES-API: [M+H] + =599.3.

[0643] Step 12: Under ice bath conditions, compound 1-11 (1.1 g, 1.84 mmol) was dissolved in tetrahydrofuran (20 mL), sodium hydroxide (0.37 g, 9.18 mmol) was added, and the mixture was stirred for 0.5 hours. Subsequently, iodoethane (570 mg, 3.67 mmol) was added and stirred at room temperature for 2 hours. The reaction solution was quenched with 20 mL of saturated ammonium chloride solution and extracted three times with 20 mL of ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified with a flash silica gel column (0-30% tetrahydrofuran / petroleum ether) to obtain compound 1-12 (1 g, yield 87%) as an oil. ES-API: [M+H] + =627.4.

[0644] Step 13: Dissolve compound 1-12 (200 mg, 0.32 mmol) in methanol (3 mL) and water (0.6 mL), add potassium hydroxide (300 mg, 5.4 mmol), and stir at 95°C overnight. After the reaction, concentrate the mixture and dissolve it in 10 mL of water. Neutralize the mixture with 1 M hydrochloric acid solution to pH = 6, extract with ethyl acetate, dry, concentrate, and purify on a flash silica gel column (0-70% tetrahydrofuran / petroleum ether) to obtain compound 1-13 (150 mg, yield 79%). ES-API: [M+H] + =599.3.

[0645] Step 14: Dissolve compound 1-13 (210 mg, 0.35 mmol) in dichloromethane (5 mL) under ice-cooling conditions, add oxalyl chloride (59 μL, 0.70 mmol) and a drop of N,N-dimethylformamide, and stir for 1 hour. Concentrate and redissolve in 5 mL of dichloromethane, add pyridine (0.5 mL), and then add compound 1-4 (174 mg, 0.42 mmol) and stir for 1 hour. After the reaction is complete, wash with 2 mL of water, dry over anhydrous sodium sulfate, filter, concentrate, and purify on a flash silica gel column (0-5% methanol / dichloromethane) to obtain compound 1-14 (220 mg) in a 63% yield. ES-API: [M+H] + =994.2.

[0646] Step 15: Dissolve compound 1-14 (210 mg, 0.211 mmol) in tetrabutylammonium fluoride in tetrahydrofuran (2 mL, 2 mmol) and stir at 60°C for 5 hours. Concentrate and purify using a flash silica gel column (0-10% methanol / dichloromethane) to obtain compound 1-15 (150 mg) in a 96% yield. ES-API: [M+H] + =742.1.

[0647] Step 16: At 95°C, slowly add a solution of compound 1-15 (200 mg, 0.27 mmol) in dichloroethane (30 mL) dropwise to a solution of N,N'-dicyclohexylcarbodiimide (556 mg, 2.70 mmol), pyridine (3.43 g, 27 mmol), and 4-methylbenzenesulfonate pyridinium (677 mg, 2.70 mmol) in dichloroethane (30 mL) and stir for three hours. After the reaction, cool the mixture and wash with 30 mL of 1M hydrochloric acid. Concentrate the mixture and purify it with a flash silica gel column (0-100% tetrahydrofuran / petroleum ether) to afford compound 1-16 (80 mg) in a 41% yield. ES-API: [M+H] + =724.2.

[0648] Step 17: Dissolve compound 1-16 (70 mg, 0.1 mmol) in methanol (0.2 mL), add 4M hydrochloric acid dioxane solution (1 mL, 4 mmol), and stir for 1 hour. The reaction solution is concentrated to obtain compound 1-17 (60 mg). ES-API: [M+H] + =624.0.

[0649] Step 18: N, N-diisopropylethylamine (0.124 mg, 0.96 mmol), 2-(7-azobenzotriazole)-N, N, N', N'-tetramethyluronium hexafluorophosphate (73 mg, 0.19 mmol) were added to (1r, 2R, 3S)-2, 3-dimethylcyclopropane-1-carboxylic acid (11 mg, 0.1 mmol) and compound 1-17 (60 mg, 0.1 mmol) in dichloromethane (2 mL) in sequence and stirred at room temperature for 2 hours. After the reaction, the mixture was washed with 2 mL of water and concentrated to give a crude compound 1A, which was purified by preparative HPLC (ammonium bicarbonate method 1) to give two isomeric compounds. The structure of one of the isomeric compounds was arbitrarily designated as (1r, 2R, 3S)-N-((8 3 S,6S,Z)-(S a )-1 1 -ethyl-1 5 -(2-((S)-1-methoxyethyl)pyridin-3-yl)-12,12-dimethyl-2,7,9-trioxo-8 1 ,8 2 ,8 3 ,8 4 ,8 5 ,8 6 -Hexahydro-1 1 H-10-oxa-3-aza-4(4,2)-thiazole-8(1,3)-pyridazine-1(3,4)-pyrrolecyclotridecan-6-yl)-2,3-dimethylcyclopropane-1-carboxamide (Z1-2, 1.73 mg, yield 2.5%, purity 98%, retention time = 6.68 min).

[0650] The structure of the other isomer compound was arbitrarily designated as (1r,2R,3S)-N-((8 3 S,6S,Z)-(R a )-1 1 -ethyl-1 5 -(2-((S)-1-methoxyethyl)pyridin-3-yl)-12,12-dimethyl-2,7,9-trioxo-8 1 ,8 2 ,8 3 ,8 4 ,8 5 ,8-hexahydro-11 H-10-oxa-3-aza-4(4,2)-thiazole-8(1,3)-pyridazine-1(3,4)-pyrrolecyclotridecan-6-yl)-2,3-dimethylcyclopropane-1-carboxamide (Z1-1, 3.73 mg, yield 5.4%, purity 98%, retention time = 6.93 min).

[0651] Example 2 Synthesis of Compounds Z2-1 and Z2-2

[0652] Step 1: To a solution of compound 2-1 (5 g, 5.721 mmol, for preparation, see intermediate 5 of WO2022060836A1) in N,N-dimethylformamide (50 mL) were added cesium carbonate (18.64 g, 57.210 mmol) and iodoethane (8.92 mg, 57.210 mmol) in sequence. The reaction mixture was stirred at room temperature overnight. LCMS detected that the reaction was complete, and the insoluble matter was removed by filtration and washed with ethyl acetate. The filtrate was diluted with 100 mL of ethyl acetate, then washed with water (200 mL) and saturated brine (50 mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a crude product, which was purified by silica gel column chromatography to obtain compound 2-2 (4.450 g, yield: 86%). ES-API: [M+H] + =901.3.

[0653] Step 2: Under nitrogen, compound 2-2 (4450 mg, 4.933 mmol), tert-butyl carbamate (1155.84 mg, 9.866 mmol), cesium carbonate (4018 mg, 12.333 mmol), palladium acetate (111 mg, 0.493 mmol), and 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (470 mg, 0.987 mmol) were dissolved in dioxane (100 mL). The reaction mixture was heated to 100°C in an oil bath and stirred overnight. LCMS confirmed the reaction was complete. The mixture was cooled to room temperature and concentrated to dryness under reduced pressure. The residue was purified by automated flash chromatography on silica gel (ethyl acetate:petroleum ether = 0-70%) to afford compound 2-3 (2.915 g, yield: 63%). ES-API: [M+H] + =938.5.

[0654] Step 3: Under an ice-water bath, trifluoroacetic acid (6.0 mL) was slowly added to a solution of compound 2-3 (1.85 g, 1.972 mmol) in dichloromethane (20 mL). After the addition was complete, the reaction solution was slowly warmed to room temperature and stirred for 3 hours. LCMS confirmed that the reaction was complete. The reaction solution was concentrated under reduced pressure, and the crude product was dissolved in dichloromethane (20 mL). Ammonia methanol solution was added to adjust the pH of the solution to approximately 8.0, and then concentrated under reduced pressure. The residue was purified by automated flash chromatography on silica gel (methanol:dichloromethane = 0-10%) to obtain compound 2-4 (1.85 g, yield: 100%). ES-API: [M+H] + =838.4.

[0655] Step 4: Under an ice-water bath, N,N-diisopropylethylamine (2.18 mL, 12.527 mmol) and p-nitrophenyl chloroformate (631 mg, 3.132 mmol) were sequentially added to a solution of compound 2-4 (1750 mg, 2.088 mmol) in dichloromethane (25 mL). The reaction mixture was stirred at 0°C under nitrogen for 10 minutes. LCMS analysis indicated the disappearance of the starting material, indicating the reaction was complete. (tert-Butoxycarbonyl)-D-serine methyl ester (1831 mg, 8.350 mmol) and N,N-diisopropylethylamine (1.46 mL, 8.352 mmol) were added to the reaction solution, and the reaction mixture was stirred at room temperature overnight. LCMS analysis indicated the reaction was complete. The reaction solution was diluted with dichloromethane (50 mL) and washed with saturated brine (20 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was purified by automated flash chromatography on silica gel (methanol: dichloromethane = 0-7%) to give compound 2-6 (1550 mg, yield: 69%). ES-API: [M+H] + =1083.5.

[0656] Step 5: Under an ice-water bath, lithium hydroxide monohydrate (78 mg, 1.869 mmol) was added to a solution of compound 2-6 (1350 mg, 1.246 mmol) in tetrahydrofuran (12 mL) and water (3 mL), and the reaction mixture was stirred for 1 hour. LCMS detected that the reaction was complete, and the solvent was removed by concentration under reduced pressure. The residue was adjusted to pH 6.0 with dilute hydrochloric acid, extracted with ethyl acetate (20 mL × 3), and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by automated flash chromatography on silica gel (methanol: dichloromethane = 0-5%) to obtain compound 2-7 (900 mg, yield: 68%). ES-API: [M+H] + =1069.5.

[0657] Step 6: To a solution of compound 2-7 (800 mg, 0.748 mmol) in dichloromethane (10 mL) was added (R)-methyl hexahydropyridazine-3-carboxylate (557 mg, 1.496 mmol), N-methylmorpholine (1.11 mL, 10.099 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (387 mg, 2.020 mmol), and 1-hydroxybenzotriazole (40 mg, 0.299 mmol) in an ice-water bath. The reaction mixture was stirred at room temperature for 3 hours. LCMS confirmed the reaction was complete. The reaction mixture was quenched by adding 30 mL of water, then extracted with dichloromethane (15 mL*3). The organic phase was washed with saturated brine (10 mL*3), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by automated flash chromatography on silica gel (tetrahydrofuran: petroleum ether = 0-40%) to give compound 2-8 (407 mg, yield: 46%). ES-API: [M+H] + =1195.6.

[0658] Step 7: Add dioxane hydrochloride solution (5.0 mL) to a methanol solution (1 mL) of compound 2-8 (150 mg, 0.125 mmol). The reaction mixture was stirred at room temperature for 7 hours. LCMS showed that the reaction was complete. The mixture was concentrated under reduced pressure to obtain crude compound 2-9 (107 mg, yield: 99%). ES-API: [M+H] + =857.3.

[0659] Step 8: To a solution of compound 2-9 (107 mg, 0.125 mmol) in N,N-dimethylformamide (5 mL) was added (1r,2R,3S)-2,3-dimethylcyclopropyl-1-carboxylic acid (17 mg, 0.150 mmol), N,N-diisopropylethylamine (0.13 mL, 0.750 mmol), and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (71 mg, 0.188 mmol) in an ice-water bath. The reaction mixture was warmed to room temperature and stirred for 10 minutes. LCMS confirmed the reaction was complete. The reaction mixture was diluted with 20 mL of ethyl acetate and then washed with water (10 mL) and saturated brine (10 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by automated flash chromatography on silica gel (tetrahydrofuran: petroleum ether = 0-80%) to give compound 2-10 (109 mg, yield: 92%). ES-API: [M+H] + =953.3.

[0660] Step 9: Under an ice-water bath, lithium hydroxide monohydrate (5.4 mg, 0.129 mmol) was added to a solution of compound 2-10 (82 mg, 0.086 mmol) in tetrahydrofuran (4 mL) and water (1 mL). The reaction mixture was stirred for 10 minutes. LCMS detected that the reaction was complete and the solvent was removed by concentration under reduced pressure. The residue was adjusted to pH 6.0 with dilute hydrochloric acid and extracted with ethyl acetate (5 mL × 4). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give crude compound 2-11 (91 mg). ES-API: [M+H] + =939.4.

[0661] Step 10: To a solution of compound 2-11 (91 mg, 0.096 mmol), N,N-diisopropylethylamine (0.5 mL, 2.895 mmol), and 1-hydroxybenzotriazole (65 mg, 0.482 mmol) in dichloromethane (8 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (518 mg, 2.702 mmol) under an ice-water bath. The reaction mixture was stirred at room temperature for 48 hours. LCMS confirmed the reaction was complete. The reaction solution was washed with dilute hydrochloric acid (10 mL × 2, 0.5 N) and saturated brine (15 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by automated flash chromatography on silica gel (tetrahydrofuran:petroleum ether = 0-60%) to afford compound 2-12 (15 mg, yield: 17%). ES-API: [M+H] + =921.5.

[0662] Step 11: Compound 2-12 (15 mg, 0.016 mmol) and paraformaldehyde (7.33 mg, 0.081 mmol) were dissolved in methanol (5 mL). Under hydrogen protection, palladium hydroxide (15 mg, 0.107 mmol) was added to the reaction solution, and the reaction mixture was stirred at room temperature for 24 hours. LCMS detection showed that the reaction was complete. The insoluble matter was removed by filtration through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC (formic acid method 1) to obtain two isomeric compounds. The structure of one of the isomeric compounds was arbitrarily designated as: (1r, 2R, 3S)-N-((7 3 S,9S)-1 1 -ethyl-1 2 -(2-((S)-1-methoxyethyl)-(R a )-5-(4-methylpiperazin-1-yl)pyridin-3-yl)-3,3-dimethyl-6,8-12-trioxo-7 1 ,7 2 ,7 3 ,7 4 ,7 5 ,76 -Hexahydro-1 1 H-5,11-Dioxa-13-aza-1(3,5)-indole-7(3,1)-pyridazine-1-azacyclotridecan-9-yl)-2,3-dimethylcyclopropane-1-carboxamide (Z2-1, 1.05 mg, yield: 8%, retention time = 1.73 min), formate salt, ES-API [M+H] + =801.3.

[0663] The structure of another isomer compound is arbitrarily designated as: (1r,2R,3S)-N-((7 3 S,9S)-1 1 -ethyl-1 2 -(2-((S)-1-methoxyethyl)-(S a )-5-(4-methylpiperazin-1-yl)pyridin-3-yl)-3,3-dimethyl-6,8-12-trioxo-7 1 ,7 2 ,7 3 ,7 4 ,7 5 ,7 6 -Hexahydro-1 1 H-5,11-Dioxa-13-aza-1(3,5)-indole-7(3,1)-pyridazine-1-azacyclotridecan-9-yl)-2,3-dimethylcyclopropane-1-carboxamide (Z2-2, 1.05 mg, yield: 8%, retention time = 1.75 min), formate salt, ES-API [M+H] + =801.3.

[0664] Example 3 Synthesis of Compound Z3

[0665] Step 1: To a solution of compound 3-1 (5 g, 11.226 mmol) in dichloromethane (25 mL) were added acetic anhydride (1.05 mL, 11.226 mmol), triethylamine (2.34 mL, 16.839 mmol), and 4-dimethylaminopyridine (137 mg, 1.123 mmol). The reaction mixture was stirred at room temperature for 1 hour. LCMS indicated that the reaction was complete, and the solvent was removed by concentration under reduced pressure. 50 mL of dichloromethane was added to the residue, which was then washed with water (20 mL) and saturated brine (30 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain the crude product. The residue was purified by automated flash chromatography on silica gel (ethyl acetate:petroleum ether = 0-100%) to obtain compound 3-2 (4.922 g, yield: 90%). ES-API: [M+H] + =487.1.

[0666] Step 2: Under nitrogen, compound 3-2 (4922 mg, 10.098 mmol), pinacol diboronate (3846.3 mg, 15.146 mmol), 1,5-cyclooctadiene iridium chloride dimer (203.48 mg, 0.303 mmol), and 4,4'-di-tert-butyl-2,2'-bipyridine (406.53 mg, 1.515 mmol) were dissolved in cyclohexane (50 mL). The reaction mixture was heated to 85°C in an oil bath and stirred overnight. LCMS confirmed the reaction was complete. The mixture was cooled to room temperature and concentrated under reduced pressure to afford crude compound 3-3 (5.364 g, yield: 99%). ES-API: [M+H] + =531.2.

[0667] Step 3: To a solution of compound 3-3 (5.364 g, 10.097 mmol) in acetonitrile (30 mL) was added hydrogen peroxide (3.5 mL, 30.291 mmol), and the reaction mixture was stirred at room temperature for 2 hours. LCMS indicated that the reaction was complete, and the solvent was removed by concentration under reduced pressure. 50 mL of dichloromethane was added to the residue, which was then washed with water (20 mL) and saturated brine (30 mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain the crude product. The residue was purified by automated flash chromatography on silica gel (ethyl acetate:petroleum ether = 0-50%) to obtain compound 3-4 (3.7 g, yield: 73%). ES-API: [M+H] + =503.2.

[0668] Step 4: To a solution of compound 3-4 (3276 mg, 6.507 mmol) in dichloromethane (10 mL) was added 4-(2-hydroxyethyl)thiomorpholine 1,1-dioxide (2332 mg, 2.687 mmol), triphenylphosphine (3413.56 mg, 13.014 mmol), and diisopropyl azodicarboxylate (3.2 mL, 16.268 mmol) in an ice-water bath. The reaction mixture was stirred at 0°C for 1 hour. LCMS confirmed the reaction was complete, and the solvent was removed by concentration under reduced pressure. The residue was purified by automated flash chromatography on silica gel (ethyl acetate:petroleum ether = 0-25%) to afford compound 3-5 (4.461 g, yield: 99%). ES-API: [M+H] + =664.2.

[0669] Step 5: Under nitrogen, compound 3-5 (4400 mg, 6.620 mmol), tert-butyl carbamate (1151 mg, 13.240 mmol), cesium carbonate (5392 mg, 16.550 mmol), palladium acetate (149 mg, 0.662 mmol), and 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (631 mg, 1.324 mmol) were dissolved in dioxane (10 mL). The reaction mixture was heated to 100°C in an oil bath and stirred for 3 hours. LCMS confirmed the reaction was complete, and the mixture was cooled to room temperature and concentrated to dryness under reduced pressure. The residue was purified by automated flash chromatography on silica gel (methanol:dichloromethane = 0-2.5%) to afford compound 3-6 (453 mg, yield: 10%). ES-API: [M+H] + =701.3.

[0670] Step 6: Under an ice-water bath, trifluoroacetic acid (3.0 mL) was slowly added to a solution of compound 3-6 (453 mg, 0.646 mmol) in dichloromethane (3 mL). The reaction mixture was stirred at 0°C for 1 hour. LCMS detected that the reaction was complete. The reaction mixture was concentrated under reduced pressure, and the crude product was dissolved in saturated sodium bicarbonate solution (10 mL). The product was extracted with dichloromethane (15 mL*3). The combined organic phases were washed with saturated brine (15 mL*3). The product was dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product compound 3-7 (296 mg, yield: 76%). ES-API: [M+H] + =601.3.

[0671] Step 7: Under an ice-water bath, N,N-diisopropylethylamine (0.34 mL, 1.971 mmol) and p-nitrophenyl chloroformate (149 mg, 0.739 mmol) were added sequentially to a solution of compound 3-7 (149 mg, 0.739 mmol) in dichloromethane (15 mL). The reaction mixture was stirred at 0°C under nitrogen for 10 minutes. LCMS analysis indicated the disappearance of the starting material, indicating the reaction was complete. Under an ice-water bath, (tert-butyloxycarbonyl)-D-serine methyl ester (431 mg, 1.966 mmol) and N,N-diisopropylethylamine (0.34 mL, 1.964 mmol) were added sequentially to the reaction mixture. The reaction mixture was stirred at room temperature overnight. LCMS analysis indicated the reaction was complete. The reaction mixture was diluted with dichloromethane (20 mL) and washed with saturated brine (15 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was purified by automated flash chromatography on silica gel (methanol:dichloromethane = 0-2%) to give compound 3-9 (178 mg, yield: 43%). ES-API: [M+H] + =846.3.

[0672] Step 8: Under an ice-water bath, lithium hydroxide monohydrate (8.8 mg, 0.210 mmol) was added to a solution of compound 35-9 (178 mg, 0.210 mmol) in tetrahydrofuran (5 mL) and water (1 mL). The reaction mixture was stirred at 0°C for 1.5 hours. LCMS indicated that the reaction was complete, and the solvent was removed by concentration under reduced pressure. The residue was adjusted to pH 6.0 with dilute hydrochloric acid and extracted with ethyl acetate (20 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give crude compound 3-10 (102 mg, yield: 58%). ES-API: [M+H] + =832.3.

[0673] Step 9: To a solution of compound 3-10 (102 mg, 0.123 mmol) in dichloromethane (10 mL) was added (R)-methyl hexahydropyridazine-3-carboxylate (91 mg, 0.245 mmol), N-methylmorpholine (0.19 mL, 1.716 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (59 mg, 0.306 mmol), and 1-hydroxybenzotriazole (8.3 mg, 0.061 mmol) in an ice-water bath. The reaction mixture was stirred at room temperature overnight. LCMS confirmed the reaction was complete. 15 mL of water was added to the reaction mixture to quench the reaction, followed by extraction with dichloromethane (10 mL x 3). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by automated flash chromatography on silica gel (methanol: dichloromethane = 0-3%) to give compound 3-11 (69 mg, yield: 59%). ES-API: [M+H] + =958.3.

[0674] Step 10: Under an ice-water bath, lithium hydroxide monohydrate (12 mg, 0.288 mmol) was added to a solution of compound 3-11 (69 mg, 0.072 mmol) in tetrahydrofuran (5 mL) and water (1 mL). The reaction mixture was stirred at room temperature overnight. LCMS confirmed that the reaction was complete, and the solvent was removed by concentration under reduced pressure. The residue was adjusted to pH 6.0 with dilute hydrochloric acid and extracted with ethyl acetate (5 mL x 4). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give crude compound 3-12 (64 mg, yield: 99%). ES-API: [M+H] + =902.3.

[0675] Step 11: To a solution of compound 3-12 (64 mg, 0.071 mmol), N,N-diisopropylethylamine (0.37 mL, 2.128 mmol), and 1-hydroxybenzotriazole (48 mg, 0.355 mmol) in dichloromethane (5 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (380.8 mg, 1.987 mmol) under an ice-water bath. The reaction mixture was stirred at room temperature for 18 hours. LCMS confirmed the reaction was complete. The reaction solution was washed with dilute hydrochloric acid (10 mL × 2, 1.0 N) and saturated brine (15 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by automated flash chromatography on silica gel (tetrahydrofuran:petroleum ether = 0-95%) to afford compound 3-13 (28 mg, yield: 45%). ES-API: [M+H] + =884.3.

[0676] Step 12: Add dioxane hydrochloride solution (1.5 mL) to a methanol solution (0.5 mL) of compound 3-13 (28 mg, 0.032 mmol). Stir the reaction mixture at room temperature for 0.5 hours. LCMS analysis indicates that the reaction is complete. Concentrate under reduced pressure to obtain crude compound 3-14 (24 mg, yield: 97%). ES-API: [M+H] + =784.3.

[0677] Step 13: Under ice-water bath, to a solution of compound 3-14 (24 mg, 0.031 mmol) in N,N-dimethylformamide (2 mL) were added (1r,2R,3S)-2,3-dimethylcyclopropyl-1-carboxylic acid (4 mg, 0.037 mmol), N,N-diisopropylethylamine (0.03 mL, 0.184 mmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (17 mg, 0.046 mmol) in sequence. The reaction mixture was warmed to room temperature and stirred for 10 minutes. LCMS detected that the reaction was...

Claims

1. A compound represented by formula (I) or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof: In the formula, Ring A is is phenyl, 5- or 6-membered heteroaryl or 5- or 6-membered heterocyclic group; one or two ring atoms of the 5- or 6-membered heteroaryl group are heteroatoms selected from nitrogen, oxygen or sulfur; one or two ring atoms of the 5- or 6-membered heterocyclic group are heteroatoms selected from nitrogen, oxygen or sulfur; the 5- or 6-membered heterocyclic group is a fully saturated heterocyclic group or a partially unsaturated heterocyclic group; or wherein, W1 is CH, C or N; W2 is CH, C or N; W3 is CR 13 , O, S, N or NH; W4 is CR 13 , O, S, N or NH; W5 is absent, O or CR 14 ; Indicates the site of connection with the left part; W6 selected from CR 13 or N; X is Y1 is N or CH; wherein N can be oxidized (N + -O - ); Y2 is N or CH; wherein N can be oxidized (N + -O - ); R 42 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 43 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or R 42 and R 43 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 Cycloalkyl or substituted or unsubstituted 3 to 8-membered heterocyclic group; R 40 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 41 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or R 40 and R 41 connected to form -CH2- or -CH2CH2-; wherein -CH2- or -CH2CH2- is optionally replaced by one or more selected from deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl radical substitution; When ring A is When L1 is -N(R 00 )C(=O)-、-N(R 00 )C(=O)-O-, -C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1- 4-alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -L2-substituted or unsubstituted C 6-10 aryl-, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl-, -L2-substituted or unsubstituted 8- or 10-membered bicyclic heteroaryl-, or -L2-substituted or unsubstituted 3- to 8-membered heterocyclyl-; L2 is C 3-6 Cycloalkyl, 3 to 8 membered heterocyclic group, -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-; When ring A is hour; When at least one of W1, W2, W3, W4, and W5 is a heteroatom selected from O, S, N, or NH; L1 is -N(R 00 )C(=O)-、-N(R 00 )C(=O)-O-, -C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1- 6-alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -L2-substituted or unsubstituted C 6-10 Aryl-, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl-, or -L2-substituted or unsubstituted 3- to 8-membered heterocyclyl-; L2 is -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-; or, When W1 and W2 are C; W3, W4, and W5 are CH, L1 is -N(R 00 )C(=O)-O-, -C 1-4 Alkyl-N(R 00 )C(=O)-、-N(R 00 )C(=O)-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O- or -substituted or unsubstituted C 2-6 alkenyl-O-; R 00 is hydrogen or C 1-6 alkyl; R1 is hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl; R2 is hydrogen, deuterium, halogen, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl; R 3a C 1-6 Alkyl or deuterated C 1-6 alkyl; R 4a is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 3-6 Cycloalkyl or substituted or unsubstituted 3 to 8 membered heterocyclic group; R5 is hydrogen, -NR 01 R 02 ,-C(R 05 )R 03 R 04 , -C 1-4 Alkyl-NR 01 R 02 , -C 1-4 Alkyl-C(R 05 )R 03 R 04 , -C 1-4 Alkyl-C(=O)-NR 01 R 02 , -C 1-4 Alkyl-C(=O)-C(R 05 )R 03 R 04 , -C 1-4 Alkyl-C(=O)-C 1-4 Alkyl-NR 01 R 02 , -C 1-4 Alkyl-C(=O)-C 1-4 Alkyl-C(R 05 )R 03 R 04 , -C 1-4 Alkyl-N(R 06 )C(=O)-NR 01 R 02 , -C 1-4 Alkyl-N(R 06 )C(=O)-C(R 05 )R 03 R 04 , -C 1-4 Alkyl-N(R 06 )C(=O)-C 1-4 Alkyl-NR 01 R 02 , -C 1-4 Alkyl-N(R 06 )C(=O)-C 1-4 Alkyl-C(R 05 )R 03 R 04 、-OC 1-4 Alkyl-NR 01 R 02 、-OC 1-4 Alkyl-C(R 05 )R 03 R 04 、-OC 1-4 Alkyl-N(R 06 )C(=O)-R 03 、-OC(R 05 )R 03 R 04 , -C 1-4 Alkyl-NR 01 R 02 , -C 1-4 Alkyl-C(R 05 )R 03 R 04 、-N(R 06 )C(=O)-NR 01 R 02 、-N(R 06 )C(=O)-C(R 05 )R 03 R 04 , -C 2-4 Alkynyl-NR 01 R 02 , -C 2-4 Alkynyl-C(=O)-NR 01 R 02 , -C 2-4 Alkynyl-C(R 05 )R 03 R 04 , -C 1-4 Alkyl-C 2-4 Alkynyl-NR 01 R 02 , -C 1-4 Alkyl-C 2-4 Alkynyl-C(R 05 )R 03 R 04 , -C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 , -C 2-4 Alkynyl-C 1-4 Alkyl-C(R 05 )R 03 R 04 , -C 1-4 Alkyl-C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 、-CH=CR 01 R 02 , -C 2-4 Alkenyl-NR 01 R 02 , -C 2-4 Alkenyl-C(R 05 )R 03 R 04 , -C 1-4 Alkyl-C 2-4 Alkenyl-NR 01 R 02 , -C 1-4 Alkyl-C 2-4 Alkenyl-C(R 05 )R 03 R 04 , -C 2-4 Alkenyl-C 1-4 Alkyl-NR 01 R 02 , -C 2-4 Alkenyl-C 1-4 Alkyl-C(R 05 )R 03 R 04 , -C 1- 4-Alkyl-C 2-4 Alkenyl-C 1-4 Alkyl-NR 01 R 02 、-C=CR 03 R 04 、-OC 1-4 Alkyl-substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, -OC 1-4 Alkyl-substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, -OC 1-4 alkyl-substituted or unsubstituted 7- to 12-membered bicyclic heterocyclyl, -O-substituted or unsubstituted 3- to 8-membered monocyclic heterocyclyl, -O-substituted or unsubstituted 5- to 15-membered tricyclic heterocyclyl, -O-substituted or unsubstituted 7- to 12-membered bicyclic heterocyclyl, -N=S(=O)(R 06 )(-C 1-4 Alkyl-NR 01 R 02 )、-N(R 06 )-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)(R 06 )(=NR 06 )、-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )(=NR 06 )、-S(=O)2(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)(-C 1-4 Alkyl-NR 01 R 02 )、-S(=O)2(-C 1-4 Alkyl-C(R 05 )R 03 R 04 )、-S(=O)(-C 1-4 Alkyl-C(R 05 )R 03 R 04 ),-C 2-4 Alkynyl-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, -C 2-4 Alkynyl-substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, -C 2-4 Alkynyl-substituted or unsubstituted 6- to 12-membered heteroaryl and heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, substituted or unsubstituted C 6-10 aryl-substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, substituted or unsubstituted 5 or 6-membered monocyclic heteroaryl-substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, substituted or unsubstituted C 6-10 Aryl-C 1-4 alkyl-substituted or unsubstituted 3 to 8-membered monocyclic heterocyclic group, substituted or unsubstituted 5 or 6-membered monocyclic heteroaryl-C 1-4 Alkyl-substituted or unsubstituted 3 to 8 membered monocyclic heterocyclic group, substituted or unsubstituted C 6-10 substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group, substituted or unsubstituted C 6-10 Aryl-C 1-4 Alkyl-NR 01 R 02 , substituted or unsubstituted 5 or 6-membered monocyclic heteroaryl-C 1-4 Alkyl-NR 01 R 02 ; R 01 , R 02 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; or, R 01 , R 02 Together with the nitrogen atom to which it is attached, it forms a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, or a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group; R 03 , R 04 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; wherein the C 1-6 Alkyl, C 1-6 The two hydrogen atoms on the same carbon atom of the alkoxy group are optionally simultaneously replaced by - (CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or R 03 , R 04 Together with the carbon atom to which it is attached, it forms a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, a 7- to 12-membered bicyclic heterocyclic group, a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group, a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl group, or a substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl group; R 05 For hydrogen, deuterium, halogen, deuterated C 1-6 Alkyl or C 1-6 alkyl; R 06 is hydrogen, deuterium or C 1-6 alkyl; Y3 is -C(=O)R6, -C(=S)R6, -S(=O)(R 07 )(=NR 08 )、-S(=O)(R 07 )(R 08 )、-S(=O)2(R 07 )(R 08 )、-P(=O)(R 07 )(R 08 ), -C(=O)-C 1-4 Alkyl-NR6-S(=O)(R 07 )(=NR 08 ), -C(=O)-C 1-4 Alkyl-N=S(=O)(R 07 )(R 08 ) or R 11 ; R 12 For hydrogen, C 1-6 Alkyl or deuterated C 1-6 alkyl; or Y3, R 12 Together with the nitrogen atom to which they are attached, they form a substituted or unsubstituted nitrogen-containing 3 to 8-membered heterocyclic group; one ring atom of the nitrogen-containing 3 to 8-membered heterocyclic group is a nitrogen atom and optionally one or more (such as 1, 2 or 3) ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; R6 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl; R 11 is a substituted or unsubstituted 3- to 10-membered heterocyclyl, a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, a substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, a substituted or unsubstituted 6- to 12-membered heteroarylcycloalkyl, a substituted or unsubstituted 6- to 12-membered heteroarylheterocyclyl, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclyl, or a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclyl; R 07 is hydrogen, deuterium, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 3-6 Cycloalkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3 or 4) groups selected from the group consisting of deuterium, C 1-6 Alkyl, C 1-6 heteroalkyl and 5- or 6-membered monocyclic heteroaryl; R 08 is hydrogen, deuterium, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 3-6 Cycloalkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3 or 4) groups selected from the group consisting of deuterium, C 1-6 Alkyl, C 1-6 heteroalkyl and 5- or 6-membered monocyclic heteroaryl; R 09 is hydrogen, deuterium, halogen or substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3 or 4) groups selected from the group consisting of deuterium and halogen; R 10 is hydrogen, deuterium, halogen or substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3 or 4) groups selected from the group consisting of deuterium and halogen; Y5 is O or S; Y4 is O or S; R3 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl; R 13 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 1-6 Alkoxy; R 14 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or In W4 and W5, R 13 and R 14 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 3- to 8-membered heterocyclic group; or R in W5 14 and R3 and the atoms to which it is connected together form a substituted or unsubstituted nitrogen-containing 4 to 8-membered monocyclic heterocyclic group; one ring atom of the nitrogen-containing 4 to 8-membered monocyclic heterocyclic group is a nitrogen atom and optionally one or more (such as 1, 2 or 3) ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; or R in W6 13 and R3 and the atoms to which it is connected together form a substituted or unsubstituted nitrogen-containing 3 to 8-membered monocyclic heterocyclic group or a substituted or unsubstituted 5 or 6-membered monocyclic heteroaryl group; one ring atom of the nitrogen-containing 3 to 8-membered monocyclic heterocyclic group is a nitrogen atom and optionally one or more (such as 1, 2 or 3) ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; In each of the above groups, the substitution independently refers to that the above groups are independently substituted by 1, 2, 3, 4, 5 or 6 groups selected from the S1 group; the groups of the S1 group are independently selected from the following groups: -SF5, deuterium, oxo (=O), thio (=S), =CR e R f , =NR e , halogen, cyano, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-20 Cycloalkyl, 3 to 20 membered heterocyclic group, C 6-14 Aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, -OC 3-20 Cycloalkyl, -O-3 to 20-membered heterocyclic group, -OC 6-14 Aryl, -O-5 or 6-membered monocyclic heteroaryl, -O-8 to 10-membered bicyclic heteroaryl, -C≡CC 3-20 Cycloalkyl, -C≡C-3 to 20 membered heterocyclic group, -C≡CC 6-14 Aryl, -C≡C-5 or 6-membered monocyclic heteroaryl, -C≡C-8 to 10-membered bicyclic heteroaryl, -C≡CC 1-4 Alkyl-C 3-20 Cycloalkyl, -C≡CC 1-4 Alkyl-3 to 20-membered heterocyclic group, -C≡CC 1-4 Alkyl-C 6-14 Aryl, -C≡CC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C≡CC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-C 3-20 Cycloalkyl, -C 1-4 Alkyl-OC 3-20 Cycloalkyl, -C 1-4 Alkyl-3 to 20 membered heterocyclic group, -C 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C 6-14 Aryl, -C 1-4 Alkyl-OC 6-14 Aryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -OC 1- 4-alkyl-hydroxyl, -OC 1-4 Alkyl-cyano, -OC 1-4 Alkyl-C 1-6 Alkyl, -OC 1-4 Alkyl-C 1-6 Alkoxy, -OC 1-4 Alkyl-C 3-20 Cycloalkyl, -OC 1-4 Alkyl-OC 3-20 Cycloalkyl, -OC 1-4 Alkyl-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-C 6-14 Aryl, -OC 1-4 Alkyl-OC 6-14 Aryl, -OC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -OC 1-4 -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-20 Cycloalkyl, -S(=O)2-3 to 20 -C(=O)OC 1-6 Alkyl, -C(=O)OC 3-20 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-20 Cycloalkyl, -C(=O)-C 6-14 Aryl, -NR a1 R b1 、-C(=O)-NR a1 R b1 、-C(=O)-NR d1 -C 1-4 Alkyl-R c1 、-OR c1 , -C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-20 Cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C(=O)OC 1-6 Alkyl, -C 1-4 Alkyl-C(=O)OC 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 1-6 Alkyl, -C 1-4 Alkyl-C(=O)-C 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 6-14 aryl, -C(=O)-5 or 6-membered monocyclic heteroaryl, -C(=O)-8 to 10-membered bicyclic heteroaryl, -C(=O)-C 1-6 Alkyl-C 3-20 Cycloalkyl, -C(=O)-C 1-6 alkyl-3 to 20-membered heterocyclic group, -C(=O)-C 1-6 Alkyl-C 6-14 Aryl, -C(=O)-C 1-6 Alkyl-5 or 6-membered monocyclic heteroaryl, -C(=O)-C 1-6 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-NR a1 R b1 , -C 1- 4-Alkyl-C(=O)-NR a1 R b1 、-C≡CC(=O)-NR a1 R b1 , -C≡CC 1-4 Alkyl-C(=O)-NR a1 R b1 , -C 1-4 Alkyl-OR c1 , -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2, -C 1-4 Alkyl-NR d1 -C(=O)-R c1 , -C 1-4 Alkyl-NR d1 -C(=O)-NR a1 R b1 , -C 1-4 Alkyl-NR d1 -S(=O)2-R c1 , -C 1-4 Alkyl-S(=O)2-NR a1 R b1 , -C 1-4 Alkyl-NR d1 -S(=O)2-NR a1 R b1 、-NR d1 -C(=O)-R c1 、-NR d1 -C(=O)-C 1-4 Alkyl-R c1 、-NR d1 -C(=O)-NR a1 R b1 、-NR d1 -S(=O)2-R c1 、-S(=O)2-NR a1 R b1 、-NR d1 -S(=O)2-NR a1 R b1 and -P(=O)-(C 1-6 Alkyl)2; wherein the C 1-6 Alkyl, the C 1-6 Alkoxy, the C 2-6 Alkenyl, the C 2-6 The alkynyl groups are each independently optionally substituted by 1, 2 or 3 groups selected from halogen, deuterium, cyano or hydroxyl; 3-20 Cycloalkyl, the 3 to 20 membered heterocyclic group, the C 6-14 The aryl group, the 5- or 6-membered monocyclic heteroaryl group, and the 8- to 10-membered bicyclic heteroaryl group are each independently optionally substituted by 1, 2, 3 or 4 groups selected from Group S2; In the above groups, each R a1 , R b1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 monocyclic cycloalkyl, 3- to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-6 monocyclic cycloalkyl, -S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-6 monocyclic cycloalkyl, -C(=O)-3 to 6-membered monocyclic heterocyclic group; wherein the C 3-6 The monocyclic cycloalkyl, the 3 to 6-membered monocyclic heterocyclic group, the phenyl, the 5 or 6-membered monocyclic heteroaryl, the 8 to 10-membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1- 6-alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 alkyl)2; or Each R a1 and R b1 Together with the nitrogen atom to which they are connected, they form a 3- to 20-membered heterocyclic group; wherein the 3- to 20-membered heterocyclic group is independently optionally substituted by 1 or 2 groups selected from the following groups: halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1- 6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 Alkyl)2; In the above groups, each R d1 Each independently is H, C 1-6 Alkyl or deuterated C 1-6 alkyl; In the above groups, each R c1 Each independently is H, C 1-6 Alkyl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-NR a1 R b1 , halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 monocyclic cycloalkyl, 3- to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl or -C 1-4 Alkyl-8 to 10 membered bicyclic heteroaryl; said C 3-6 The monocyclic cycloalkyl, the 3 to 6-membered monocyclic heterocyclic group, the phenyl, the 5 or 6-membered monocyclic heteroaryl, the 8 to 10-membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1- 6 alkyl, C 3-6 Monocyclic cycloalkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 Alkyl)2; In the above groups, each group of S2 is independently selected from the following group: deuterium, oxo (=O), thio (=S), =CR e R f , =NR e , halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -(C=O)-NHC 1-6 Alkyl, -(C=O)-N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2, -(C=O)C 1-6 Alkyl, -SF5 and -C 1-4 Alkyl-hydroxyl; In the above groups, the -C 1-4 Alkyl- is unsubstituted; or -C 1-4 The 1, 2, 3 or 4 hydrogen atoms on the alkyl group are independently selected from halogen, cyano, hydroxyl, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -CH2-hydroxy, -CH2-cyano, phenyl, C 3-6 or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by -(CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by =CR e R f replace; In the above groups, R e are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl; In the above groups, R f are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl; In each of the above groups, one or more (e.g., 1, 2, 3 or 4) ring atoms of the 3- to 8-membered heterocyclic group, the 3- to 10-membered heterocyclic group or the 3- to 8-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; 1-6 One or more (e.g., 1, 2, 3, or 4) ring atoms of the heteroalkyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 7- to 12-membered bicyclic heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 3- to 20-membered heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- or 6-membered monocyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 8- to 10-membered bicyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; One or more (e.g. 1, 2, 3 or 4) ring atoms of the cyclic group are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g. 1, 2, 3, 4 or 5) ring atoms of the 5- to 15-membered tricyclic heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g. 1, 2, 3, 4 or 5) ring atoms of the 6- to 12-membered heteroaryl and cycloalkyl are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g. 1, 2, 3, 4 or 5) ring atoms of the 6- to 12-membered heteroaryl and heterocyclyl are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; Wherein, when the ring atom is a sulfur atom, the sulfur atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above; Wherein, when the ring atom is a phosphorus atom, the phosphorus atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above.

2. The compound according to claim 1 or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof: wherein: Select from the following group: Wherein, X is defined as above; R3 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl.

3. The compound according to claim 1 or its stable deuterated derivative or stereoisomer, or its pharmaceutically acceptable salt, solvate or prodrug: wherein, Selected from Wherein, X is defined as above; R3 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl; R 13 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 1-6 Alkyl; or R 13 and R3 together with the atoms to which they are connected form a substituted or unsubstituted nitrogen-containing 3 to 8-membered monocyclic heterocyclic group or a substituted or unsubstituted 5 or 6-membered monocyclic heteroaryl group; one ring atom of the nitrogen-containing 3 to 8-membered monocyclic heterocyclic group is a nitrogen atom and optionally one or more (such as 1, 2 or 3) ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus.

4. The compound according to claim 1 or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof: wherein: The compound of formula (I) is represented by formula (A1), formula (A2), formula (A3), formula (A4), formula (A5), formula (A6), formula (B1), formula (B2), formula (B3) or formula (B4): In the formula, R3 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl; R 13 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl or substituted or unsubstituted C 1-6 Alkoxy; or R 13 and R3 and the atoms to which they are attached together form a substituted or unsubstituted nitrogen-containing 3- to 8-membered monocyclic heterocyclic group; R 42 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 43 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or R 42 and R 43 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 Cycloalkyl or substituted or unsubstituted 3 to 8-membered heterocyclic group; L1 is -N(R 00 )C(=O)-、-N(R 00 )C(=O)-O-, -C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, substituted or unsubstituted C 1-6 Alkyl, -substituted or unsubstituted C 1-6 Alkyl-O-, -substituted or unsubstituted C 2-6 Alkenyl-O-substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted 5 or 6 membered monocyclic hetero Aryl, substituted or unsubstituted 8-10 membered bicyclic heteroaryl, -L2-substituted or unsubstituted C 6-10 aryl, -L2-substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or -L2-substituted or unsubstituted 3- to 8-membered heterocyclic group; L2 is -O-, -C 1-4 Alkyl-, -N(R 00 )-、-C(=O)-、-CR 09 =CR 10 -、-N(R 00 )C(=O)-or-N(R 00 )C(=S)-; R 00 is hydrogen or C 1-6 alkyl; R1 is hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl; R2 is hydrogen, deuterium, halogen, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl; R 4a is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 3-6 Cycloalkyl or substituted or unsubstituted 3 to 8 membered heterocyclic group; R5 is -NR 01 R 02 or -C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 ; R 01 , R 02 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; or, R 01 , R 02 Together with the nitrogen atom to which it is attached, it forms a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, or a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group; R 09 is hydrogen, deuterium, halogen or substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3 or 4) groups selected from the group consisting of deuterium and halogen; R 10 is hydrogen, deuterium, halogen or substituted or unsubstituted C 1-6 Alkyl; the substitution refers to substitution by one or more (e.g., 1, 2, 3 or 4) groups selected from the group consisting of deuterium and halogen; R6 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl; In each of the above groups, the substitution independently refers to that the above groups are independently substituted by 1, 2, 3, 4, 5 or 6 groups selected from the S1 group; the groups of the S1 group are independently selected from the following groups: -SF5, deuterium, oxo (=O), thio (=S), =CR e R f , =NR e , halogen, cyano, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-20 Cycloalkyl, 3 to 20 membered heterocyclic group, C 6-14 Aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, -OC 3-20 Cycloalkyl, -O-3 to 20-membered heterocyclic group, -OC 6-14 Aryl, -O-5 or 6-membered monocyclic heteroaryl, -O-8 to 10-membered bicyclic heteroaryl, -C≡CC 3-20 Cycloalkyl, -C≡C-3 to 20 membered heterocyclic group, -C≡CC 6-14 Aryl, -C≡C-5 or 6-membered monocyclic heteroaryl, -C≡C-8 to 10-membered bicyclic heteroaryl, -C≡CC 1-4 Alkyl-C 3-20 Cycloalkyl, -C≡CC 1-4 Alkyl-3 to 20-membered heterocyclic group, -C≡CC 1-4 Alkyl-C 6-14 Aryl, -C≡CC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C≡CC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-C 3-20 Cycloalkyl, -C 1-4 Alkyl-OC 3-20 Cycloalkyl, -C 1-4 Alkyl-3 to 20 membered heterocyclic group, -C 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C 6-14 Aryl, -C 1-4 Alkyl-OC 6-14 Aryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -OC 1- 4-alkyl-hydroxyl, -OC 1-4 Alkyl-cyano, -OC 1-4 Alkyl-C 1-6 Alkyl, -OC 1-4 Alkyl-C 1-6 Alkoxy, -OC 1-4 Alkyl-C 3-20 Cycloalkyl, -OC 1-4 Alkyl-OC 3-20 Cycloalkyl, -OC 1-4 Alkyl-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-C 6-14 Aryl, -OC 1-4 Alkyl-OC 6-14 Aryl, -OC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -OC 1-4 -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-20 Cycloalkyl, -S(=O)2-3 to 20-membered heterocyclic group, -C(=O)OC 1-6 Alkyl, -C(=O)OC 3-20 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-20 Cycloalkyl, -C(=O)-C 6-14 Aryl, -NR a1 R b1 、-C(=O)-NR a1 R b1 、-C(=O)-NR d1 -C 1-4 Alkyl-R c1 、-OR c1 , -C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-20 Cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C(=O)OC 1-6 Alkyl, -C 1-4 Alkyl-C(=O)OC 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 1-6 Alkyl, -C 1-4 Alkyl-C(=O)-C 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 6-14 aryl, -C(=O)-5 or 6-membered monocyclic heteroaryl, -C(=O)-8 to 10-membered bicyclic heteroaryl, -C(=O)-C 1-6 Alkyl-C 3-20 Cycloalkyl, -C(=O)-C 1-6 alkyl-3 to 20-membered heterocyclic group, -C(=O)-C 1-6 Alkyl-C 6-14 Aryl, -C(=O)-C 1-6 Alkyl-5 or 6-membered monocyclic heteroaryl, -C(=O)-C 1-6 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-NR a1 R b1 , -C 1- 4-Alkyl-C(=O)-NR a1 R b1 、-C≡CC(=O)-NR a1 R b1 , -C≡CC 1-4 Alkyl-C(=O)-NR a1 R b1 , -C 1-4 Alkyl-OR c1 , -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2, -C 1-4 Alkyl-NR d1 -C(=O)-R c1 , -C 1-4 Alkyl-NR d1 -C(=O)-NR a1 R b1 , -C 1-4 Alkyl-NR d1 -S(=O)2-R c1 , -C 1-4 Alkyl-S(=O)2-NR a1 R b1 , -C 1-4 Alkyl-NR d1 -S(=O)2-NR a1 R b1 、-NR d1 -C(=O)-R c1 、-NR d1 -C(=O)-C 1-4 Alkyl-R c1 、-NR d1 -C(=O)-NR a1 R b1 、-NR d1 -S(=O)2-R c1 、-S(=O)2-NR a1 R b1 、-NR d1 -S(=O)2-NR a1 R b1 and -P(=O)-(C 1-6 Alkyl)2; wherein the C 1-6 Alkyl, the C 1-6 Alkoxy, the C 2-6 Alkenyl, the C 2-6 The alkynyl groups are each independently optionally substituted by 1, 2 or 3 groups selected from halogen, deuterium, cyano or hydroxyl; 3-20 Cycloalkyl, the 3 to 20 membered heterocyclic group, the C 6-14 The aryl group, the 5- or 6-membered monocyclic heteroaryl group, and the 8- to 10-membered bicyclic heteroaryl group are each independently optionally substituted by 1, 2, 3 or 4 groups selected from Group S2; In the above groups, each R a1 , R b1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 monocyclic cycloalkyl, 3- to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-6 monocyclic cycloalkyl, -S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-6 monocyclic cycloalkyl or -C(=O)-3 to 6-membered monocyclic heterocyclic group; wherein the C 3-6 monocyclic cycloalkyl, the 3 to 6-membered monocyclic heterocyclic group, the phenyl, the 5 or 6-membered monocyclic heteroaryl, the The 8- to 10-membered bicyclic heteroaryl is optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1- 6-alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 alkyl)2; or Each R a1 and R b1 Together with the nitrogen atom to which they are attached, they form a 3- to 20-membered heterocyclic group; wherein the 3- to 20-membered heterocyclic group is independently optionally substituted by 1 or 2 groups selected from the following groups: halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1- 6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 Alkyl)2; In the above groups, each R d1 Each independently is H, C 1-6 Alkyl or deuterated C 1-6 alkyl; In the above groups, each R c1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 monocyclic cycloalkyl, 3- to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl or -C 1-4 Alkyl-8 to 10 membered bicyclic heteroaryl; said C 3-6 The monocyclic cycloalkyl, the 3 to 6-membered monocyclic heterocyclic group, the phenyl, the 5 or 6-membered monocyclic heteroaryl, the 8 to 10-membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1- 6 alkyl)2 and -P(=O)-(C 1-6 Alkyl)2; In the above groups, each group of S2 is independently selected from the following group: deuterium, oxo (=O), thio (=S), =CR e R f , =NR e , halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -(C=O)-NHC 1-6 Alkyl, -(C=O)-N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2, -(C=O)C 1-6 Alkyl and -SF5; In the above groups, the -C 1-4 Alkyl- is unsubstituted; or -C 1-4 The 1, 2, 3 or 4 hydrogen atoms on the alkyl group are independently selected from halogen, cyano, hydroxyl, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 alkyl, -CH2-hydroxy, -CH2-cyano, phenyl; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by -(CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously =CR e R f replace; In the above groups, R e are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl; In the above groups, R f are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl; In each of the above groups, one or more (e.g., 1, 2, 3 or 4) ring atoms of the 3- to 8-membered heterocyclic group, the 3- to 10-membered heterocyclic group or the 3- to 8-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; 1-6 One or more (e.g., 1, 2, 3, or 4) ring atoms of the heteroalkyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 7- to 12-membered bicyclic heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 3- to 20-membered heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- or 6-membered monocyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; The ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g., 1, 2, 3, 4 or 5) ring atoms of the 8- to 10-membered bicyclic heteroaryl are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g., 1, 2, 3 or 4) ring atoms of the 3- to 6-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g., 1, 2, 3, 4 or 5) ring atoms of the 5- to 15-membered tricyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; Wherein, when the ring atom is a sulfur atom, the sulfur atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above; Wherein, when the ring atom is a phosphorus atom, the phosphorus atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above.

5. The compound according to claim 1 or its stable deuterated derivative or stereoisomer, or its pharmaceutically acceptable salt, solvate or prodrug: wherein, The compound of formula (I) is shown in formula (C1): R 42 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; R 43 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl; or R 42 and R 43 Together with the connected carbon atom, it forms a substituted or unsubstituted C 3-6 Cycloalkyl or substituted or unsubstituted 3 to 8-membered heterocyclic group; L1 is -N(R 00 )C(=O)-O-, -C 1-4 Alkyl-N(R 00 )C(=O)-、-C(=O)N(R 00 )-C 1-4 Alkyl-, -C 1-4 Alkyl-N(R 00 )C(=S)-, -substituted or unsubstituted C 1-6 Alkyl-O- or -substituted or unsubstituted C 2-6 alkenyl-O-; R 00 is hydrogen or C 1-6 alkyl; R1 is hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl; R2 is hydrogen, deuterium, halogen, C 1-6 Alkyl or substituted or unsubstituted C 1-6 heteroalkyl; R3 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl; R 4a is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 3-6 Cycloalkyl or substituted or unsubstituted 3 to 8 membered heterocyclic group; R5 is -NR 01 R 02 or -C 2-4 Alkynyl-C 1-4 Alkyl-NR 01 R 02 ; R 01 , R 02 are each independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Alkoxy, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; or, R 01 , R 02 Together with the nitrogen atom to which it is attached, it forms a substituted or unsubstituted 5- to 15-membered tricyclic heterocyclic group, a substituted or unsubstituted 7- to 12-membered bicyclic heterocyclic group, or a substituted or unsubstituted 3- to 8-membered monocyclic heterocyclic group; R6 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-6 Heteroalkyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocyclic group, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl; In each of the above groups, the substitution independently refers to that the above groups are independently substituted by 1, 2, 3, 4, 5 or 6 groups selected from the S1 group; the groups of the S1 group are independently selected from the following groups: -SF5, deuterium, oxo (=O), thio (=S), =CR e R f , =NR e , halogen, cyano, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-20 Cycloalkyl, 3 to 20 membered heterocyclic group, C 6-14 Aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, -OC 3-20 Cycloalkyl, -O-3 to 20-membered heterocyclic group, -OC 6-14 Aryl, -O-5 or 6-membered monocyclic heteroaryl, -O-8 to 10-membered bicyclic heteroaryl, -C≡CC 3-20 Cycloalkyl, -C≡C-3 to 20 membered heterocyclic group, -C≡CC 6-14 Aryl, -C≡C-5 or 6-membered monocyclic heteroaryl, -C≡C-8 to 10-membered bicyclic heteroaryl, -C≡CC 1-4 Alkyl-C 3-20 Cycloalkyl, -C≡CC 1-4 Alkyl-3 to 20-membered heterocyclic group, -C≡CC 1-4 Alkyl-C 6-14 Aryl, -C≡CC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C≡CC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-C 3-20 Cycloalkyl, -C 1-4 Alkyl-OC 3-20 Cycloalkyl, -C 1-4 Alkyl-3 to 20 membered heterocyclic group, -C 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C 6-14 Aryl, -C 1-4 Alkyl-OC 6-14 Aryl, -C 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-O-8 to 10-membered bicyclic heteroaryl, -OC 1- 4-alkyl-hydroxyl, -OC 1-4 Alkyl-cyano, -OC 1-4 Alkyl-C 1-6 Alkyl, -OC 1-4 Alkyl-C 1-6 Alkoxy, -OC 1-4 Alkyl-C 3-20 Cycloalkyl, -OC 1-4 Alkyl-OC 3-20 Cycloalkyl, -OC 1-4 Alkyl-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-O-3 to 20-membered heterocyclic group, -OC 1-4 Alkyl-C 6-14 Aryl, -OC 1-4 Alkyl-OC 6-14 Aryl, -OC 1-4 Alkyl-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-O-5 or 6-membered monocyclic heteroaryl, -OC 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -OC 1-4 -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-20 Cycloalkyl, -S(=O)2-3 to 20-membered heterocyclic group, -C(=O)OC 1-6 Alkyl, -C(=O)OC 3-20 Cycloalkyl, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-20 Cycloalkyl, -C(=O)-C 6-14 Aryl, -NR a1 R b1 、-C(=O)-NR a1 R b1 、-C(=O)-NR d1 -C 1-4 Alkyl-R c1 、-OR c1 , -C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-20 Cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 20-membered heterocyclic group, -C 1-4 Alkyl-C(=O)OC 1-6 Alkyl, -C 1-4 Alkyl-C(=O)OC 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 1-6 Alkyl, -C 1-4 Alkyl-C(=O)-C 3-20 Cycloalkyl, -C 1-4 Alkyl-C(=O)-C 6-14 aryl, -C(=O)-5 or 6-membered monocyclic heteroaryl, -C(=O)-8 to 10-membered bicyclic heteroaryl, -C(=O)-C 1-6 Alkyl-C 3-20 Cycloalkyl, -C(=O)-C 1-6 alkyl-3 to 20-membered heterocyclic group, -C(=O)-C 1-6 Alkyl-C 6-14 Aryl, -C(=O)-C 1-6 Alkyl-5 or 6-membered monocyclic heteroaryl, -C(=O)-C 1-6 Alkyl-8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-NR a1 R b1 , -C 1- 4-Alkyl-C(=O)-NR a1 R b1 、-C≡CC(=O)-NR a1 R b1 , -C≡CC 1-4 Alkyl-C(=O)-NR a1 R b1 , -C 1-4 Alkyl-OR c1 , -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2, -C 1-4 Alkyl-NR d1 -C(=O)-R c1 , -C 1-4 Alkyl-NR d1 -C(=O)-NR a1 R b1 , -C 1-4 Alkyl-NR d1 -S(=O)2-R c1 , -C 1-4 Alkyl-S(=O)2-NR a1 R b1 , -C 1-4 Alkyl-NR d1 -S(=O)2-NR a1 R b1 、-NR d1 -C(=O)-R c1 、-NR d1 -C(=O)-C 1-4 Alkyl-R c1 、-NR d1 -C(=O)-NR a1 R b1 、-NR d1 -S(=O)2-R c1 、-S(=O)2-NR a1 R b1 、-NR d1 -S(=O)2-NR a1 R b1 and -P(=O)-(C 1-6 Alkyl)2; wherein the C 1-6 Alkyl, the C 1-6 Alkoxy, the C 2-6 Alkenyl, the C 2-6 The alkynyl groups are each independently optionally substituted by 1, 2 or 3 groups selected from halogen, deuterium, cyano or hydroxyl; 3-20 Cycloalkyl, the 3 to 20 membered heterocyclic group, the C 6-14 The aryl group, the 5- or 6-membered monocyclic heteroaryl group, and the 8- to 10-membered bicyclic heteroaryl group are each independently optionally substituted by 1, 2, 3 or 4 groups selected from Group S2; In the above groups, each R a1 , R b1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, -C 1-4 Alkyl-hydroxyl, -C 1-4 Alkyl-cyano, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 monocyclic cycloalkyl, 3- to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl, -C 1-4 Alkyl-8 to 10-membered bicyclic heteroaryl, -S(=O)2-C 1-6 Alkyl, -S(=O)2-C 3-6 monocyclic cycloalkyl, -S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-S(=O)2-C 1-6 Alkyl, -C 1-4 Alkyl-S(=O)2-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-S(=O)2-3 to 6-membered monocyclic heterocyclic group, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-6 monocyclic cycloalkyl or -C(=O)-3 to 6-membered monocyclic heterocyclic group; wherein the C 3-6 The monocyclic cycloalkyl, the 3 to 6-membered monocyclic heterocyclic group, the phenyl, the 5 or 6-membered monocyclic heteroaryl, the 8 to 10-membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1- 6-alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 alkyl)2; or Each R a1 and R b1 Together with the nitrogen atom to which they are connected, they form a 3- to 20-membered heterocyclic group; wherein the 3- to 20-membered heterocyclic group is independently any It is optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1- 6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2 and -P(=O)-(C 1-6 Alkyl)2; In the above groups, each R d1 Each independently is H, C 1-6 Alkyl or deuterated C 1-6 alkyl; In the above groups, each R c1 Each independently is H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkyl, -C 1-4 Alkyl-deuterated C 1-6 Alkyl, -C 1-4 Alkyl-C 1-6 Alkoxy, -C 1-4 Alkyl-halide C 1-6 Alkoxy, -C 1-4 Alkyl-deuterated C 1-6 Alkoxy, C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-C 3-6 Monocyclic cycloalkyl, -C 1-4 Alkyl-OC 3-6 monocyclic cycloalkyl, 3- to 6-membered monocyclic heterocyclic group, -C 1-4 Alkyl-3 to 6-membered monocyclic heterocyclic group, -C 1-4 alkyl-O-3 to 6-membered monocyclic heterocyclic group, phenyl, -C 1-4 Alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, -C 1-4 alkyl-5 or 6-membered monocyclic heteroaryl, 8 to 10-membered bicyclic heteroaryl or -C 1-4 Alkyl-8 to 10 membered bicyclic heteroaryl; said C 3-6 The monocyclic cycloalkyl, the 3 to 6-membered monocyclic heterocyclic group, the phenyl, the 5 or 6-membered monocyclic heteroaryl, the 8 to 10-membered bicyclic heteroaryl are optionally substituted by 1 or 2 groups selected from the group consisting of halogen, hydroxy, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1- 6 alkyl)2 and -P(=O)-(C 1-6 Alkyl)2; In the above groups, each group of S2 is independently selected from the following group: deuterium, oxo (=O), thio (=S), =CR e R f , =NR e , halogen, hydroxyl, carboxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2, -(C=O)-NHC 1-6 Alkyl, -(C=O)-N(C 1-6 Alkyl)2, -C 1-4 Alkyl-P(=O)-(C 1-6 alkyl)2, -P(=O)-(C 1-6 Alkyl)2, -(C=O)C 1-6 Alkyl and -SF5; In the above groups, the -C 1-4 Alkyl- is unsubstituted; or -C 1-4 The 1, 2, 3 or 4 hydrogen atoms on the alkyl group are independently selected from halogen, cyano, hydroxyl, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 alkyl, -CH2-hydroxy, -CH2-cyano, phenyl; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by -(CH2) j -substituted to form a cycloalkyl group, wherein j is 2, 3, 4, 5 or 6; or C 1-4 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously =CR e R f replace; In the above groups, R e are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl; In the above groups, R f are independently H, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 alkyl; In each of the above groups, one or more (e.g., 1, 2, 3 or 4) ring atoms of the 3- to 8-membered heterocyclic group, the 3- to 10-membered heterocyclic group or the 3- to 8-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; 1-6 One or more (e.g., 1, 2, 3, or 4) ring atoms of the heteroalkyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 7- to 12-membered bicyclic heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 3- to 20-membered heterocyclyl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; one or more (e.g., 1, 2, 3, 4, or 5) ring atoms of the 5- or 6-membered monocyclic heteroaryl group are heteroatoms selected from nitrogen, oxygen, sulfur, or phosphorus; The ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g., 1, 2, 3, 4 or 5) ring atoms of the 8- to 10-membered bicyclic heteroaryl are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g., 1, 2, 3 or 4) ring atoms of the 3- to 6-membered monocyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; one or more (e.g., 1, 2, 3, 4 or 5) ring atoms of the 5- to 15-membered tricyclic heterocyclic group are heteroatoms selected from nitrogen, oxygen, sulfur or phosphorus; Wherein, when the ring atom is a sulfur atom, the sulfur atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above; Wherein, when the ring atom is a phosphorus atom, the phosphorus atom is optionally substituted by one or two selected from oxo and =NR e The group substituted; R e Same definition as above.

6. The compound according to claim 1 or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof: wherein: R 4a For -C 1-6 Alkyl-C 1-6 Alkoxy.

7. The compound according to claim 1 or its stable deuterated derivative or stereoisomer, or its pharmaceutically acceptable salt, solvate or prodrug: wherein, R5 is selected from hydrogen, 8. The compound according to claim 1 or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof: wherein: R3 is hydrogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl or C 3-6 Cycloalkyl.

9. The compound according to claim 1 or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof: wherein: R1 is hydrogen; R2 is hydrogen.

10. The compound according to claim 1 or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof: wherein: L1 is selected from 11. The compound according to claim 1 or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof: wherein: R6 is selected from 12. The compound according to claim 1 or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof: wherein: The compound is selected from Table A, Table B or Table C.

13. A pharmaceutical composition comprising the compound according to any one of claims 1 to 12 or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof; and a pharmaceutically acceptable carrier.

14. Use of a compound according to any one of claims 1 to 12 or a stable deuterated derivative or stereoisomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or a pharmaceutical composition according to claim 13 in the preparation of a medicament for preventing and / or treating a disease or condition associated with RAS protein activity.

15. The use according to claim 14, wherein The disease or disorder associated with RAS protein activity is cancer.

16. The use according to claim 15, wherein The cancer is pancreatic cancer, colorectal cancer, non-small cell lung cancer, acute myeloid leukemia, multiple myeloma, thyroid adenocarcinoma, myelodysplastic syndrome, squamous cell lung cancer, esophageal cancer, ovarian cancer, uterine cancer, melanoma, bladder cancer or head and neck cancer.